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Abstract 
 
Background: Saliva is a common problem in tracheostomised patients, 
whereby saliva is spilled through the faucial isthmus creating risk of aspiration. 
These individuals are dependent on tracheal suctioning to clear saliva from 
the airway. There is currently no evidence about the relative effectiveness of 
any of the pharmacological treatments to manage saliva in this patient 
population.  
 
Methods and Procedures: This prospective interrupted time series study 
investigated the medical management of saliva in tracheostomised patients. 
Three inpatients at The Wellington Hospital London were enrolled, prescribed 
treatment using Hyoscine (Scopoderm® TTS). Unstimulated whole saliva was 
collected, using the swab method, at one-week prior, one-week, two-weeks, 
four-weeks, eight-weeks and at 12 weeks post treatment.  The primary 
outcome measure was dental roll weights measured at these time-points. 
Primary carer and nursing reports in relation to the amount of oral secretions 
and tracheostomy self-perceptions were also recorded at these same time 
intervals, using a visual analogue scale and a questionnaire. The frequency 
and reasoning of tracheal suctioning was also recorded, by the same nurse at 
these time-points. Data was analysed using linear regression for oral 
secretions and a Chi-Square test was performed for frequency of tracheal 
suctioning.  
 
Outcomes and Results: There was a significant reduction in oral secretions 
post treatment intervention, F= 27.252, df= 1, 52; p<0.001, F=11.62, df=1, 52, 
p<0.001, F=159.314, df=1, 52, p<0.001. There was a significant reduction in 
the frequency of tracheal suctioning performed post intervention, Fisher’s 
Exact Test p=0.094; with the primary reason recorded as audible or visible 
secretions. All primary caregivers and the same one-to-one nurse reported 
that oral secretions had reduced. 
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Conclusion and Implications: The medical management of saliva in 
tracheostomised patients, using Hyoscine (Scopoderm® TTS) was effective in 
reducing saliva and tracheal suctioning. This study suggests that further 
research is required in order to establish clinical practice guidelines in the use 
of Hyoscine (Scopoderm® TTS) in this patient population. 
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Introduction 
 
Patients who have swallowing difficulties and who are unable to safely swallow 
their saliva, following neurological injury are often managed with the insertion of 
a tracheostomy tube. A tracheostomy is an opening (made by an incision) 
through the neck into the trachea (windpipe). A tracheostomy tube is a small 
tube inserted into the tracheostomy, which aids breathing and allows access to 
the windpipe, in order to assist in the clearance of saliva that has fallen into the 
airway, during tracheal suctioning. The problems that arise when managing 
these patients are that; 
 
 
1. There are no national government supported guidelines or policies to 
direct the medical management of saliva 
 
2. There are no licensed medications to manage excessive pooled saliva, 
secondary to swallowing difficulties (UK Medicines Information 2012) 
 
3. All prescribed medication is issued ‘off-label’. This is when a licensed 
medicine is used in a manner that is not described in the medicine’s 
summary of product characteristics (SPC), for example, a different dose, 
indication, patient group or route of administration. It is therefore being 
prescribed outside its approved terms of use, known as being used ‘off-
label’ or ‘off-licence’ (Medicines and Healthcare Products Regulatory 
Agency 2009) 
 
4. Knowledge and practice amongst healthcare professionals caring for the 
tracheostomised patient, including tracheal suctioning is poor (Day, 
Farnell et al. 2002) 
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5. If tracheal suctioning is required long-term to clear aspirated saliva, the 
tracheostomy tube cannot be removed successfully, as airway access is 
required in order to remove the saliva and therefore the tracheostomy 
tube cannot be closed-off   
 
If saliva can be successfully managed in this patient population, then the 
tracheostomy tube can be closed-off and ultimately result in the removal of the 
tube, resulting in ‘normalised’ breathing via the nose and mouth and removal of 
the artificial opening in the neck (Kent and Christopher 2005).  
 
 
As well as swallowing difficulties, patients post neurological injury may also 
present with a disorder of consciousness or with receptive and / or expressive 
cognitive-communication impairments which result in an inability to participate in 
direct therapy programmes or benefit from more conservative management 
options to treat the pooling of saliva orally, such as behavioural techniques or 
postural changes. It has also been documented that the presence of a 
tracheostomy tube can occasionally adversely affect swallowing in patients who 
previously had no dysphagia, and may further impair the swallowing function in 
those who already have neurological or mechanical disorders of swallowing. 
 
It is clearly documented in the evidence that knowledge and practice in caring 
for the tracheostomised patient is poor (Day, Farnell et al. 2002) and associated 
tracheal suctioning practice is poor amongst healthcare professionals (Day, 
Farnell et al. 2002). Poor practice often leads to further complications such as 
hypoxia microatelectasis (alveolar damage), laryngospasm and tracheal wall 
damage (Fiorentini 1992; Kapadia, Bajan et al. 2000) and delays removal of the 
tracheostomy tube. There are no clear national or government guidelines or 
policies that direct how to clinically manage excessive pooled saliva, this being 
the main reason for the tracheostomy tube being in-situ, in order to clear 
aspirated saliva. As a result of requiring regular tracheal suctioning to remove 
aspirated saliva the tracheostomy tube cannot be closed-off and removed.  
In everyday clinical practice, patients with swallowing difficulties who are at high 
risk of aspirating their own saliva and who have a tracheostomy tube in-situ are 
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referred to the speech and language therapist for assessment of swallowing 
and laryngeal function. These patients may be cared for in an intensive care 
setting or in a ward environment, where they continue to receive one-to-one 
nursing care to prevent secondary complications, such as airway occlusion, as 
a result of having a tracheostomy tube in-situ.  
  
Patients admitted to The Wellington Hospital, London, with a tracheostomy tube 
in-situ are referred to the speech and language therapist for assessment and 
management of communication and swallowing. Following assessment by the 
speech and language therapist, recommendations may be made to the medical 
team to consider management options to reduce the flow of saliva to aid cuff 
deflation trials and to determine the suitability for safe decannulation. There is 
however no evidence of a clear decision making process to guide practice on 
how best to medically manage saliva in the tracheostomised patient and what 
implications this may have on commencing therapy with the aim of  eventual 
successful decannulation. In a study by McGowan et al. (McGowan, Ward et al. 
2014), they investigated the working practices of 106 speech and language 
therapists, with prior experience in tracheostomy management across various 
areas. In their study they wanted to determine the level of clinical consistency 
for speech and language therapy practice in adult tracheostomy care, including 
clinical patterns in relation to current scientific evidence and national guidelines. 
Their study concluded that there was a moderate to high consistency in a 
number of areas of clinical practice consistent with current research evidence 
(McGowan, Ward et al. 2014). These areas included the role of the speech and 
language therapists in swallowing assessment and management, increased 
utilisation of instrumental assessments such as fibreoptic endoscopic evaluation 
of swallowing (FEES), use of cuff deflation protocols in order to aid decision 
making in decannulation, increased use of speaking valves and use of 
manometers to measure cuff pressures during re-inflation. A highlighted area of 
concern for tracheostomy management was the feeling that care was not being 
provided in optimal team environments, despite the emerging evidence that 
working in such teams enhances patient outcomes (McGowan, Ward et al. 
2014). Their data showed that there is a requirement for greater consistency in 
the speech and language therapy management of the tracheostomised patient 
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in order to enhance and optimise patient outcomes (McGowan, Ward et al. 
2014). 
 
However when considering the management of saliva in the tracheostomised 
patient and across other patient populations, there appears to be a lack of 
consistency or guidance and that decision making is not provided in an optimal 
team environment, despite emerging evidence that tracheostomy teams may 
enhance patient outcomes (McGowan, Ward et al. 2014).     
 
The purpose of this study is to investigate the current medical practice and 
management of excessive pooled saliva in tracheostomised patients and to 
examine how this affects the reduction in saliva and subsequent need to 
perform tracheal suctioning and ultimate closure of the tracheostomy tube. 
Successful reduction in orally pooled saliva in patients with a tracheostomy tube 
decreases the frequency and amount of tracheal suctioning and can instigate 
the successful removal of the tracheostomy tube.  
 
Saliva is a valuable oral fluid that is often taken for granted. Saliva is a clear, 
slightly acidic, watery and usually frothy substance produced in the mouths of 
mammals. Saliva is produced in and secreted by the salivary glands and is 
crucial to the preservation and maintenance of oral health. However, it is not 
until the quantity or quality changes from the normal range, either through an 
excess or diminished amount of saliva, that it becomes an area of concern. Too 
much saliva and the inability to control oral secretions, can lead to subsequent 
anterior and / or posterior drooling, which can be devastating and affect quality 
of life and health status. Drooling is not due to the excessive production of 
saliva, but is a problem in the coordinated control of the muscles of the oral 
cavity, face and tongue, usually due to impaired neurological control. This 
impaired control results in a dysfunctional swallow and may lead to an 
excessive accumulation of saliva in the oral cavity and unintentional loss of 
saliva from the mouth.  Furthermore, the inability to swallow adequately also 
increases the risk of developing aspiration pneumonia, which can be life-
threatening or even fatal.  
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Although a number of studies have investigated the management of drooling in 
different patient populations there are no formal guidelines detailing how to 
manage drooling or the build-up of saliva within the oral cavity, secondary to 
swallowing difficulties. Furthermore there are no licensed medications that are 
available to physicians that can be prescribed in order to assist patients who 
have problems in managing their saliva. Therefore medications for managing 
saliva are typically prescribed ‘off-label’, using medications, not specifically 
designed and not licensed for this use. ‘Off-label’ prescribing can potentially 
harm patients, and the harm is greatest when ‘off-label’ use lacks an evidence 
base.   
 
Although the medicinal use of Botulinum Toxin and Scopolamine TTS® has 
been shown to be a safe and effective method for managing drooling and 
excessive saliva in people with Parkinson’s disease and in children with 
Cerebral Palsy (Porta, Gamba et al. 2001; Banerjee, Glasson et al. 2006; 
Lagalla, Millevolte et al. 2006); to date there has been no reported studies 
investigating its use in patients who have a tracheostomy tube in-place. There is 
no evidence about the relative effectiveness, side-effect profiles or patient 
acceptability of one of the most commonly used medications - Hyoscine 
hydrobromide (Scopoderm® TTS), to manage saliva reduction in patients who 
have a tracheostomy tube in-situ. Consequently, there is no consensus or 
guideline to aid in clinical decisions about which drug to use.  
 
In reviewing these case series investigating the clinical management of saliva in 
tracheostomised patients, the initial two chapters will provide a literature review 
beginning with saliva, and the clinical options in managing excess saliva.  
 
Subsequent chapters will describe the methodology and results obtained in this 
study and discuss the findings. The final chapter will consider the wider 
implications this study has on current practice and will comment on future 
research options in order to add to the knowledge-base when investigating the 
clinical management of saliva in this patient population.  
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Chapter 1 
 
1. Saliva  
 
1.01 Saliva secretion and regulation 
Saliva is produced in and secreted from salivary glands. The basic secretory 
units of salivary glands are clusters of cells called acini. These cells secrete a 
fluid that contains water, electrolytes, mucus and enzymes, all of which flow out 
of the acinus into collecting ducts.  
Saliva is secreted into the mouth by three major pairs of salivary glands; the 
parotid, submandibular and sublingual glands, and by a number of minor 
mucous glands, such as the accessory parotid gland and glands within the 
tongue and palate (Humphrey and Williamson 2001). The parotid, 
submandibular and sublingual salivary glands account for approximately 90% of 
daily salivary production, whilst the minor glands present within the lips, buccal 
mucosa, posterior hard palate, soft palate, tongue and uvula produce about 
10% (Figure 1). 
 
 
 
Figure 1 The major salivary glands, adapted from the website http://www.mdconsult.com/  
 
Parotid Duct 
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The type of secretion produced by the different salivary glands is determined by 
the acinar cells, in which saliva is first secreted. The type of secretion can be 
classified into three categories; as serous, mucous or mixed (Humphrey and 
Williamson 2001). Serous secretions, which are produced mainly by the parotid 
glands, are watery secretions.  
Mucous secretions are produced by the minor glands, whereas mixed serous 
and mucous secretions are produced by the sublingual and submandibular 
glands (Roth and Calmes 1981).   
The origins of  different salivary glands secreting saliva of differing composition 
can be understood by examining the glands histology, in which two types of 
acinar epithelial cells can be found; serous and mucous cells, which produce 
the corresponding secretion (Bailey 2013). The cells (stained pink here) are 
serous cells, whereas the white foamy cells are mucous secreting cells (Figure 
2). 
 
 
 
 
 
Figure 2 The histologic sections of canine salivary gland: the cells stained pink are 
serous cells, while the white, foamy cells are mucus-secreting cell (Bowen 2012) 
 
Salivary production is principally under the control of the autonomic nervous 
system and modifications of the nervous system can be indirectly monitored by 
observing alterations in saliva production (Denniss, Schneyer et al. 1978). At 
rest, without stimulation, there is a small continuous salivary flow, referred to as 
the basal unstimulated secretion, which is present in the form of a film that 
coats and covers, moisturises and provides lubrication to the oral tissues. 
Stimulated saliva is produced as a result of some mechanical, gustatory, 
olfactory, or pharmacological stimulus, and contributes approximately 80% to 
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90% of daily saliva production. A healthy individual’s mean daily salivary 
production is between 1 to 1.5 litres (Humphrey and Williamson 2001). 
 
1.02 Salivary flow 
 
In the unstimulated state, the parotid glands contribute 20% of the volume of 
saliva, whereas the submandibular contribute 65% and sublingual glands 7-8%. 
The minor salivary glands collectively contribute less than 10% (Humphrey and 
Williamson 2001). However in the stimulated state, saliva flow rates drastically 
change the percentage contributions from each gland, with the parotid gland 
contributing more than 50% of total salivary secretions (Edgar 1990), producing 
large volumes of serous secretions, in response to a stimulant. 
Salivary flow does not occur evenly throughout the mouth and there are 
variations in intra-oral flow, which is site specific due to the contribution and 
location of the salivary glands, with the mandibular lingual area being a site of 
high volume and the maxillary anterior glands and interproximal glands being 
sites of low volume flow (Edgar 1990). These sites of high and low volume flow 
have been referred to as "salivary highways and byways" (Moss 1995). The 
regional clearance rate of acid produced by bacteria is directly influenced by 
regional flow rates within the mouth (Dawes and Macpherson 1993).  
 
Measuring salivary flow is important because saliva is being studied extensively 
and used for risk assessment, diagnosis and monitoring disease progression. A 
variety of medical conditions and medications are associated with salivary gland 
dysfunction. Salivary gland hypofunction may result in a lack of salivary flow, 
which affects a person’s quality of life by causing difficulties in speaking, eating, 
swallowing and tasting (von Bultzingslowen, Sollecito et al. 2007).  Salivary 
gland hyperfunction may be attributed to medical conditions such as 
gastroeosophageal reflux disease, pancreatitis, liver disease, serotonin 
syndrome and oral ulcers.  
 
The salivary flow index is a measure which enables stimulated and 
unstimulated saliva flow to be classified as normal, low or very low (Tenovuo 
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and Lagerlof 1994). In adults, the normal unstimulated salivary flow rate ranges 
from 0.25 to 0.35 millilitres per minute (ml/min), with low rates in the range of 
0.1 to 0.25ml/min, whilst very low salivary flow is classified as less than 
0.1ml/min (Tenovuo and Lagerlof 1994; Axelsson 2000). The normal total 
stimulated salivary flow ranges from 1 to 3ml/min, low ranges from 0.7 to 1.0 
ml/min and very low salivary flow rate is characterised by less than 0.7 ml/min 
(Table 1). Despite this classification for the “normal” ranges given in the 
stimulated and unstimulated flow rates, there remain large variations. It is 
important that individual salivary flow is measured regularly as a base reference 
to avoid any variations associated throughout the day, in periods of stimulated 
and unstimulated states (Edgar 1990), and not classified and rated solely on 
one measurement, but rather measured a number of times to take account of 
this variation (Axelsson 2000). Ship et al  (Ship, Fox et al. 1991) suggested that, 
if an individual’s base rate has been established, then a 50% reduction in this 
rate should be considered as abnormal flow (Ship, Fox et al. 1991).  
 
 
Table 1 Salivary flow rates in stimulated and unstimulated conditions (Tenovuo and 
Lagerlof 1994) 
 
 
 Unstimulated Stimulated 
Normal flow rates 0.25 – 0.35 ml/min 1 – 3 ml/min 
Low flow rates 0.1 – 0.25 ml/min 0.7 – 1.0 ml/min 
Very-low flow rates < 0.1 ml/min < 0.7ml/min 
 
 
Clinical reports of dry lips, dryness of buccal mucosa, absence of saliva in 
response to gland palpation, and a high number of missing, decayed or filled 
teeth have been put forward as an easily assessed set of clinical parameters for 
identifying most individuals with salivary gland dysfunction affecting salivary 
flow (Navazesh, Christensen et al. 1992). However, in a study investigating the 
relationship between gingival and periodontal health and salivary gland function, 
results suggested that there was no consistent relationship between the parotid 
salivary flow rates and gingival bleeding, tartar, tooth loss or severity of tooth 
loss (Crow and Ship 1995). The authors concluded that periodontal disease 
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was not an indicator of decreased salivary flow. As salivary glands age the acini 
cells decrease in number and are replaced with adipose and fibrotic tissues 
(Atkinson and Baum 1992). Despite this finding the impact these changes have 
on salivary output is disputed in the literature. Although more than 50% of 
elderly subjects, aged 65 years and older report occasional dry-mouth (Nahri, 
Meurman et al. 1999), studies researching salivary flow rates related to age and 
gender in the stimulated and in the unstimulated state, showed that there were 
no changes in the rate of salivary flow in the stimulated state related to age 
(Heft and Baum 1984; Percival, Challacombe et al. 1994). A few studies have 
suggested no significant differences in salivary flow rates between males and 
females (Billings, Proskin et al. 1996; Ghezzi, Lange et al. 2000), although the 
majority of studies report that  flow rates are significantly higher in males 
(Percival, Challacombe et al. 1994; Bergdahl 2000; Fenoll-Palomares, Munoz-
Montagud et al. 2004). In a study examining healthy volunteers and salivary 
flow rate Fenoll-Palomares et al. (Fenoll-Palomares, Munoz-Montagud et al. 
2004), reported that the salivary flow rate in males was significantly greater 
(0.57 ml/min) than in females (0.42 ml/min). This may be explained by the 
variances in the sizes of salivary glands between males and females. Scott 
(Scott 1975) determined weighing of salivary glands and reported that male 
glands were larger than female glands by 50% on average. In a recent study by 
Smith et al (Smith, Boland et al. 2013), they collected whole stimulated saliva 
(which is a mixture of the secretions from all of the various salivary glands 
located in the mouth), in healthy volunteers in three age groups (young = 20-30; 
middle-aged = 40-50; older ≥ 70), and concluded that there was a significant 
reduction in saliva flow in the older participants when compared to the younger 
and middle-aged groups, but no difference between the young and middle-aged 
group (Smith, Boland et al. 2013). In their study there was no significant effect 
on gender or interaction of age and gender (Smith, Boland et al. 2013). 
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1.03 Circadian / Circannual rhythms in salivary flow rate 
 
There are daily and annual peaks and troughs in saliva flow, with low flow 
occurring during sleep, and high flow occurring during high stimulation periods, 
such as presentation of food stimuli and olfactory stimulus (Dawes 1974). There 
are also annual (circannual) variations in saliva flow, with peak flow observed 
during winter and low flow rates during the summer (Edgar 1990). In a study by 
Shannon (Shannon 1966), he examined circannual rhythms in salivary flow rate 
in 3868 military recruits in the San Antonio region of Texas and concluded the 
peak flow rate was in December to January, when the mean temperature 
was100C and the minimum was in June to August, when the mean temperature 
was 290C. The lower flow rate was attributed by Shannon to the possible 
dehydration of recruits during the summer months (Shannon 1966). Kavanagh 
et al. (Kavanagh, O'Mullane et al. 1998) collected unstimulated saliva from 43 
adolescents, on a monthly basis from September to June in North Wales. In 
their study they did not attempt to fit a rhythm to their data, but did report 
statistically significant higher salivary flow rates (0.87 ml/min) during the winter 
months than in the summer months (0.52 ml/min).  
 
In a study by Kariyawasam and Dawes (Kariyawasam and Dawes 2005), 
examining unstimulated salivary flow rates in 46 healthy students. They 
collected unstimulated saliva during set times each month over a 12-month 
period and concluded that even a small change in ambient temperature 
(approximately 20C), may  be enough to influence the unstimulated salivary flow 
rate (Kariyawasam and Dawes 2005). 
 
1.04 Measuring salivary flow 
 
Accurate measurements of salivary flow (sialometry) are required in clinical and 
experimental practice. In 1910, Carlson and Crittenden devised a two-
chambered metal cup with two outlet tubes, one connected to a vacuum, which 
held the cup in place and the other connected to a collection receptacle 
(Stephen and Spiers 2012). This basic design has since been updated by 
Lashley, who subsequently has been credited with the original design now 
known as a ‘Lashley’ cup (Percival, Challacombe et al. 1994) (figure 3).  
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The design is made-up of two chambers, an inner and outer chamber, whereby 
the inner chamber is placed over the parotid duct and suction applied to the 
outer chamber to hold it in place (Stephen and Spiers 2012). 
 
 
 
 
 
 
 
Figure 3 Method of saliva collection using a ‘Lashley’ cup illustration from 
http://news.ifr.ac.uk/wp-content/uploads/2012/01/AnthonyAshSETforBritain.pdf 
 
Submandibular saliva collection can be collected using a design first described 
by Truelove et al. (Wolff, Begleiter et al. 1997). This is a ‘V’ shaped collector 
with two outer suction chambers and an inner collection chamber (Stephen and 
Spiers 2012). 
 
In 1955, Schneyer described a ‘segregator’ device, which enables secretions 
from the right and left sublingual glands to be collected separately from the 
submandibular glands. This device has since been modified and does not 
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require suction to hold it in place, as they are individually made to fit each 
subject (Stephen and Spiers 2012). Measurements of the other major and minor 
salivary glands are not performed routinely, due to their relative inaccessibility. 
 
Methods for measuring saliva are usually based on (i) draining the saliva 
collected into a receptacle, known as the ‘draining’ method, (ii) collection by 
aspiration, known as the ‘spitting’ method or (iii) measuring the increase in 
weight of an absorbent material that is chewed or placed in the mouth, known 
as the ‘swab’ method. A frequent and easy means of collection used in the 
swab method is the absorption of saliva by rolls of cotton. The weight of these 
cotton rolls is established before and after measurement. This method of 
collection has proved to be valid, reliable and sensitive (White 2007). However, 
some adverse effects of this procedure make it less desirable, such that it is 
always necessary to interrupt the experimental procedure by inserting and 
removing the dental rolls and the pressure of the rolls on the salivary glands 
may induce a salivary response, thereby affecting the experimental response 
(Nederkoorn, Wit et al. 2001). Suskind and Tilton (Suskind and Tilton 2002) 
however found that their patients either continually gagged or tried to swallow 
the rolls. Another technique is measuring the frequency of swallows, determined 
by counting peaks in the electromyographic activity of the diagastric muscle. 
This technique allows effects of timing on salivary response to be monitored 
and although it does not directly measure salivary flow, it does measure 
response to a given stimuli (Nederkoorn, Wit et al. 2001). Their study concluded 
subjects swallowed significantly more (F 1, 12 = 50·1, p<0·001), after being 
presented with a stimulus (tasting lemon juice) than when compared to a control 
(tasting still water) (Nederkoorn, Smulders et al. 1999). 
 
Experiments have shown that the data collected using this technique correlated 
well with that of cotton rolls, providing that some precautions are taken against 
artificial movements, such as coughing (Nederkoorn, Smulders et al. 1999).  
 
An alternative method for measuring salivation is via electrophysiological 
measurement of the activity of the parotid gland (Davis, Bauslaugh et al. 1996). 
In this procedure a recording electrode is placed on the cheek to lie over the 
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parotid gland and extends to the upper cheek, the joint action of the secretory 
and muscle cells in the gland produces a change in electrical potential over the 
gland, which can be recorded at the skin’s surface. A peak in activity in 
response to lemon juice was reported, with a latency of 2.5 – 3 seconds, the 
highest peak around 3.5 – 7 seconds, and recovery between 13 – 25 seconds, 
when compared to a water control (Davis, Bauslaugh et al. 1996). 
 
Nederkoorn (Nederkoorn, Wit et al. 2001) devised an experiment to test the 
three methods of collection (cotton rolls, electromyographic activity of the 
diagastric muscle and electrophysiological measurement of the parotid gland) 
and compared the results of each collection method.  They presented four 
stimuli to 48 subjects in succession and concluded that electrophysiological 
measurement of activity of the parotid gland is not a reliable or valid method of 
measuring salivary response to stimulation with different foods. However, both 
the dental roll (swab) method and swallowing technique did differentiate 
between the stimuli (Nederkoorn, Wit et al. 2001).  
 
Measurement of unstimulated saliva flow rates using the spitting or draining 
methods are thought to be unreliable in children of younger than 10 years of 
age, as these methods depend on the child being fully co-operative, when they  
have to sit still for some time (Ben-Aryeh, Fisher et al. 1990). Measuring saliva 
flow in young children or in those with physical or cognitive impairment can be 
challenging using the swab method, as it requires the individual to be compliant 
and remain in a static position. Measuring flow rates in these children is usually 
performed by measuring the amount of saliva spill (drooling) or counting the 
number of bibs saturated with saliva. Volumetric measurements to obtain 
absolute quantification of saliva spill or intra-oral pooling, using external 
collection devices or intra-oral suction hooks can assist and guide treatment 
and assess treatment outcomes. Counting the number of bibs changed in a 
day, despite being an objective quantitative measure, relies on care-giver 
observation and their judgement as to when a bib is sufficiently soaked to 
require changing. 
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An accurate evaluation of drooling is difficult because of variations between 
individuals, but also because drooling fluctuates throughout the day and 
between activities. Several systems have been devised and used by authors, 
either in isolation or in combination. Measurements can be objective and 
quantitative or subjective and qualitative. 
 
Wilkie and Brody (Wilkie and Brody 1977) provided a classification of efficacy of 
therapeutic procedures for drooling into excellent, good, fair and poor. Most 
popular scales categorise drooling into dry, mild, moderate or frequent (Scully, 
Limeres et al. 2009). The clinical evaluation of drooling severity and frequency 
is difficult because of within-subject fluctuation during the day and a large 
between-subject variation. Several systems have been used and advocated for 
assessment of the extent of drooling. Since its introduction, various 
modifications of the Drooling Quotient (DQ) have been used (Rapp 1980; 
Jongerius, Van Limbeek et al. 2004). The Drooling Quotient is a validated, 
semi-quantitative, direct observational method; the presence or absence of 
drooling is assessed every 15 seconds during two 10-minute periods (40 
observations in 10 minutes), separated by a 60-minute break (Rapp 1980; 
Jongerius, Van Limbeek et al. 2004). Although this is a validated method it may 
be very disruptive to an individual’s routine and therefore unsuitable to use in 
certain environments. Furthermore it would need to take in to account 
stimulated and unstimulated periods of stimulation and record time at which it 
was rated. 
 
DQ (%) = No. of drooling episodes / No. of observations in 10 mins x 100  
 
Rating scales such as the Teacher Drooling Scale (TDS) (Camp-Bruno, 
Winsberg et al. 1989) have been designed to assess drooling severity and 
frequency. The TDS is a quantitative scale for periodic assessment of drooling 
(Nickel and Desch 2000)  and rates the frequency of drooling on a score of 1 to 
5 (Table 2). The difficulty with using this scale is the variance in inter-rater 
reliability and without any pre-training on the use of the scale, one rater may 
score an individual as ‘infrequent drooling’ and another rater score the same 
individual as ‘occasional drooling’, thus leading to inconsistencies in scoring in 
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the scale. This scale does not separate severity and frequency of drooling and 
may not be considered sensitive enough, as it does not explain all possible 
variations, such as an individual who may infrequently drool, but when they do 
may do so in large quantities, but this is not a given option within the scale.  
 
 
Table 2  The Teacher Drooling Scale (Camp-Bruno, Winsberg et al. 1989) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thomas-Stonell and Greenberg (Thomas-Stonell and Greenberg 1988), 
described a drooling scale, using severity and frequency of drooling. The 
severity of drooling is rated on a scale of 1 to 5, with 1 being dry and 5, profuse 
wetness, whilst frequency is rated on a 1 to 4 scale, ranging from 1, never to 4, 
constant (Table 3).  
 
Table 3 Drooling Severity and Frequency Rating Scale (Thomas-Stonell and Greenberg 
1988) 
 
 
Drooling severity 
1. Dry – never drools 
2. Mild – wet lips only 
3. Moderate – wet lips and chin 
4. Severe – damp clothing 
5. Profuse – damp clothing, hands and surrounding objects 
 
Drooling frequency 
1. Never – no drooling 
2. Occasionally 
3. Frequently 
4. Constantly 
 
1. No drooling 
2. Infrequent drooling, small amount 
3. Occasional drooling, on and off all day 
4. Frequent drooling, but not profusely 
5. Constant drooling, always wet 
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Another method of measuring drooling is the use of  subjective questionnaires 
to record the views of the carer or patient (Van der Berg, Didden et al. 2007). If 
designed carefully in relation to content and construct validity, these can be 
sensitive to reflect the concerns of the patient and / or the carer and can assist 
in measuring clinical change. A valid and reliable questionnaire is the Drooling 
Impact Scale (Reid, Johnson et al. 2010) (Table 4) , which is composed of 10 
items, rated on a scale of 1 to 10, which is completed by either the patient, their 
carer or someone who knows the individual well. The Drooling Impact Scale 
highlights the changes in drooling as perceived by the person completing the 
questionnaire. 
Reid et al. (Reid, Johnson et al. 2010) commented that objective measures may 
be invasive, unsuitable and sometimes inaccurate and that the main aim of 
reducing drooling is to improve quality of life. 
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Table  4  Drooling Impact Scale (Reid, Johnson et al. 2010) 
 
 
  OVER THE PAST WEEK 
 
  
  1. How frequently did your child dribble? 
   
  Not at all   1 2 3 4 5 6 7 8 9 10   Constantly 
 
  2. How severe was the drooling? 
 
  Remained dry   1 2 3 4 5 6 7 8 9 10   Profuse 
 
 
  3. How many times a day did you have to change bibs or clothing due to drooling? 
 
  Once or not at all  1 2 3 4 5 6 7 8 9 10   10 or more 
 
 
  4. How offensive was the smell of the saliva on your child? 
 
  Not offensive   1 2 3 4 5 6 7 8 9 10   Very offensive 
 
 
  5. How much skin irritation has your child had due to drooling? 
 
  None    1 2 3 4 5 6 7 8 9 10   Severe rash 
 
  6. How frequently did your child’s mouth need wiping? 
 
 Not at all   1 2 3 4 5 6 7 8 9 10   All the time 
 
 
  7. How embarrassed did your child seem to be about his/her dribbling? 
 
  Not at all   1 2 3 4 5 6 7 8 9 10   Very embarrassed 
 
  8. How much do you have to wipe or clean saliva from household items, e.g. toys, furniture, 
computers? 
 
  Not at all   1 2 3 4 5 6 7 8 9 10   All the time 
 
 
  9. To what extent did your child’s drooling affect his or her life? 
 
  Not at all   1 2 3 4 5 6 7 8 9 10   Greatly 
  
 10. To what extent did your child’s dribbling affect you and your family’s life?  
   
   Not at all   1 2 3 4 5 6 7 8 9 10   Greatly 
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There are also two specific assessments available to measure drooling and 
drooling related discomfort in patients who have Parkinson’s Disease; found 
within subsection II, activities of daily living, number 6, of the Unified 
Parkinson’s Disease Rating Scale (UPDRS), (Goetz, Tilley et al. 2008) (Table 
5). This scale cannot be rated in isolation, but only as part of the wider rating 
system and within this population.  
 
Table 5 Unified Parkinson’s Disease Rating Scale (UPDRS), (Goetz, Tilley et al. 2008) 
 
 
 
II. ACTIVITIES OF DAILY LIVING - No. 6 Salivation 
 
0 = Normal.  
1 = Slight but definite excess of saliva in mouth; may have night-time drooling.  
2 = Moderately excessive saliva; may have minimal drooling.  
3 = Marked excess of saliva with some drooling.  
4 = Marked drooling, requires constant tissue or handkerchief. 
 
 
The Visual Analogue scale (VAS), a semi-quantitative scale, is usually given to 
parents/primary caregivers. Scales of exactly 10cm without visible subdivisions, 
on which the average degree of drooling is marked, are given. A score of ten 
indicates severe drooling and a score of zero (0) indicates no drooling. An 
independent person then scores the VAS with a ruler in millimetres, resulting in 
a number ranging from 0 to 100 (Jongerius, Rotteveel et al. 2004). 
 
In 2006, Perez et al (Perez, Piran et al. 2007) carried out a study to develop and 
validate a clinical scale for subjective evaluation of sialorrhea (drooling) in 
Parkinson’s disease; the Sialorrhea Clinical Scale for Parkinson’s disease (SCS 
– PD), (Perez, Piran et al. 2007). In Phase I of their study they established 
internal consistency and in phase II of their study they established scale validity. 
In their study the SCS-PD scores showed significant correlation with saliva 
volume and with total Unified Parkinson's Disease Rating Scale (UPDRS) 
scores. Sialorrhoea or drooling is known to affect 75–80 per cent of patients 
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with Parkinson’s Disease (Mancini, Zangaglia et al. 2003). It has long been 
thought this was due to hypersecretion of saliva as a result of autonomic 
dysfunction. However, more recent research has suggested that, far from 
producing excess saliva, people with Parkinson’s Disease actually tend to 
produce less saliva than matched controls (Bagheri, Damase-Michel et al. 1999; 
Proulx, de Courval et al. 2005). These studies suggest that, due to delayed 
swallowing disorders also common in Parkinson’s Disease, patients are unable 
to swallow all their saliva as it is being produced; this then leads to an 
accumulation of saliva and the apparent drooling symptoms, due to weak oral 
musculature. 
 
A variety of subjective and objective methods for assessment of excessive 
saliva and subsequent drooling have been described (Sochaniwskyj 1982). 
Assessment of the severity of drooling and its impact on quality of life for the 
patient and their carers is important as it helps establish a prognosis and to 
decide the therapeutic regimen.  
 
1.05 Saliva Composition 
 
Salivary fluid consists of approximately 99% water, containing a variety of 
electrolytes and proteins, in the form of enzymes (Young and Van Lennep 
1979). Saliva is normally a colourless fluid with a pH value of approximately 
6.64, but this varies depending on the level of carbon dioxide (CO2) in the blood 
(Guyton 1996). When blood CO2 level is raised, a higher proportion of CO2 is 
transferred to the saliva and therefore salivary pH decreases. Conversely, if 
blood CO2 levels fall, the salivary pH increases, as a result of minimal transfer 
of blood CO2 to the saliva (Chicharro, Lucia et al. 1988). The two additional 
gases present within saliva are oxygen (O2) and Nitrogen (N2). Other 
components (of saliva) include maltese, serum albumin, urea, uric acid, 
creatinine, mucin, ascorbic acid (vitamin C), amino acids, lactate and hormones 
such as testosterone and cortisol (Chicharro, Lucia et al. 1988). 
 
‘Total’ or ‘whole’ saliva describes the composite mixture of fluids from the 
salivary glands, oral mucosa and the mucous of the nasal cavity and pharynx. It 
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also contains blood cells and traces of medications or chemical products 
(Humphrey and Williamson 2001). 
 
The mean concentrations of the main substances found in saliva are shown in 
Table 6. The salivary flow rate can significantly alter some of these values in 
that as it increases, sodium and bicarbonate levels and pH rise, while 
potassium, calcium, phosphate, chloride, urea and protein levels fall. Because 
salivary components are considered multifunctional and change depending on 
the intraoral environment, the development of an effective artificial saliva is a 
difficult task (Levine 1993). This is particularly important when considering 
patients who experience reported symptoms of ‘dry-mouth’ and prescribing 
artificial saliva, which cannot react to chemical changes intra-orally and help 
maintain chemical balance.   
 
Saliva provides an easily available non-invasive diagnostic medium for a rapidly 
widening range of diseases and clinical situations (Mandel 1990). Saliva is a 
defensive factor in the mouth, and a reduction in its flow rate affects oral and 
dental health. A reduced or increased salivary flow may cause a variety of 
symptoms and so the establishment of patients’ saliva flow is of primary 
importance.  
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Table  6 Saliva Composition (Rice 1984) 
 
 
       Salivary Gland 
      Parotid  Submandibular  
  
Substance     mEq*/ Litre   mEq/ Litre 
  
 
Potassium        20.0    17.0 
Sodium      23.0    21.0 
Chloride      23.0    20.0 
Bicarbonate      20.0    18.0 
Calcium      2.0    3.6 
Magnesium      0.2    0.3 
Phosphate      6.0    4.5 
mg/dl**    mg/dl 
 
Urea       15.0   7.0 
Proteins (mucins, MG1 & MG2)   250.0   150.0 
Ammonia       0.3   0.2 
Uric acid      3.0   2.0 
Lysozymes     2.3   1.5 
Glucose       <1.0   <1.0 
IgA       4.0   2.0 
Amylase      0.1   0.0025 
Cholesterol     <1.0   unknown 
pH       5.92   5.73 
 
*mEq – molar equivalent; **milligrams per decilitre 
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1.1 Saliva Functions 
 
The functions of saliva can be organised into five main actions that are 
necessary for the maintenance of  oral health; (1) lubrication, binding and 
protection, (2) buffering action, (3) maintenance of tooth integrity, (4) 
antibacterial activity, and (5) taste and digestion (Moss 1995).  
 
1.11 Lubrication, binding and protection 
 
Saliva forms a covering that lubricates and protects the oral tissues against 
irritating agents (Stack and Papas 2001). These irritants may include, 
proteolytic and hydrolytic enzymes produced in plaque, potential carcinogens 
from smoking and exogenous chemicals and drying out of the mouth from 
mouth breathing (Grant, Stern et al. 1988). This effect of lubrication occurs due 
to the presence of mucins, which are proteins with high carbohydrate content, 
excreted from minor salivary glands, submandibular and sublingual glands. 
Mucins act as lubricants, providing protection against dehydration, and 
maintaining the elasticity and viscosity of saliva. These complex protein 
molecules are formed from polypeptide chains that stick together and have 
properties of low solubility, high viscosity, high elasticity and strong 
adhesiveness. In addition, the lubricant effects of these proteins also aid in 
mastication, speech and swallowing (Humphrey and Williamson 2001; 
Amerongen and Veerman 2002). The mucous in saliva is highly effective in 
binding masticated food into a slippery bolus that can then easily be passed 
through the oesophagus, without causing damage to the mucosa. Saliva also 
coats the oral cavity and oesophagus, and food never directly touches the 
epithelial cells of these tissues (Bailey 2013). 
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1.12 Buffering action  
 
Saliva acts as a buffering and clearance system through the following 
components: bicarbonate, phosphate, urea and amphoteric proteins and 
enzymes. Bicarbonate is the most important buffering system and it diffuses into 
plaque and acts to neutralise acids (Humphrey and Williamson 2001). In 
addition it generates ammonia to form amines, which also acts as a buffer by 
neutralising acids (Mandel 1989). Urea another buffer present in saliva, 
releases ammonia after being metabolised by plaque and thus increases the pH 
of plaque (Johnson 1987). In summary saliva buffers and protects the mouth in 
two ways: 1) It prevents the colonisation of potentially pathogenic 
microorganisms by preventing the optimal environmental conditions that they 
require to thrive (Nagler 2004); 2) Saliva neutralises and cleans the acids 
produced by microorganisms, thereby preventing enamel erosion (Almeida, 
Gregio et al. 2008). The buffering action of saliva works most efficiently at times 
of stimulated high flow rates, but is almost ineffective during periods of low flow, 
with unstimulated saliva (Edgar 1990). The pH of saliva is not necessarily an 
important measure for buffering action on caries, as it changes depending on 
the pH of plaque. (Roth and Calmes 1981). The resting pH of plaque, after 
approximately 2 to 2.5 hours after consumption of carbohydrates is 6 to 7 
(Edgar 1990). The pH rises during the first 5 minutes of food intake. The pH 
then falls to its lowest level, to 6.1 or lower, approximately 15 minutes after food 
intake, unless there is further consumption of fermentable carbohydrates, the 
pH of plaque then gradually returns to its resting value of 6 to 7 (Edgar 1976). 
 
1.13 Maintenance of tooth integrity 
 
Saliva has a fundamental role in sustaining the physical-chemical integrity of 
tooth enamel, by regulating re-mineralisation and demineralisation. Tooth 
enamel demineralisation is triggered by an increase in the acidity of bacterial 
plaque, which initiates the caries process (Fejerskov and Kidd 2008). 
Demineralisation occurs when acid diffuses through enamel and the pellicle. 
The pellicle is a layer of salivary glyco-proteins that forms on the tooth surface, 
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which protects against caries, as it slows the diffusion of calcium and phosphate 
ions away from the tooth surface. 
 Crystalline dissolution occurs at a pH of 5 to 5.5, which is the critical pH range 
for the development of caries (Edgar 1990). The main factors controlling the 
stability of enamel are the high salivary concentrations of calcium, phosphate 
and fluoride, and the normal salivary pH value of approximately 6.6 (Axelsson 
2000). Statherin, a salivary peptide, aids the stabilisation of calcium and 
phosphate solutions and serves as a lubricant to protect the tooth from wear 
(Dowd 1999). The presence of fluoride in saliva, even at low levels is essential 
for stabilising dental minerals and is dependent on fluoride in drinking water and 
in other sources, such as pastes, liquids or powders used to help maintain good 
oral hygiene (dentifrices) and other products used in the prevention of tooth 
decay (caries). It has also been identified that fluoride reduces the production of 
acids in the saliva and speeds up crystal precipitation, forming a coating more 
resistant to caries than the original tooth structure (Humphrey and Williamson 
2001). The presence of fluoride in saliva speeds up crystal precipitation, forming 
a fluorapatite-like coating more resistant to caries than the original tooth 
structure. It has been suggested that small amounts of demineralisation are 
therefore advantageous for the tooth (Edgar 1990). 
 
1.14 Antibacterial activity 
 
The salivary glands secrete fluid containing immunologic and non-immunologic 
agents for the protection of teeth and mucosal surfaces. Immunologic contents 
of saliva include immunoglobulin A (IgA), immunoglobulin G (IgG), and 
immunoglobulin M (IgM). Non-immunologic contents of saliva include selected 
proteins, mucins, peptides and enzymes. Secretory IgA is the largest 
immunologic constituent of saliva and is produced by plasma cells in connective 
tissues and is transported and located within the duct cells of both major and 
minor salivary glands. IgA whilst active on the mucosal surface, also works to 
neutralise viruses, acts as an antibody to bacterial antigens by isolating and 
clumping harmful bacteria, and inhibits their adherence to oral tissue (Dowd 
1999). MG2, the low molecular-weight mucin and IgA bind mucosal pathogens 
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with greater affect, than either MG2 or IgA alone (Biesbrock and Levine 1991). 
Non-immunologic antibacterial contents such as proteins, mucins, peptides and 
enzymes, all products of acinar gland cells, help protect the teeth against 
chemical, physical and micro-organism attack (Rudney 1995). Lactoferrin is a 
protein produced in the salivary ducts; it acts to binds ferric iron in saliva and 
thereby makes ferric iron unavailable as a food source for microbes, which 
require iron to work successfully (Roth and Calmes 1981). This process of 
starving bacteria of vital nutrients is called ‘nutritional immunity’ (Mandel 1976). 
Other proteins such as glycoproteins, statherins, agglutinins, histadine-rich 
proteins, and proline-rich proteins work to aggregate bacteria and ‘clump’ them 
together, thereby reducing the ability of bacteria to adhere to hard or soft tissue 
of the intraoral surfaces and thus controls bacterial, fungal and viral colonisation 
(Mandel 1989). These proteins assist in reducing bacterial growth and protect 
the teeth.  
 
1.15 Taste and digestion 
 
The chemical substance responsible for taste is released in the mouth and 
comes in to contact with a nerve cell, which activates the cell by changing 
specific proteins in the sensory cell (Institute for Quality and Efficiency in Health 
Care 2012). This change causes the sensory cell to transmit messenger 
substances, which then activate further nerve cells. These nerve cells then pass 
on information for a particular perception of flavour on to the brain (Institute for 
Quality and Efficiency in Health Care 2012). Numerous wart-like bumps on the 
mucous membrane of the tongue are where the substance producing taste is 
transformed into nerve signals. These bumps are called taste papillae and 
contain many sensory cells including taste buds. Most of the taste buds are on 
the tongue, but there are also cells that detect taste in the back of the throat, 
epiglottis, the nasal cavity and in the upper part of the oesophagus (Institute for 
Quality and Efficiency in Health Care 2012). Based on the information that is 
transported from the tongue to the brain, there are thought to be at least five 
basic qualities of taste. The basic tastes are sweet, sour, salty, bitter and 
savoury all of which can be sensed by all parts of the tongue (Institute for 
Quality and Efficiency in Health Care 2012).  
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Saliva is responsible for the initial digestion of starch and aids in the formation 
of the food bolus (Ten Cate 1998). This occurs primarily because of the 
presence of the digestive enzyme amylase, a major component of parotid 
saliva, which initially begins the breakdown of starch (Mandel 1987; Moss 
1995). The involvement of saliva in the break-down of starch is limited as most 
of the digestion of starch results from pancreatic amylase, and not salivary 
amylase (Grant, Stern et al. 1988). The presence of amylase is thought to be a 
good indicator of properly functioning salivary glands (Enberg, Alho et al. 2001), 
contributing 40% to 50% of the total salivary enzyme produced by the glands. 
Salivary enzymes also initiate the digestion of fats (Valdez and Fox 1991). 
 
1.2 Xerostomia, drooling and its management 
 
Saliva is required in order for the mouth to be able to work properly. Saliva 
keeps the mouth moist, and it helps to break down food and helps with 
swallowing. It is constantly present around the mouth and teeth, fighting decay 
and helping to keep the teeth clean. Dry mouth or ‘xerostomia' is a condition in 
which individuals report a feeling of dry-mouth. 
Drooling, also known as ptyalism can be defined as salivary incontinence or the 
spillage of saliva over the lower lip. It may reflect a disturbance of the oral 
phase of deglutition which is associated with inefficient, uncoordinated 
swallowing and poorly synchronised lip closure. It is frequently associated with 
abnormal tone of the muscles that open the mouth. Individuals who drool have 
difficulty managing normal salivary flow; sialorrhea, which some use 
interchangeably with drooling, indicates an increase in salivary flow, which can 
be due to inflammation in the oral cavity, such as teething, dental caries, or due 
to medications such as antiepileptic or antipsychotic drugs, alternatively due to 
certain conditions, such as gastroeosophageal reflux, which can all also lead to 
drooling. In either case a feeling of dry-mouth or drooling can be distressing for 
individuals. 
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1.21 Xerostomia  
 
Xerostomia is a reported complaint of feelings of dry mouth and is highly 
prevalent in the elderly population (Billings, Proskin et al. 1996). Its prevalence 
ranging from 10% to 38% (O'Grady 1990; Locker 1995). Xerostomia can occur 
due to severe reduction in salivary flow (Sreebny 1987), even where there 
appears to be normal salivary gland function (Fox, van der Ven et al. 1985; 
Sreebny 1987). The most common reason for xerostomia is Sjogren’s 
syndrome (van der Berg, Pijpe et al. 2007); a condition where the body's 
immune system malfunctions and begins to attack healthy tissue (an 
autoimmune condition). In Sjogren's syndrome the immune system usually 
targets the tear and saliva glands, leading to a reduction in the production of 
saliva and tears (van der Berg, Pijpe et al. 2007), which results in the perception 
of dry-mouth. In the past, complaints of dry mouth were often thought to be as a 
result of aging. However it is now generally accepted that salivary function is 
preserved throughout life in healthy individuals (Matear and Barbaro 2005) and 
aging is not an associated factor with xerostomia. However, the use of 
medications or presence of systemic disease (Fox, van der Ven et al. 1985) can 
be a causal factor and explain the reason for the salivary hypofunction in older 
individuals. 
 
 
Cystic fibrosis affects all of the exocrine glands to varying degrees (Ferguson 
1999). The most noticeable change is that in the composition of saliva, in which 
there are reported changes in elevation in calcium (Ca) and proteins which 
reduce the flow rate of minor salivary glands to virtually zero. Normally the flow 
rate of a single labial gland is 0.1 µl/min (microlitres per minute) (Ferguson 
1999). This phenomenon can be used as a diagnostic test by measuring the 
flow from labial glands of the lower lip (Mandel 1990). The sodium (Na) and 
potassium (K) concentrations of saliva are markedly affected by corticosteroids, 
especially aldosterone. The Na / K ratio of stimulated whole saliva can be used 
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in diagnosing and monitoring ‘Cushing’s syndrome’ and ‘Addison’s disease’ 
(Mandel 1990). Investigators have also demonstrated the diagnostic value of Na 
/ K ratio in primary aldosteronism, a type of hormonal disorder that  leads to 
high blood pressure (Wotman, Goodwin et al. 1969). In several clinical settings 
salivary analysis has provided valuable diagnostic information. This includes 
digitalis toxicity, affective disorders, stomatitis in chemotherapy, specific 
secretory IgA deficiency, smoking, ovulation time, relation of dietary factors to 
cancer and chronic pain syndromes (Mandel 1990). 
 
Another frequent cause of dry mouth is medication (Nahri 1994), which can 
affect aspects of salivation and saliva flow rate. Some of the medications 
associated with dry mouth include anti-convulsion, anti-hypertensive, anti-
psychotic, anti-depressant, anti-Parkinsonian and sedative drugs (Laclede 
1999); the intake of these drugs have a dryness-inducing (xerogenic) effect. A 
number of diseases, conditions and treatments can also cause dry mouth, such 
as diabetes, Parkinson’s Disease, thyroid disorders and head and neck 
radiation therapy (Laclede 1999), due to the symptoms they produce, such as 
dehydration in diabetes and excessive sweating as sometimes seen in 
individuals who have  an overactive thyroid gland (Laclede 1999). 
 
Symptoms of dry mouth may include an itching or burning sensation of the oral 
mucosa and the tongue, difficulties with speech, eating and swallowing 
(Sreebny and Valdini 1988), as well as taste impairments (Spielman 1990). 
Other causes of dry mouth include wearing dentures and malnutrition (Laclede 
1999). The condition of xerostomia is known to seriously damage the quality of 
life among the affected individuals (Gerdin, Einarson et al. 2005). 
 
Because saliva plays a vital role in lubricating and protecting the mouth from 
infection, it has a critical role in daily oral functioning. Without adequate 
amounts of saliva, normal oral function is compromised. Individuals who present 
with xerostomia can be highly prone to the development of dental decay, since 
saliva has buffering properties which increase the intra-oral pH level to a neutral 
value, assisting in the reduction of dental decay.  
30 
 
 
 
1.22 Drooling 
 
Currently there is no generally accepted existing definition for the term 
‘drooling’. Drooling is also sometimes described as ‘dribbling’, or ‘saliva loss’. It 
is important to distinguish the differences between anterior and posterior 
drooling in relation to aetiology and clinical impact (Reddihough, Erasmus et al. 
2010). Saliva spilled from the mouth, which can be visibly seen, is known as 
anterior drooling (Reddihough, Erasmus et al. 2010). Posterior drooling is where 
saliva is spilled through the faucial isthmus (Reddihough, Erasmus et al. 2010), 
leading to a risk of aspiration (Smith 2008). Posterior drooling occurs in 
individuals who present with oropharyngeal dysphagia (Jongerius, Van Hulst et 
al. 2005).  Blasco’s definition of drooling is often used, describing it as ‘the 
unintentional loss of saliva and contents from the mouth’, (Blasco and Allaire 
1992). This is not due to excessive saliva production (hypersalivation or 
sialorrhea), but is more commonly a problem in coordinating the control 
mechanisms of the oral-facial and palatolingual muscles, associated with a 
neurological disturbance (Blasco and Allaire 1992). Studies have shown that 
patients who produce less saliva (e.g. patients with Parkinson’s Disease), 
(Bagheri, Damase-Michel et al. 1999; Proulx, de Courval et al. 2005) can also 
have difficulties with drooling. Impairments in neurological control leads to 
difficulties with the swallowing function; this results in excessive pooling of 
saliva in the anterior part of the oral cavity and subsequently causes 
unintentional loss of saliva from the mouth, due to impaired lip-seal. Drooling is 
a normal finding in healthy infants, but usually ceases by about the age of 18 
months as oral motor and sensory ability improves. Drooling is considered as 
abnormal if it persists beyond the age of 4 years (Crysdale and White 1989).   
 
Anterior drooling (Reddihough, Erasmus et al. 2010) can be extremely 
distressing for patients and their caregivers, with the possibility of social 
rejection, continuous wetness of clothing and physical distress adding to the 
special care and attention they require. Anterior drooling has been found to be a 
significant  impediment to socialisation, building interpersonal relationships and 
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integrating into society for individuals with disabilities (Tahmassebi and Curzon 
2003). The presence of pooled saliva may cause articulatory imprecision, 
resulting in communication breakdown. In addition there may be associated 
posterior drooling (Reddihough, Erasmus et al. 2010), due to an inability to 
swallow effectively leading to an increased risk of aspiration pneumonia.  
  
1.23 Prevalence of drooling 
 
The most common cause of drooling in children is cerebral palsy. It has been 
estimated that drooling abnormally persists in 10-38% of individuals with 
cerebral palsy (Johnson and Scott 1993), although it has been reported to 
exceed 50% (Tahmassebi and Curzon 2003). In a study by Morales et al. 
(Morales, Grollmus et al. 2008), 50 individuals with Cerebral Palsy comprising 
of both children and adults were evaluated and it was concluded that 58 % 
presented with drooling. In adults, Parkinson’s disease is the most common 
cause. Approximately 45% of Parkinsonian patients complain about drooling, 
which in 15% of cases is detected in the early phases of the disease (Volonte, 
Porta et al. 2002). However a study by Molloy suggested that drooling occurs in 
70-80% of patients with Parkinson’s disease (Molloy 2007). Drooling is also 
commonly associated with other neurological conditions such as stroke, 
pseudobulbar palsy, or bulbar palsy, where it is seen in almost 30% of patients 
(Sullivan, Lambert et al. 2000). 
 
1.24 Drooling and reduced level of consciousness 
 
Teasdale and Jennett (Teasdale and Jennett 1974) published the Glasgow 
Coma Scale (GCS) an aid in the clinical assessment of post-traumatic 
unconsciousness. It was devised as a formal scheme to overcome the 
ambiguities that arose when information about comatose patients was 
presented and groups of patients compared.  The GCS evaluates three 
components: eye (E), verbal (V) and motor (M) responses to external stimuli 
(Teasdale and Jennett 1974). The scale consists of 15 points and is used to 
predict the progression of a person’s condition (figure 4). Clinicians use the 
scale to rate the best eye opening response, the best verbal response, and the 
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best motor response an individual makes. The final GCS score is the sum of 
these numbers.  
 
Best Eye Response (4) 
1. No eye opening 
2. Eye opening to pain 
3. Eye opening to verbal command 
4. Eyes open spontaneously 
Best Verbal Response (5) 
1. No verbal response 
2. Incomprehensible sounds 
3. Inappropriate words 
4. Confused 
5. Orientated 
Best Motor Response (6) 
1. No motor response 
2. Extension to pain 
3. Flexion to pain 
4. Withdrawal from pain 
5. Localising pain 
6. Obeys Commands 
Figure 4 Glasgow Coma Scale (Teasdale and Jennett 1974), illustration from 
http://www.trauma.org/archive/scores/gcs.html  
 
A GCS of 8 or less indicates severe injury, one of 9-12 a moderate injury, and a 
GCS score of 13-15 is obtained when the injury is minor. The lowest score for 
each category is 1; therefore the lowest score is 3, where there is no response 
to pain, no verbalisation and no eye opening, sometimes termed as vegetative 
state (McPherson and Stephens 2012). Patients with a reduced conscious level 
are unable to clear their own secretions and cannot protect their own airway. A 
Glasgow Coma Scale of 8/15 or below is often considered the threshold at 
which intubation is necessary (McPherson and Stephens 2012). Patients with 
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reduced conscious level are at risk of aspiration (McPherson and Stephens 
2012). 
 
 
1.25 The management of drooling 
 
Management of excess pooled saliva, which may result in drooling, ranges from 
the conservative, such as postural changes, oral motor therapy and 
biofeedback, to the more aggressive such as medication, radiation and surgical 
intervention. This section investigates and describes the different ways of 
managing drooling and the efficacy of these techniques. 
 
Oral motor therapy  
 
Oral motor training can be used to attempt to normalise muscle tone, stabilise 
the positions of the body, head and jaw, reduce tongue thrust, increase lip 
closure and promote swallowing, but can be time-consuming, and requires 
motivation. Harris and Dignam (Harris and Dignam 1980) showed that through 
training programmes, mirrors, games and positive reinforcement with children 
with Cerebral Palsy, they were able to reduce drooling and achieve an 
appropriate anterior oral lip seal (Harris and Dignam 1980). Stonell and 
Greenberg (Thomas-Stonell and Greenberg 1988), offered three conservative 
treatment approaches in reducing drooling: no direct intervention, feeding / oral 
stimulation programmes and finally behavioural modification programmes. They 
concluded that 66% of participants who received conservative treatment 
showed an effective reduction in the severity or frequency of drooling (Thomas-
Stonell and Greenberg 1988). However in their study they assigned individuals 
to each of one of the three treatment groups following initial multidisciplinary 
team assessment, rather than random allocation, which may have introduced a 
selection bias, for example participants were allocated to the no direct 
intervention group, if further neurologic maturation was anticipated, but these 
individuals may have had severe drooling and therefore altered the outcomes 
by assigning them to a given treatment intervention. 
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Behavioural modification  
 
Koheil (Koheil, Sochaniwsky et al. 1987) reported on the success of a training 
programme using auditory electromyography (EMG) biofeedback, using 
electrodes placed on the muscles surrounding the lips, conditioning the patient 
to swallow at the sound of an auditory stimulus. However the study concluded 
that patients had to have intact communication skills and intellectual function, 
present only with a moderate drooling difficulty and be reasonably well 
motivated. Consequently, these techniques were not used in clinical practice 
(Koheil, Sochaniwsky et al. 1987). Stonell and Greenberg (Thomas-Stonell and 
Greenberg 1988), offered behaviour modification programmes in their study and 
found that 73% of participants who engaged in this programme showed an 
improvement in their drooling control (Thomas-Stonell and Greenberg 1988). 
 
Drug therapy 
 
Studies have shown that the use of medications, such as glycopyrrolate and 
scopolamine, are effective in reducing drooling, but have many adverse side 
effects, such as excessive dry mouth, constipation, urinary retention, decreased 
sweating and skin flushing (Bachrach, Walters et al. 1998; Meir, Bachrach et al. 
2000; Hockstein, Samadi et al. 2004). A systematic review by Jongerius 
(Jongerius, van Tiel et al. 2003), investigated the efficacy of anticholinergic 
drugs in the treatment of drooling in children with multiple disabilities, they  
found only seven articles. From their review they suggested that at least some 
of these medications are effective, but were unable to conclude which one drug 
is preferable (Jongerius, van Tiel et al. 2003). In a further study by Jongerius et 
al. (Jongerius, Rotteveel et al. 2004), 45 children who experienced severe 
drooling, were recruited to a controlled clinical trial. Using a within-subject 
design each participant received treatment with transdermal scopolamine and 
then treatment with single-dose botulinum toxin injections in the submandibular 
glands. Measurements on the drooling quotient (DQ), teacher drooling scale 
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(TDS) and visual analogue scale (VAS) all showed that drooling was reduced 
during scopolamine application as well as after botulinum toxin injections. 
However 71.1% of the patients had moderate to severe side effects as a 
reaction to scopolamine, and in comparison only non-severe, incidental side 
effects were reported from the use of botulinum toxin. Side effects of the 
scopolamine application included xerostomia, restlessness, drowsiness, blurred 
vision and confusion, whereas a mild temporary disturbance in swallowing was 
reported in one individual who received botulinum toxin injections, but did not 
require any additional intervention. The botulinum toxin injections were given 
under general anaesthesia, which also has potential risks, but when weighed 
against the possible adverse effects encountered when using scopolamine for a 
longer period, was deemed acceptable (Jongerius, Rotteveel et al. 2004). 
Walshe et al. (Walshe, Smith et al. 2012) conducted a review to examine the 
effectiveness and safety of interventions with the objective of reducing or 
eliminating drooling in children with cerebral palsy. In their review they identified 
two studies, using pharmacological treatments which although did not fully meet 
their inclusion criteria of age and included some children without cerebral palsy, 
did include these as they were the only studies to describe the use of 
glycopyrrolate and benztrophine intervention, which is commonly prescribed in 
this population (Walshe, Smith et al. 2012). They concluded that the 
pharmacological intervention only took into account immediate change and did 
not measure longer-term effects, and whilst there was some evidence available 
for short-term benefits, no conclusions could be reached on the efficacy and 
safety of either of these two treatments, due to the methodological quality and 
variations in the designs of the studies (Walshe, Smith et al. 2012). 
 
Radiotherapy 
 
Studies using radiation therapy, with radiation doses targeting the 
submandibular and sublingual salivary gland tissue, have shown initial 
satisfactory responses in the management of sialorrhea, with up to 80% 
success rate, although there were some reported side effects, including oral 
candidiasis and mild skin reactions amongst participants (Borg and Hirst 1998). 
Due to the risk of malignancy, xerostomia, mucositis, radiation caries and 
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osteoradionecrosis, it has been advised that radiotherapy be avoided in young 
children (Borg and Hirst 1998). Conversely, in elderly patients who may have a 
limited life expectancy, these long-term side effects would not be expected to 
develop. Following a review of their results Borg and Hirst (Borg and Hirst 1998) 
concluded that the desired response in controlling drooling, with minimal 
discomfort, can be expected by controlling the amount of radiation exposure to 
both the parotid and submandibular glands (Borg and Hirst 1998). In a study of 
18 patients with amyotrophic lateral sclerosis and severe drooling Anderson 
(Anderson, Gronberg et al. 2001) showed that irradiation of the larger part of the 
parotid salivary glands and the posterior part of the submandibular glands 
reduced drooling without producing permanent xerostomia in all but of one of 
their patients.  
 
Surgical salivary duct and gland procedures 
 
Three studies involving the surgical management of drooling have investigated 
parotid duct relocation from the buccal vestibule to the area of the maxillary 
second molar and the tonsillar fossa, along with bilateral removal of the sub-
mandibular gland. The aim of duct relocation is to redirect the saliva to the 
posterior part of the mouth, in order to initiate the swallowing reflex and prevent 
drooling. Some studies of surgical management have reported good outcomes, 
showing a success rate of 86%, showing good to excellent results in 58 patients 
who have undergone surgical resection of the sub-mandibular gland with 
bilateral parotid duct ligation. (Dundas and Peterson 1979; Brundage and 
Moore 1989; Shott, Myer et al. 1989). However more recent research has 
shown the long-term efficacy of intra-oral surgery for the management of 
sialorrhea to be minimally effective and that over two-thirds of patients had a 
recurrence of drooling following surgery and additional medication or surgical 
intervention was required (Martin and Conley 2007). Scheffer et al. (Scheffer, 
Erasmus et al. 2010) studied 19 children and young adults (15 children 
diagnosed with bilateral cerebral palsy, three with unilateral cerebral palsy, and 
one with non-progressive developmental delay), and compared the use of 
Botulinum Toxin injections versus submandibular duct ligation for the 
management of severe drooling. In their study they used the drooling quotient 
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and measured this at eight-weeks and then again at 32-weeks. Each participant 
first underwent botulinum toxin injections and then surgical re-routing of the 
submandibular duct, at least six months after having had the injections. 
Compared with a baseline value of 28, the mean drooling quotient 8 weeks 
post-surgery was 10, and 32 weeks post-surgery was 4 (p<0.001). Among the 
group treated with botulinum toxin, the drooling quotient showed a significant 
reduction from a baseline value of 30 to 18 after 8 weeks (p=0.02), and an 
ongoing but diminished effect after 32 weeks drooling quotient score of 22 
(p=0.05). They concluded that both methods were effective in reducing drooling, 
but surgical relocation had a larger and longer-lasting effect  (Scheffer, Erasmus 
et al. 2010). 
 
Injection of botulinum toxin 
 
Many studies have investigated the management of drooling in both patients 
with Parkinson’s Disease and in children with Cerebral Palsy, using botulinum 
toxin injected into the salivary glands (Jongerius, Joosten et al. 2003; Caline, 
Rodrigues et al. 2007; Scheffer, Erasmus et al. 2010). Several studies report on 
the use and efficacy of ultra-sound guided injection versus direct ‘blind’ injection 
into the salivary gland or glands (Dogu, Apaydin et al. 2004; Caline, Rodrigues 
et al. 2007; Contarino, Pompili et al. 2007). These studies concluded that ‘blind’ 
injections are as effective as ultra-sound guided injections, when solely injecting 
into the parotid gland. When injecting into both the parotid and submandibular 
glands, the use of guided injections during administration is superior and that 
this technique is safe and effective in the treatment of sialorrhea (Porta, Gamba 
et al. 2001; Dogu, Apaydin et al. 2004). In their study Porta et al. (Porta, Gamba 
et al. 2001) injected the parotid and submandibular glands of 10 patients with 
neurological disorders with botulinum toxin-A, using ultrasound guidance. Prior 
to injection, the baseline rate of salivation was assessed using a visual 
analogue scale. Post-injection, assessments were repeated at regular intervals 
for up to 1year. They concluded that nine out of the ten (90%) reported a 
subjective reduction in salivation post-treatment and one patient (10%) found no 
improvement. Visual analogue scale scores showed a reduction of 60.8% for 
the nine respondents who reported a reduction. There were no reported serious 
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side-effects or procedural-related difficulties reported within their study (Porta, 
Gamba et al. 2001). 
Dogu et al (Dogu, Apaydin et al. 2004) investigated the efficacy and safety of 
intra-parotid botulinum toxin-A injections into parotid gland using ultrasound-
guided versus non-guided techniques for the treatment of sialorrhea in patients 
with Parkinson’s Disease. Fifteen patients with Parkinson’s Disease were 
allocated to one of the two groups and saliva secretion was assessed 
quantitatively at baseline and at weeks 1, 4, and 12. Patients and / or caregivers 
also assessed the saliva secretion using visual analogue scale (VAS). All 
patients except one reported subjective improvement in sialorrhea after one-
week. Comparisons of quantitative saliva assessments at each follow-up visit 
showed that ultrasound-guided injections were superior to blind injections for 
saliva reduction. The VAS scores showed an improvement in the mean rate of 
saliva secretion in each group at first week (P<0.05). Two of the 15 patients 
suffered from dry mouth, which was described mild in severity, lasting 1 month. 
They concluded intra-parotid botulinum toxin injections using ultrasound 
guidance may be an effective, easy, and safe treatment for Parkinsonian 
sialorrhea (Dogu, Apaydin et al. 2004). In a review by Walshe et al (Walshe, 
Smith et al. 2012) to evaluate the effectiveness and safety of interventions for 
drooling in children with cerebral palsy, they performed a comprehensive search 
of databases from inception through to December 2010, and also included 
searches for ongoing clinical trials. In their review they only selected 
randomised controlled trials and controlled clinical trials and found a total of six 
trials that were eligible for inclusion. Of these six trails, four studies examined 
the effectiveness of botulinum toxin A, They found that all studies differed in the 
products used, how these products were made-up and dosages, injection sites 
and number of injections administered and how the dosage was determined 
and anaesthesia administered (Walshe, Smith et al. 2012). Their findings also 
reported that the control interventions differed and that outcomes were 
examined medium term at three to 18 months, but none of the studies reviewed 
outcome beyond this time (Walshe, Smith et al. 2012). Walshe et al reported 
that no conclusions could be reached on the efficacy and safety of the use of 
botulinum toxin A in the treatment of drooling in children with cerebral palsy 
(Walshe, Smith et al. 2012). 
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Optimal treatment options 
 
The treating physician may feel confused with so many different causes of 
drooling, different pathogenic mechanisms and so many treatments available. 
However it is important to be aware that a team including at least an 
otolaryngologist, neurologist, dentist, speech and language therapist, 
occupational therapist and physiotherapist is recommended (Blasco 2002). The 
initial step is to correct the many situational factors that may worsen the 
drooling, such as head positioning, airway difficulties, unnecessary medications, 
malocclusion, and significant dental disease and where possible to actually 
correct the underlying cause (Meningaud, Pitak-Arnnop et al. 2006). Following 
the consideration of situational factors, it is thereafter important to offer 
physiological treatment options, such as oral-motor therapy and behaviour 
modification. If this is not possible, or unsuccessful, it is appropriate to suggest 
drug therapy. When these means have been shown to be ineffective, or are 
seen to be detrimental, due to the number of associated side-effects, more 
aggressive treatments may be indicated. However, when considering more 
aggressive treatment options preference should be given to the more reversible 
treatments like botulinum toxin, over the non-reversible surgical and radiological 
options available (Meningaud, Pitak-Arnnop et al. 2006). 
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Chapter 2 
 
2. The Clinical Management of Saliva in Tracheostomised Patients 
 
The clinical management of saliva in tracheostomised patients is either 
botulinum toxin or the prescription of medications ‘off-label’, or a combination of 
both. Both interventions aim to reduce saliva production and reduce the amount 
of pooled saliva in the oral cavity, which may fall into the airway, secondary to 
swallowing difficulties.  In addition, patients with a tracheostomy tube, who have 
difficulties in swallowing their saliva, are assisted in saliva clearance by using 
tracheal or oral suctioning in order to remove pooled saliva orally and / or within 
the airway. This chapter will discuss the use of botulinum toxin in the 
management of excessive pooled saliva and how it affects saliva production, its 
side-effects and how botulinum toxin has been used in some studies to manage 
drooling. The chapter will discuss the reasons for tracheostomy tube insertion, 
why tracheal suctioning is required and associated complications with having a 
tracheostomy tube in place. It will detail clinical knowledge and skills in the 
management of tracheostomised patients and current practice and perceptions 
of patients that have a tracheostomy tube. The final section will comment on the 
use of medications that are prescribed ‘off-label’ for the management of saliva, 
national guidelines that relate to prescribing medications ‘off-label’ and informed 
consent and decision making when prescribing these medications.     
 
2.1. Use of anticholergenic medications to reduce saliva flow 
 
A systematic review for evidence of efficacy of anticholinergic drugs to treat 
drooling concluded benztropine, glycopyrrolate, and benzhexol hydrochloride, 
as being effective in the treatment of drooling (Jongerius, van Tiel et al. 2003), 
but all have adverse side-effects and none of the drugs were identified as being 
superior (Jongerius, van Tiel et al. 2003). Jongerius et al (Jongerius, van Tiel et 
al. 2003) performed an in-depth review of the literature in order to carry-out a 
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meta-analysis, but due to limitations within the studies only identified a total of 
seven. They concluded that due to methodological drawbacks within the 
studies, no general conclusions could be made about the efficacy or average 
effect of anticholergenic medications to treat drooling (Jongerius, van Tiel et al. 
2003). 
Anticholinergic medications block the parasympathetic innervation of the 
salivary glands. Several studies (Lawrence and Klingbeil 1991; Lewis, Fontana 
et al. 1994; Blasco and Stansbury 1996; Meir, Bachrach et al. 2000; Robb, Lee 
et al. 2008) involving the use of glycopyrrolate and scopolamine (Scopoderm 
TTS® patches) has shown them to be effective in the management of drooling. 
The anticholinergic medications most commonly used are atropine, 
benztrophine, glycopyrrolate bromide, benzhexol hydrochloride and 
scopolamine. These medications are administered in a number of different ways 
and can be given orally, intravenously, applied topically as patches, injected, 
and via nebulisation (Nair and Hunter 2004). 
 
2.11 Glycopyrrolate  
 
Studies (Meir, Bachrach et al. 2000; Robb, Lee et al. 2008) have shown 70-90% 
response rates but with a high rate of side effects. Approximately 20% of 
patients choose to discontinue due to unacceptable side effects such as 
excessive dry mouth, urinary retention, decreased sweating, skin flushing, 
irritability and behavior changes (Meir, Bachrach et al. 2000). In a study by Mier 
et al. (Meir, Bachrach et al. 2000) they reported glycopyrrolate to be effective in 
the control of excessive sialorrhea in children with developmental disabilities. In 
their placebo-controlled, double-blind, crossover study 39 children with 
developmental disabilities and excessive sialorrhea, were given glycopyrrolate 
in doses of 0.10mg/kg. They concluded that administering glycopyrrolate in 
these dosages (0.10mg/kg) was effective in controlling sialorrhea, however 
found approximately 20% of children given glycopyrrolate experienced 
substantial adverse effects, enough to require discontinuation of the medication 
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(Meir, Bachrach et al. 2000). In addition to this Mier et al. found that 25 out of 36 
participants (69%) reported side-effects, which included behavioural changes, 
such as hyperactivity and irritation, also reported were diarrhoea, dry mouth, 
constipation, dehydration, urinary tract infection and retention, headache, fever, 
drowsiness, dizziness, disturbed vision, facial flushing, rash, nasal congestion, 
vomiting dehydration, deterioration of epilepsy and thickened secretions in a 
child who had a tracheostomy in-situ (Meir, Bachrach et al. 2000). In another 
study (Robb, Lee et al. 2008) glycopyrrolate was used for the treatment of 
clozapine induced sialorrhea in three adolescents. Three adolescent 
participants (aged 13-16), who developed sialorrhea secondary to clozapine 
treatment, for psychotic illness were given glycopyrrolate (4-8 mg), whilst 
inpatients. In their study Robb et al (Robb, Lee et al. 2008) concluded that the 
symptom of sialorrhea was improved in all three cases with all participants 
reporting a decrease, which was also confirmed by staff observations. However 
one participant reported constipation, which improved with symptomatic 
treatment and another participant complained of dry mouth, which was 
improved with a reduction in the dose of glycopyrrolate (Robb, Lee et al. 2008).  
 
2.12 Scopolamine (Scopoderm TTS
®
) Transdermal Patches 
 
Studies (Lawrence and Klingbeil 1991; Mato, Limeres et al. 2010) have reported 
a positive effect in the use of Scopoderm TTS® transdermal patches at reducing 
drooling. Scopoderm TTS® transdermal patches are prescribed in 1.5mg 
circular patches and applied behind the ear, releasing scopolamine through the 
skin into the bloodstream. One single patch application is considered to render 
a stable serum concentration for 72 hours at which point it will require 
replacement (ASHP 2013). 
 
In a prospective, randomised, double-blind, crossover, placebo-controlled 
clinical trial Mato et al. (Mato, Limeres et al. 2010) investigated the 
management of drooling in disabled patients using scopolamine. They studied 
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30 disabled patients (age range 12–58 years), who presented with persistent 
drooling, which was determined subjectively by means of interviews with the 
carers and medical staff and by direct observation. The frequency of drooling 
was estimated using the number of bibs used each day and drooling was 
quantified using the Thomas-Stonell and Greenberg scale (Thomas-Stonell and 
Greenberg 1988). They reported a significant reduction in drooling (P < 0.005) 
in the scopolamine group in and the mean number of bibs/day decreased during 
the scopolamine phase from 6 bibs per day at baseline to 3 bibs per day (Mato, 
Limeres et al. 2010). Four patients (13.3%) dropped out because of moderate 
scopolamine side-effects: one case of irritability, one case of agitation and two 
cases of skin reaction. In conclusion, Mato et al. suggested that transdermal 
scopolamine is an effective and safe therapeutic option to control drooling in 
severely disabled patients, however it requires appropriate patient selection and 
is not free from adverse side-effects and the long-term efficacy is unknown 
(Mato, Limeres et al. 2010). 
 
In a study to control drooling in a child of two-years of age, with severe spastic 
quadriparetic cerebral palsy and developmental delay, Lawrence and Klingbeil 
(Lawrence and Klingbeil 1991) provided treatment using transdermal 
scopolamine patches (1.5mg). They reported the child responded well to 
scopolamine therapy, with a reduction in drooling, which also resulted in 
secondary reduction in respiratory distress and frequency of suctioning with no 
significant side-effects reported (Lawrence and Klingbeil 1991). 
 
2.13 Benzatrophine 
 
Benzatropine, also known as benztropine is an anticholinergic drug which is 
used in patients to reduce the side effects of antipsychotic treatment, such as 
Parkinsonism and dystonia. Benztropine is an anticholinergic and works by 
decreasing the effects of acetylcholine, a chemical in the brain. This results in 
decreased tremors or muscle stiffness. Some of the adverse side effects may 
include dry mouth, visual disturbances, cognitive difficulties, constipation, 
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urinary retention, tachycardia (fast heart rate) and possible psychosis (in 
overdose) (Ogbru 2010).  
In a study by Camp-Bruno et al (Camp-Bruno, Winsberg et al. 1989), they 
examined the efficacy of benztropine therapy for drooling. They administered 
benztropine to 20 developmentally-disabled participants with severe drooling to 
see if there was a reduction in salivary flow and also monitored the incidence of 
side-effects in these cases. They used a double-blind, placebo controlled, 
crossover design and found a statistically significant difference in salivary flow 
(p < .001), between patients on placebo and those taking benztropine 
immediately post-intervention. In their study they used the Teacher Drool Scale 
(TDS), to measure changes in drooling and found a statistically significant 
difference between both placebo and intervention in the frequency and severity 
of drooling immediately post-intervention (p ≤ 0.001) (Camp-Bruno, Winsberg et 
al. 1989). The incidence of side-effects was so severe in three participants that 
they were excluded from the study. The side-effects included increased 
irritability, lethargy, vomiting, insomnia, dilated pupils, disorientation, facial-
flushing, stomach-ache and dry-mouth. Although they reported that minor 
problems, such as dry-mouth were eradicated by adjusting the dose of 
benztrophine in other participant (Camp-Bruno, Winsberg et al. 1989). 
 
 
2.14 Contraindications for the use of anticholinergic medications 
 
Anticholinergic medications are contraindicated in patients with glaucoma, 
obstructive uropathy, gastrointestinal motility disorders, and myasthenia gravis. 
Furthermore these medications are poorly tolerated in elderly patients who 
present with multiple comorbidities (Mintzer and Burns 2000). 
 
The two main interventions for the clinical management of saliva in 
tracheostomised patients at The Wellington Hospital is primarily through the use 
of either anticholinergic medications and/ or with the use of intraglandular 
injections of botulinum toxin into the salivary glands. When considering which 
intervention to assign in the management of saliva in tracheostomised patients, 
it is usually the primary consultant who makes the decision and prescribes the 
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course of intervention. The need for management of saliva is raised to the 
primary consultant by the multidisciplinary team caring for the patient. It is also 
highlighted and documented by the hospital’s tracheostomy team, who perform 
ward-rounds, at least once-a–week, with every patient who has a tracheostomy 
tube in-situ. The tracheostomy team, which primarily consists of a nurse, 
speech and language therapist, physiotherapist and ear, nose and throat (ENT) 
specialist, determines through rounding which patients have copious amounts 
of saliva, difficulties with management of their saliva and therefore requiring 
regular tracheal suctioning. Following team discussion recommendations are 
made to the primary consultant to consider treatment options to assist in the 
management of saliva in their patient. The prescription of treatment modality is 
then determined solely by the consultant. 
 
2.2 Tracheostomy tubes and tracheal suctioning  
 
2.21 What is a tracheostomy tube? 
 
 A tracheostomy tube is a small tube designed to be placed directly into a 
patient's windpipe (trachea) through the neck (Figure 1), via a tracheotomy 
procedure. The tracheotomy can be performed in the operating room or at the 
patient's bedside, typically requiring only minimal anaesthesia. The 
tracheostomy tube can be inserted in one of two ways; the open technique or 
the percutaneous technique. The open technique involves a small incision 
made in the lower part of the neck just above the trachea (Weller 2000). 
Subsequently, an incision is made in the trachea and the tracheostomy tube is 
inserted. The percutaneous technique involves the formation of a small opening 
in the trachea that is gradually dilated to the size of the tracheostomy tube.  
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 Figure 1 Lateral view of a tracheostomy tube, adapted from https://www.vivature.com/  
 
 
 
2.22 Why is a tracheostomy tube needed?  
 
A tracheostomy tube may be needed for patients who are unable to breathe 
independently, require long-term mechanical ventilation, are unable to cough 
effectively to clear their secretions, or have an obstructed or blocked airway. 
Mechanical ventilation is a method to mechanically assist or replace 
spontaneous breathing, using a machine called a ventilator. 
 
The decision to insert a tracheostomy tube often follows the use of a breathing 
(endotracheal) tube (Dikeman and Kazandjian 1995). Tracheostomy tubes are 
commonly inserted in patients who require long-term ventilation, and play a vital 
role in maintaining a clear airway, allowing access for bronchial toileting and 
weaning from ventilation (Serra 2000; Choate and Barbetti 2003; The Intensive 
Care Society 2008). 
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2.23 Incidence of tracheostomy tubes 
 
Tracheostomy care has traditionally been specific to specialised areas, such as 
ear, nose and throat (ENT) departments and intensive care units (ICU) 
(Heafield, Karnik et al. 1999). The number of tracheostomy tubes inserted 
internationally is increasing (Parker, Shylan et al. 2007), evidence indicating 
that both ventilation time and time in the intensive care unit (ICU) setting are 
reduced when a tracheostomy is performed early and this service and flow 
efficiency also results in patients being moved out of ICU making way for other 
patients (Arabi, Haddad et al. 2004). This is particularly true in the intensive 
care unit settings (The Intensive Care Society 2008), where as many as a third 
of patients will need a tracheostomy tube to assist in mechanical ventilation 
(Casserly, Lang et al. 2007). In a UK survey it was indicated that approximately 
50 – 200 tracheostomy tubes are inserted annually in ICUs, although this figure 
varied according to location (Veenith, Ganeshamoorthy et al. 2008). 
 
Most tracheostomised patients are decannulated, whereby the tracheostomy 
tube is successfully removed, prior to discharge from ICU (Stelfox, Crimi et al. 
2008), but some patients continue to require the tracheostomy tube after their 
acute episode of care in order for secretion and airway management (Barnett 
2008), whereby they are unable to swallow or clear their saliva safely and are 
dependent on tracheal suctioning to be performed to clear aspirated saliva. As a 
result an increased number of people are now being nursed on general hospital 
wards and within the community (Haines and Coad 2001), requiring staff in 
these settings to be able to provide safe and effective care for these individuals 
(Russell 2005). Despite increased international literature and care guidelines in 
tracheostomy tube care (Littlewood 2005), some health care professionals 
continue to lack the specialist skills, knowledge and confidence to provide this 
care (Parker, Shylan et al. 2007). 
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2.24 Types of tracheostomy tubes 
 
A tracheostomy tube is a curved tube that is inserted into a tracheostomy (a 
hole made in the neck and trachea). There are different types of tracheostomy 
tubes that vary in certain features for different purposes.  These are 
manufactured by different companies.  However a specific type of tracheostomy 
tube will be the same no matter which company manufactures them.  
A commonly used tracheostomy tube consists of three parts: outer cannula with 
flange (neck plate), inner cannula, and an obturator. The outer cannula is the 
outer tube that holds the tracheostomy open. A neck plate extends from the 
sides of the outer tube and has holes to attach cloth ties or velcro strap around 
the neck. The inner cannula fits inside the outer cannula. It has a lock to keep it 
from being coughed out, and it is removed for cleaning. The obturator is used to 
insert a tracheostomy tube.  It fits inside the tube to provide a smooth surface 
that guides the tracheostomy tube when it is being inserted. 
There are different types of tracheostomy tubes available and the patient should 
be given the tube that best suits his / her needs. The different types of tubes, 
indications for use and limitations are outlined in Table 4. 
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Table 1 Types of tracheostomy tubes, indications for use and limitations 
 
Tube type and description Indications for use Risks and limitations 
Cuffed tracheostomy tubes 
have a balloon (cuff) 
surrounding the distal end of 
the tube, which inflates in an 
attempt to seal the airway. 
A cuffed tube allows for 
positive pressure ventilation 
and it reduces the risk of 
aspiration (Russell 2005). 
Over-inflation of the balloon 
can cause damage to the 
mucosal wall of the trachea 
and necrosis (Serra 2000). If 
the lumen is occluded with the 
balloon (cuff) inflated the 
individual will not be able to 
breathe. 
 
Uncuffed tracheostomy tubes 
do not have a balloon (cuff) 
that can be inflated. 
This tube is used for patients 
who can breathe 
independently, who are able 
to swallow safely  
(Russell 2005). 
 
The individual requires an 
effective cough reflex to 
protect them from any 
potential aspiration. 
Fenestrated tracheostomy 
tubes have openings in the 
tube that allows air to pass 
through. They require a non-
fenestrated inner cannula 
(with no opening), to allow for 
suctioning and to make sure 
the suction catheter does not 
go through the opening. 
 
Air movement allows the 
patient to speak with 
placement of a special 
speaking-valve (Russell 
2005). These tubes are 
sometimes used in patients 
weaning-off ventilation (The 
Intensive Care Society 2008). 
Granulated tissue can 
develop around the 
fenestrations (Conlan and 
Kopec 2000). This type of 
tube may increase airway 
resistance if positioned 
incorrectly (The Intensive 
Care Society 2008). 
Adjustable-flanged 
tracheostomy tubes are 
longer than the standard 
tubes and have outer flanges 
that secure the tube, which 
can be adjusted. 
 
This type of tube is used 
where a standard length tube 
will not fit properly (Russell 
2005). 
There is increased risk of 
discomfort or movement of 
the tube whilst mobilising. 
Silver tubes / long-term 
tracheostomy tubes, with no 
need for repeated cleaning 
(Serra 2000). 
These tubes have an in-built 
speaking valve system, with 
no need to have an additional 
attachment of a valve (Russell 
2005).  
This type of tube should only 
be used for long-term 
tracheostomy care. These 
tubes tend to be expensive 
and are heavy. 
 
 
 
 
 
 
 
50 
 
2.25 Complications with tracheostomy tubes 
 
Complications with the insertion and management of tracheostomy tubes 
include haemorrhage, aspiration and an increased risk of infection (Beards and 
Nightingale 1994). Law (Law, Barnhart et al. 1993) indicated that 58% of 
patients who had a long-term tracheostomy tube developed tracheal granuloma, 
a growth of inflammatory tissue, which is caused by the irritation of the airway 
by the tracheostomy tube (Law, Barnhart et al. 1993). They concluded that 
removal of the tracheal granuloma, even in asymptomatic tracheostomised 
patients, resulted in successful decannulation in 20 out of 25 patients. They 
suggested that for a large number of patients with a long-term tracheostomy 
tube in-situ, tracheal granulomas were a significant complication and impacted 
on the patient’s airway (Law, Barnhart et al. 1993). Mucosal trauma is another 
complication, as a consequence of rigorous suctioning technique. The use of 
excessive or prolonged negative pressure can result in tearing of the mucosal 
lining, as the suction catheter touches the surface (Dikeman and Kazandjian 
1995). 
Tracheomalacia is where there is a softening of the cartilaginous structure of 
the trachea, and is caused by erosion of the tracheal rings. This is usually 
secondary to any trauma to the tracheal walls that exposes cartilage and thus 
leads to tissue breakdown (Dikeman and Kazandjian 1995). Another 
complication associated with longer-term tracheostomy tubes is tracheal 
stenosis, which is a narrowing that occurs when the tracheal rings begin to heal 
following trauma (Dikeman and Kazandjian 1995). Tracheal stenosis can occur 
at the tracheal stoma and the cuff site. 
 
2.26 Tracheal suctioning 
 
If the patient is unable to clear saliva or other material effectively from the 
airway, these need to be removed manually, using suctioning, before potentially 
resulting in an airway obstruction. Tracheal suctioning involves the removal of 
secretions from the trachea or bronchi, by inserting a catheter through the 
tracheostomy tube. In addition to assisting in the removal of saliva, tracheal 
suctioning also stimulates a cough reflex. This procedure helps maintain a 
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patent airway to allow optimal exchange of oxygen and carbon dioxide and 
minimises the risk of the development of aspiration pneumonia, which results 
from saliva that has fallen into the airway. Tracheal suctioning requires a strict 
aseptic technique and can be performed as is required, dependent on patient 
need. According to the American Association for Respiratory Care guidelines 
(AARC 1993), prior to suctioning the patient needs to be hyper-oxygenated with 
100% oxygen for 30 seconds. The duration of the suction should not exceed 10 
to 15 seconds and should adopt a sterile technique. The negative pressure 
used during suctioning should ideally be kept to a minimum, but enough to allow 
sufficient clearance of saliva pooled within the trachea. Finally, following 
removal of the suctioning catheter from the airway, the patient should receive 
hyper-oxygenation once again for up to a minute (AARC 1993).  
 
Airway suctioning is associated with clinically significant complications, such as 
hypoxia microatelectasis (alveolar damage), laryngospasm and tracheal wall 
damage (Fiorentini 1992; Kapadia, Bajan et al. 2000). Hooper (Hooper 1996) 
suggested that the presence of a tracheostomy tube may cause irritation, 
resulting in the increased production of sputum (Hooper 1996). Despite the 
hazards associated with tracheal suctioning there is little evidence to show how 
well it is performed in everyday practice. Day (Day, Farnell et al. 2002) 
observed 28 nurses to investigate nursing practices in endotracheal suctioning. 
Using non-participant observations and structured observations from three 
acute and high dependency wards within a large teaching hospital in the United 
Kingdom, she investigated knowledge and competence in performing tracheal 
suctioning. She concluded that both knowledge and practice were poor, with no 
significant relationship between the two (Day, Farnell et al. 2002). Day (Day, 
Farnell et al. 2002) reported on these results in three sections, a) prior to 
suctioning; b) during suctioning and, c) post suctioning. She found that prior to 
suctioning there were incorrect procedures relating to chest auscultation and 
although a large number (n=19) indicated that suctioning should be performed 
after auscultation in actual practice only 2 subjects did. In practice only 2 out of 
the 28 subjects provided pre-oxygenation prior to suctioning, although 10 
indicated knowledge to do so. Finally there were errors relating to infection 
control prior to suctioning, with only two subjects carrying-out correct hand-
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washing prior to undertaking tracheal suctioning. During suctioning Day (Day, 
Farnell et al. 2002) discovered that in practice only nine subjects chose the 
correctly-sized catheter and only two used the correct negative pressures whilst 
suctioning, whilst all other subjects used higher pressures than those 
recommended. Following suctioning only one of the 28 subjects performed 
auscultation post suctioning; although a greater number (n=17) performed 
correct post-suction hand-washing, 11 subjects failed to do so (Day, Farnell et 
al. 2002). 
 
Patients have reported sensations of pain, pressure, crushing, choking and 
gagging, whereas in the hands of a skilled practitioner, suctioning may not be 
more than a discomfort (Feber 2000). In a descriptive study by Arroyo-Novoa 
(Arroyo-Novoa, Figueroa-Ramos et al. 2008) almost half of 755 patients 
reported moderate to severe pain intensity during tracheal suctioning.  
 
 
2.27 Why perform tracheal suctioning? 
 
Tracheal suctioning is usually performed to maintain a clear airway and 
maximise respiratory function (Dougherty and Lister 2004). It is carried out 
when a patient with an artificial airway such as a tracheostomy or endotracheal 
tube cannot cough and remove pulmonary secretions. When a tracheostomy 
tube is in place, inspired and expired air bypass the normal humidification and 
warming processes that occur during passage through the upper airway. This 
may cause the drying of secretions and reduce the efficiency of muco-ciliary 
transport in the removal of secretions. The presence of a tracheostomy tube 
also impedes the ability to cough, a mechanism that requires glottic closure to 
generate the necessary high air flow and speed. While some patients may be 
able to clear their saliva via a tracheostomy tube independently, many will 
require assistance in the form of tracheal suctioning.  
The Joanna Briggs Institute for evidenced based nursing and midwifery 
produced a best practice information sheet on “Suctioning Adults with an 
artificial Airway”, following a systematic review of research (Thompson 2000). 
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This identified six main clinical indicators for performing tracheal suctioning, 
which were coarse breath sounds, noisy breathing, increased or decreased 
pulse, increased or decreased respiration, increased or decreased blood 
pressure and prolonged expiratory breath sounds. In daily practice nursing staff 
at the Wellington Hospital use a recording sheet to document the reason why 
tracheal suctioning is performed on individual patients (Appendix A). 
 
2.28 Tracheostomy tubes and patient perceptions  
 
The presence of a tracheostomy tube may lead to significant mental and 
emotional morbidity. It causes disfigurement of the anterior neck and is 
associated with reduced body image perception, and may lead to anxiety and 
depression (Bronheim, Strain et al. 1991). Gilony et al. (Gilony, Gilboa et al. 
2005) explored the quality of life after tracheostomy tube insertion by measuring 
its impact on well-being and body image perceptions. In their study they asked 
three groups of patients; cannulated, decannulated and non-cannulated patients 
to complete 3 conventional questionnaires. The questionnaires were; 1) 
Satisfaction-with-life scale; 2) Personality traits: neuroticism and extroversion; 
and 3) Body cathexis scale   
They concluded that patients with a tracheostomy tube had significantly 
reduced life-satisfaction and body-image perceptions. Patients who had their 
tracheostomy tube removed showed slight improvement in their body-image 
perception, but still had reduced life-satisfaction scale scores (Gilony, Gilboa et 
al. 2005). 
 
In a study investigating patients who had a temporary tracheostomy tube in-situ 
Sherlock et al. (Sherlock, Wilson et al. 2009) conducted semi-structured 
interviews with eight patients to gain an understanding of their experiences. 
Their interviews covered four main themes; physical sensations, understanding, 
information, and experiences following removal of the tracheostomy tube.  
 
They concluded that the experience of having a tracheostomy tube in-situ is a 
complex mixture of physical sensations and emotions. They found that most 
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patients reported the physical and psychological effects more disturbing than 
they expected (Sherlock, Wilson et al. 2009). Their research also suggested 
that the information given to patients may be insufficient and not tailored to 
individual needs. Following removal of the tube patients still reported fears and 
feelings of discomfort, which suggested that they still required further support in 
order to cope (Sherlock, Wilson et al. 2009).   
 
2.3 Off-label use of medications 
 
The management of saliva in tracheostomised patients is often through the 
pharmacological methods, by prescribing medications which have an adverse 
effect of reducing saliva. However none of these medications are licensed for 
this treatment and therefore are given ‘off-label’ (UK Medicines Information 
2012).   
The “off-label usage” of a medication is commonly used; however, no 
standardised statutory definition is available. Off-label prescribing of 
medications relates to prescribing a registered medicine for a use that is not 
within or is disclaimed within the product information (Turner 1999). The term 
refers to the practice of issuing prescriptions or ordering a medication for a use 
that is not recognised as an official indication by a national licensing authority, 
e.g., the Medicines Healthcare Regulations Authority in the United Kingdom and 
Food and Drug Administration in the United States. 
 
Once a licensing authority has undertaken a review of the manufacturer’s data 
of a medication, the medication may be approved for one or more indications, 
directed by specific dosages and administration requirements. The approved 
indication or indications then become part of the official “label” for the product. 
Once approved and licensed for market, the medication can be made available 
to use as a clinical tool and is not necessarily restricted to use in only the 
licensed (approved) indications, but for use outside the licensed indication and 
as such termed “off-label”. 
Off-label use is legal and does not necessarily mean that the medication is 
being used inappropriately (Gazarian, Graudins et al. 2006). Many physicians 
prescribe a medication off-label as they believe it is the best treatment for a 
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specific condition, although it may not yet have been formally tested for use in 
that condition (Gazarian, Graudins et al. 2006; Meadows and Hollowell 2008). 
Some views suggest that off-label prescribing may actually push the frontiers of 
clinical knowledge and lead to improvements in care (Torres 1994). 
 
 
2.31 National Licensing Authorities 
 
In all industrialised countries, a dedicated governmental agency, department or 
ministry has the authority to review scientific data and make decisions regarding 
the eligibility for introducing a medicinal or therapeutic product into a specific 
national market. The name commonly given to this authority is product 
licensing. There are a number of similarities in the licensing process. 
 
United Kingdom 
 
In the United Kingdom (UK), prescription medications are licensed for marketing 
by the Medicines and Healthcare products Regulatory Agency (MHRA). The 
MHRA is an executive agency of the Department of Health. There seems to be 
no specific parliamentary declaration that corresponds to allowing off-label 
prescribing. However the MHRA has a statement relating to off-label prescribing 
in the UK which reads;  
 
“Advice for prescribers: 
 
Consider…  
Before prescribing an unlicensed medicine, be satisfied that an alternative, 
licensed medicine would not meet the patient’s needs  
Before prescribing a medicine off-label, be satisfied that such use would better 
serve the patient’s needs than an appropriately licensed alternative  
Before prescribing an unlicensed medicine or using a medicine off-label: 
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a)  be satisfied that there is a sufficient evidence base and/or experience of 
using the medicine to show its safety and efficacy 
 
b)  take responsibility for prescribing the medicine and for overseeing the 
patient’s care, including monitoring and follow-up 
 
c)  record the medicine prescribed and, where common practice is not 
being followed, the reasons for prescribing this medicine; you may wish 
to record that you have discussed the issue with the patient  
 
Communicate: best practice is that… 
You give patients, or those authorising treatment on their behalf, sufficient 
information about the proposed treatment, including known serious or common 
adverse reactions, to enable them to make an informed decision  
Where current practice supports the use of a medicine outside the terms of its 
licence, it may not be necessary to draw attention to the licence when seeking 
consent. However, it is good practice to give as much information as patients or 
carers require or which they may see as relevant  
You explain the reasons for prescribing a medicine off-label or prescribing an 
unlicensed medicine where there is little evidence to support its use, or where 
the use of a medicine is innovative  
Report suspected adverse reactions… 
Healthcare professionals have a responsibility to help monitor the safety of 
medicines in clinical use through submission of suspected adverse drug 
reactions to the MHRA and CHM via the Yellow Card Scheme. Such reporting 
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is equally important for unlicensed medicines or those used off-label as for 
those that are licensed” (MHRA 2009). 
The Yellow Card Scheme, run by the MHRA and the Commission on Human 
Medicines (CHM), is used to collect information from both health professionals 
and the general public on suspected side effects. It allows the on-line reporting 
of suspected side effects (also known as adverse drug reactions) to a medicine, 
vaccine, herbal or complementary remedy (MHRA 2009). 
USA 
In the United States (US), medicated prescriptions are licensed by the federal 
Food and Drug Administration (FDA). The FDA has no policy that confines the 
use of medications for off-label purposes.  However the FDA periodically 
releases statements and guidance to assist health-care providers in 
understanding prescribing limitations. Recently the FDA has released an 
information sheet relating to off-label use of investigational drugs, which states; 
“Good medical practice and the best interests of the patient require that 
physicians use legally available drugs, biologics and devices according to their 
best knowledge and judgement. If Physicians use a product for an indication not 
in the approved labelling, they have the responsibility to be well informed about 
the product, to base its use on firm scientific rationale and on sound medical 
evidence, and to maintain records of the product’s use and effects. Use of a 
marketed product in this manner when the intent is the “practice of medicine” 
does not require the submission of an Investigational New Drug Application 
(IND), Investigational Device Exemption (IDE) or review by an Institutional 
Review Board (IRB). However, the institution at which the product will be used 
may, under its own authority, require IRB review or other institutional oversight” 
(Food and Drug Administration 2011). 
European Union 
In the European Union (EU), licensing of prescription medications is authorised 
by the European Medicines Authority – European Medicines Evaluation Agency 
(EMEA). The EU does not have legislation against the use of off-labelling 
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prescribing and there are not any specific statements from the European 
Medicines Authority to limit the use of licensed medicines to only labelled uses. 
 
 
 
2.32 Off-label prescribing  
 
 
The practice, called "off-label" prescribing, is entirely legal and very common 
(Blum 2002; Kelly, Gazarian et al. 2005), and may sometimes be clinically 
appropriate (e.g. exceptional use in an appropriately informed patient with a 
serious disease, when there are no other alternatives and where the potential 
benefits outweigh the potential risks), (American Academy of Pediatrics 2002), it 
can be associated with a number of clinical, safety and ethical issues (Neubert, 
Dorman et al. 2004). Furthermore some long established off-label uses have 
been shown to be either ineffective or harmful, when they’ve undergone 
extensive evaluation, (e.g. deaths associated with the use of propofol 
medication, in the sedation of patients in paediatric intensive care), (Schreiner 
2003). There is a large amount of literature about the extent and consequences 
of off-label prescribing, yet there is no specific and little guidance to help 
clinicians attempting to make decisions about the appropriateness of such 
prescribing. Radley et al. reported on off-label prescribing in office-based US 
medical practitioners (Radley, Finkelstein et al. 2006). In their study they 
collected data on the top 100 prescribed medications in 2001 and also on 
another 60 randomly selected medications from a database of prescribed 
medications. They concluded that the most frequently prescribed classes of off-
label medications were for cardiac and anticonvulsant conditions and formed 
46% of prescriptions (Radley, Finkelstein et al. 2006). They found that the 
individual medications most commonly prescribed off-label were gabepentin 
(83%) and amitriptyline (81%), but they did not report on the most common off-
label uses for these medications (Radley, Finkelstein et al. 2006). However 
Radley et al did report that the off label uses for gabapentin had minimal or no 
scientific support in 66% of uses, and off-labelling prescription for amitriptyline, 
had minimal or no scientific support in 60% of uses (Radley, Finkelstein et al. 
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2006). In a study by Chen et al, they surveyed 1199 physicians’ knowledge of 
FDA-approved medications for commonly prescribed medications (Chen, Wynia 
et al. 2009). The Physicians were presented with 14 drug-indication pairs and 
asked whether the pair had FDA licensing approval. One of these pairs was the 
medication gabapentin for use in diabetic neuropathy. Their study showed that 
although diabetic neuropathy was an off-label use of gabapentin, it was 
considered to be a labelled indication by 45% of all surveyed physicians (Chen, 
Wynia et al. 2009). In the 1960s, John Vane found that aspirin, a drug that was 
used for many years for primarily relieving minor pain and fevers, could disrupt 
a pathway needed for platelet aggregation. Further studies in the 1980s showed 
that this effect can be used in the prevention of heart attacks and stroke. 
Despite the evidence, the Food and Drug Administration (FDA) prevented 
manufacturers from advertising this information until more convincing clinical 
trials of aspirin’s anticoagulant properties were completed. However doctors 
were still allowed to prescribe aspirin for this use and it was not until 1998 that 
the FDA finally approved aspirin for the prevention of cardiovascular events 
(Jeffreys 2004). 
 
2.33 Informed consent and shared decision-making when prescribing “off-label”  
 
 
Informed consent is the principle that is observed to ensure that patient 
autonomy is conserved, requiring that competent patients are made fully aware 
and adequately understand the intended benefits and potential risks of a 
proposed treatment to be undertaken, in order to then make an informed 
decision (Riley and Basilius 2007). Doctors are legally bound to fully inform their 
patients of risks. The fact that there may be little evidence or research for off-
label use should be considered a risk to the patient. Physicians should follow 
legal standards that require them “to obtain informed consent from a person, 
prior to performing a test or carrying-out a specified treatment, especially where 
a treatment may involve some uncertainty” (Wilkes and Johns 2008). Doctors 
are encouraged to engage with an approach known as shared decision making, 
a model that promotes enhanced patient-physician relationships. This shared 
decision approach requires that both the physician and the patient share 
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information and work together in order to decide on a treatment plan (Wilkes 
and Johns 2008). Therefore withholding the intent to prescribe a medication for 
off-label use fails to honour this decision making process. Anytime a physician 
prescribes a medication for use that is not approved by the national licensing 
body, the physician can be seen as essentially carrying-out experimental 
research on the patient. The division between off-label use and research is 
important, because the national licensing authority closely regulates the sale, 
manufacture and licensing of medications. These regulations include 
development and clinical investigations using a medicinal product. Clinical 
investigations of medicines on human patients require obtaining approval from 
the MHRA in the United Kingdom and ethical approval, prior to beginning a 
study, as well as close oversight by local review boards. The licensing 
authority’s primary focus is to protect human subjects involved in clinical drug 
trials. However they do not regulate practice of medicine, and physicians are 
allowed to prescribe approved drugs for off-label uses, as long as such 
prescriptions do not qualify as “research”. 
 
The General Medical Council produced a supplementary guidance on good 
practice in prescribing medicines (General Medical Council 2008), and expects 
doctors to comply with the standards of good practice set out in the guidance.  It 
states that when prescribing medicines for use outside the terms of their licence 
(off-label); 
 
“You may prescribe medicines for purposes for which they are not licensed. 
Although there are a number of circumstances in which this may arise, it is likely 
to occur most frequently in prescribing for children. Currently, pharmaceutical 
companies do not usually test their medicines on children and as a 
consequence, cannot apply to license their medicines for use in the treatment of 
children. The use of medicines that have been licensed for adults, but not for 
children, is often necessary in paediatric practice” (General Medical Council 
2008). 
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When prescribing a medicine for use outside the terms of its license you must: 
 
i) “be satisfied that it would better serve the patient’s needs than an 
appropriately licensed alternative 
ii) Be satisfied that there is a sufficient evidence base or experience of using 
the medicine to demonstrate its safety and efficacy; the manufacturer’s 
information may be of limited help, in which case the necessary information 
must be sought from other sources 
iii) take responsibility for prescribing the medicine and for overseeing the 
patient’s care, monitoring and any follow up treatment, or arrange for 
another doctor to do so 
iv) make a clear, accurate and legible record of all medicines prescribed and, 
where you are not following common practice, your reasons for prescribing 
the medicine in the patient’s notes” (General Medical Council 2008). 
 
2.34 Evidence levels to guide off-label prescribing 
 
 
The National Institute for Health and Clinical Excellence (NICE) identifies that 
off-label medicines are invaluable in the care of certain patients in the absence 
of any other suitable licensed medicines which meet their needs.  The 
information available for healthcare professionals and patients to decide 
whether these off-label medicines are safe and effective, and when they’re most 
likely to give good outcomes, can be difficult to find. Therefore NICE have 
provided the first nationally available source of information for healthcare 
professionals and patients called ‘Evidence summaries for unlicensed / off-label 
medicines’ (ESUOMs) (National Institute of Health and Care Excellence 2013). 
ESUOMs are intended to provide information for clinicians and patients to 
inform their decision-making and support the development and updating of local 
medical formularies. The strengths and weaknesses of the relevant evidence 
are critically reviewed within each ESUOM.  
The key activities involved in the production of each ESUOM are: 
 “identifying, prioritising and selecting the topic 
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 summarising the published evidence  
 critically reviewing the strengths and weaknesses of the evidence 
 placing the evidence in the context of the wider evidence base for the 
management of the condition for which the unlicensed or off-label use is 
being considered, particularly NICE guidance, if available 
 highlighting any potential implications for local decision-making or clinical 
practice 
 producing a summary for patients for each ESUOM 
 identifying any new evidence relevant to published ESUOMs through 
scanning the literature, reviewing and, if necessary, updating or 
withdrawing an ESUOM” (National Institute of Health and Care 
Excellence 2013) 
 
The American Medical Association have suggested that we divide potentially 
appropriate off-label prescribing into three evidentiary categories: supported, 
suppositional and investigational (Largent 2009). Each of these categories is 
differentiated by the level of certainty obtained through objective assessment of 
existing evidence that a patient will experience a net health gain from the 
treatment. Supported off-label use relates to moderate to high level of certainty 
in net health benefit, whereas suppositional off-label use correlates with a low 
level of certainty. Investigational off-label use corresponds with a very low level 
of certainty. The US Preventative Services Task Force (USPSTF) (Sawaya, 
Guirguis-Blake et al. 2007) have developed such an approach and propose that 
judgements of evidence include consideration of the number and size of clinical 
trials, study design and conduct and the consistency of the results. By 
rigorously evaluating a piece of evidence in this manner, a judgement can be 
arrived as to the level of certainty for the net health benefit that can be gained 
from a particular intervention. 
 
Unfortunately physicians do not always have the skills or time to perform their 
own systematic review of the evidence on potential risks and benefits of off-
label prescribing. They should therefore access the most rigorous evidence that 
is readily available and take an objective approach to judgment (Largent 2009). 
Where available, professional body recommendations or guidelines should be 
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sought as they often reflect a thorough assessment of the available evidence, 
beyond the capability of any individual physician, and therefore can play a vital 
role in determining the physician’s level of certainty when prescribing (Largent 
2009). Although it can be argued that professional group recommendations may 
have conflicts of interest, these professional body recommendations are still 
likely to signify a greater understanding and reflection on the evidence, than that 
of an individual physician (Sox 2009).  
 
Gazarian et al. developed a practical and clear approach to guide clinicians, 
policymakers and funders of health care in systematically evaluating the 
appropriacy of medicines recommended for off-label use (Gazarian, Graudins et 
al. 2006). They established a working party from the New South Wales 
Therapeutic Advisory Group (NSW TAG), which is an independent state 
government-funded organisation whose aim is to promote quality use of 
medicines. The working party was founded by identifying areas of expertise 
considered relevant to address the issue of off-label prescribing and to develop 
recommendations in order to guide practice. They provided a systematic 
process for evaluating the appropriacy of any proposed off-label use and a 
decision algorithm with explanatory notes was developed (Figure 3). This 
provides recommendations to support prescribers in determining off-label use 
that is supported by high-quality evidence, its use in pioneering therapy that is 
justified in individual clinical circumstances or that which should be pursued in a 
research environment (Gazarian, Graudins et al. 2006).  
 
 
64 
 
 
 
Figure 2 Assessing appropriateness of off-label medicines use, (Gazarian, Graudins et al. 
2006) 
 
The algorithm provides guidance to clinicians who are considering off-label 
usage of a particular medicine and essentially in answering the question, “Is 
there high-quality evidence supporting its use?” (Gazarian, Graudins et al. 
2006). 
 
Prescribing medicines for off-label use makes patients vulnerable and 
compromises evidence-based practice. Clinical trials and other formalised 
studies attempt to fill in the evidentiary gaps, but currently there are no formal 
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guidelines on the off-label use of medications and clinical practitioners, 
manufacturers, patient advocates and professional organisations need to 
collaborate on systematic gathering of evidence to assist and justify off-label 
uses of medicines. It is also important that practitioners involve the patient in 
shared decision making and gain informed consent when prescribing off-label. 
Physicians should be encouraged that their prescriptions for off-label uses are; 
(1) made in conjunction with the patient’s knowledge that the medicine is being 
prescribed as off-label use; (2) primarily motivated by a desire to diagnose, treat 
or benefit the patient; (3) based on the physician’s own expert opinion; (4) 
supported by peer-reviewed literature, that reflects scientific evidence; and (5) 
in general supported by the views of the physicians colleagues. 
 
2.4 Purpose and aims of this study 
 
The management of saliva ranges from conservative (postural changes and 
biofeedback) to more aggressive such as pharmacological, surgical and 
radiological intervention. Studies using medications such as glycopyrrolate and 
scopolamine, have shown them to be effective in reducing drooling, but may 
have adverse side effects; excessive dry mouth, constipation, urinary retention, 
decreased sweating and skin flushing (Bachrach, Walters et al. 1998; Meir, 
Bachrach et al. 2000; Hockstein, Samadi et al. 2004). Other investigations have 
studied the management of drooling in patients with Parkinson’s Disease and in 
children with Cerebral Palsy, using injections of botulinum toxin into the salivary 
glands, which showed positive outcomes in the management of drooling with 
minimal, transient (swallowing difficulties) or no adverse effects (Jongerius, 
Rotteveel et al. 2004; Banerjee, Glasson et al. 2006; Lagalla, Millevolte et al. 
2006). However other reviews have reported that the efficacy and safety of 
botulinum toxin injections to the salivary glands is inconclusive (Walshe, Smith 
et al. 2012) and much more work is required to ascertain the benefits and 
longer-term adverse effects of the intervention (Reddihough, Erasmus et al. 
2010). Given the wide-range of clinical competencies necessary for the safe 
and effective administration of tracheal suctioning (AARC 1993) any 
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pharmacologically induced benefit could attenuate the incidence of secondary 
complications associated to performing tracheal suctioning.   
 
This prospective interrupted time-series experimental design was used to 
investigate the medical management of saliva in tracheostomised patients at 
The Wellington Hospital, in London, UK. The study wanted to determine the 
medical interventions which are prescribed in the management of pooled saliva, 
secondary to neurological impairment in this patient population and how 
effective this treatment was in reducing saliva. 
This study aimed to address the following questions; 
 
1) Whether treatment intervention resulted in a reduction in saliva in 
participants who had a tracheostomy tube in-situ 
2) Whether there is a reduction in the need to perform tracheal suctioning in 
these participants as a result of the intervention 
3) To determine participant and/or carer perceptions on saliva, tracheal 
suctioning and social well-being using a visual analogue scale and 
patient survey 
4) To determine the one-to-one nurses perceptions on saliva and frequency 
of tracheal suction required, using a visual analogue scale and nurse 
survey   
 
This interrupted time-series design had two phases, the first prior to intervention 
(baseline), followed by the second phase, with introduction of the intervention. 
All observations obtained subsequent to the introduction of the intervention 
condition, also continued throughout the second phase (the intervention-phase). 
The major purpose of this design was to evaluate the possible differential 
performance under the two conditions (pre and post intervention) of the time 
series. There are no other documented studies that have investigated the 
medical management of saliva in this patient population and this is the first 
study of its kind to do so. 
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Chapter 3 
 
Methods Chapter 
 
3 Ethics and the process of gaining approval for the study 
 
The following chapter describes the processes and outcomes involved in 
applying for ethical approval for the study involving a medicinal product. It 
explains the procedures that were undertaken in order to register the study with 
the Medicines Healthcare Regulations Authority (MHRA) and considers local 
requirements and stipulations made by the Clinical Trials Office (CTO), which is 
a division of the Hospital Corporation of America (HCA) group, which owns The 
Wellington Hospital, where the study was undertaken. It details the process in 
how approval was obtained for the study and why participant numbers were 
limited following an audit of patients admitted to the service with a tracheostomy 
tube in-situ during a four-year period. 
 
3.1 The Clinical Trials Office (CTO) 
 
The Clinical Trials Office (CTO) is a department within Hospital Corporation of 
America (HCA), which was set-up in 2009 to oversee and manage any research 
undertaken at any of its HCA facilities within the United Kingdom. HCA Inc. is 
the world's largest private hospital group. HCA’s private hospitals in London are 
the company’s overseas division and are made up of a total of six hospitals; 
The Harley Street Clinic, The Lister Hospital, London Bridge Hospital, The 
Portland Hospital, The Princess Grace Hospital and The Wellington Hospital. 
Prior to embarking on any research within one of its facilities, a protocol of the 
study must be submitted to the Head of the CTO, who would, in turn, meet with 
the Clinical Governance Committee and members of the CTO. The initial 
protocol for this study was titled “A randomised placebo controlled trial to 
explore the effectiveness of Botulinum Toxin injection at reducing oral 
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secretions and frequency of tracheal suctioning in tracheostomised patients”.  
This protocol can be found in Appendix B. 
The CTO employs a specialist Pharmacist who is responsible for overseeing 
pharmacovigilance in any studies using medicinal products, for supporting the 
process of completing the ‘IRAS’ ethics application form and procedures 
required to make an application to the Medicines Healthcare Regulatory 
Authority (MHRA). 
3.2 Is the product an investigational medicinal product (IMP) or a 
non-investigational medicinal product (NIMP)? 
 
The decision as to whether a product is an IMP or a NIMP depends on the 
product being used and the design of the study. The MHRA have designed an 
algorithm which allows investigators to determine whether their research is a 
clinical trial using a medicinal product, which then determines the need to gain 
MHRA approval (Appendix C). Therefore, to classify a "medicinal product" as an 
"investigational medicinal product" a sponsor must consider both its intended 
use and the objectives of the study. For example, if it is to be used as the test 
substance or reference substance (active comparator or placebo) in a study it 
would meet the first criteria of an IMP. However, if the study is not intended to 
discover or verify: (a) its clinical, pharmacological and/or other 
pharmacodynamic effects or (b) to identify any adverse reactions associated 
with its use or (c) to study its absorption, distribution, metabolism and excretion; 
with the objective of ascertaining its safety or efficacy, it would fail the second 
test. It would therefore not be classified as an IMP (European Commission 
2011). Medicinal products with a marketing authorisation (MA) are classified as 
IMPs when they are to be used as the test substance or reference substance in 
a clinical trial. 
3.3 Clinical Trials and Legal Framework 
 
The undertaking of Clinical Trials occurs in a highly regulated environment, 
requiring compliance at numerous local and international levels. In 1964, the 
World Medical Association (WMA) developed the “Declaration of Helsinki” 
(World Medical Organization 1996), a statement of ethical principles for medical 
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research involving human subjects, including research on identifiable human 
material and data. It was primarily established as a framework for physicians. 
However the Declaration was subsequently amended and is now a worldwide-
agreed policy for guiding the conduct of Clinical Trials and the protection of 
subjects. The requirement of ethical and scientific review of the trial protocol 
expressed in the Declaration is implemented in the national legal conditions for 
the conduct of Clinical Trials.  
 
In 1996, the International Conference on Harmonisation (ICH) (ICH Expert 
Working Group 1996) 
adopted the Guideline for Good Clinical Practice (GCP), which explicitly refers 
to the ethical 
standards of the Declaration of Helsinki. It defines GCP as an international 
quality standard for  
clinical trials in human subjects in ethical and scientific respects, clinical trials 
should be scientifically sound, and described in a clear, detailed protocol and 
trials should be conducted in 
compliance with the protocol that has received prior institutional review board 
(IRB)/independent 
ethics committee (IEC) approval/favourable opinion (ICH Expert Working Group 
1996). 
 
Adherence to the guideline should assure the protection of the rights, safety and 
wellbeing of the subjects as well as the reliability of the data generated in the 
Clinical Trial. The International Conference on Harmonisation (ICH)-guidelines 
and therefore also the Declaration of Helsinki are implemented  in national law 
in the three ICH regions, the European Union, Japan and in the United States 
(ICH Expert Working Group 1996). 
  
  
As well as these guidelines, further national requirements have to be taken into 
account, which do not address the conduct of Clinical Trials but address the 
involved parties such as the investigator, manufacturer and pharmaceutical 
companies.  
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Therefore before submitting to Ethics (‘IRAS’) and the MHRA the proposal to 
conduct a clinical trial using an Investigational Medicinal Product GCP training 
had to be undertaken, by the primary investigator and a Consultant 
Neurophysiologist (Dr. Peter Misra), who was originally listed as an investigator 
in the study. Both investigators were enrolled to complete this GCP training and 
were successful in gaining GCP certification. 
 
Good Clinical Practice training ensures that the investigators are aware of 
legislation, guidance and good practice relating to the ways in which clinical 
trials using medicinal products are conducted. The MHRA's Good Clinical 
Practice (GCP) (MHRA 2013) Inspectorate is part of the Inspection, Standards 
and Enforcement Division of the MHRA. It assesses the compliance of 
organisations conducting clinical trials using investigational medicinal products 
with UK and EU legislation (MHRA 2013). 
 
GCP training includes issues relating to the; 
 
 Protection of subjects in clinical trials through 
 
 Adherence to the Declaration of Helsinki 
 Risk assessment based on toxicological results 
 Protection of confidential personal data 
 Approval processes by ethics committees and competent 
authorities 
 Informed consent of the subjects and special provisions for those 
not able to give legal consent 
 
 Harmonisation of regulatory requirements in all European Union – 
Member States 
 
 Competitiveness and effectiveness of European research taking into 
account the requirements of pharmaceutical industry and non-
commercial researchers 
 
 Transparency and moral responsibility to both the study participants and 
society to share results and assist in the development of further research 
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involving improved trial design, fewer patients and thereby avoiding 
unnecessary duplication. This means that information about clinical trial 
methodologies and outcomes is collected prospectively and is made 
available to healthcare professionals and the public. 
 
  Pharmacovigilance (via EudraVigilance), the process and science of 
monitoring the safety of medicines and taking action to reduce the risks 
and increase the benefits of medicines.  EudraVigilance is a data 
processing network and management system for reporting and 
evaluating suspected adverse drug reactions (ADRs) during the 
development, and following the marketing authorisation of medicinal 
products in the European Economic Area (EEA). 
 
 
 Verification of compliance with GCP by inspections, which are performed 
in order to verify protection of the rights and well-being of trial 
participants, compliance with the provisions of Good Clinical Practice and 
the quality of data generated within clinical trials. 
 
3.31 EudraCT 
 
Following attendance at GCP training and as part of the Ethics (IRAS) 
application a EudraCT number was applied for from the MHRA, along with 
payment1 in support of the application. In order for an application to be 
considered as valid by the MHRA, a submission should contain a file for each of 
the following documents: 
 Covering letter  
 Clinical Trial Application  
 Protocol  
 Investigators Brochure (IB) or document replacing the IB  
 Investigational Medicinal Product Dossier (IMPD) / simplified IMPD  
 Non-IMP Dossier (if required)  
                                                          
1
 £3600.00 
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 Scientific advice - A summary of scientific advice from any Member State 
or the European Medicines Agency (EMA) with regard to the clinical trial 
(if available).  
 European Medicines Agency (EMA) Decision - A copy the EMA’s 
Decision on the decision of the Paediatric Investigation Plan and the 
opinion of the Paediatric Committee (if applicable).  
 The content of the labelling of the IMP (or justification for its absence)  
 Proof of payment  
 Manufacturer’s authorisation or Importer’s authorisation plus Qualified 
Person (QP) declaration on Good Manufacturing Practice (GMP) for 
each manufacturing site.  
A EudraCT number was successfully obtained on 27/02/2009 (2009-011204-
27). 
 
3.4 The Sarah Cannon Research Institute (SCRI) UK 
 
Sarah Cannon Research Institute (SCRI) is a global strategic research 
organisation focusing on advancing therapies and accelerating drug 
development. It is one of the largest clinical research programmes, conducting 
community-based clinical trials in oncology and cardiology through affiliations 
with a network of more than 700 physicians in the United States and United 
Kingdom. Additionally, SCRI offers management, regulatory and other research 
support services to drug development sponsors and strategic investigator sites.  
SCRI participates in both industry-sponsored and investigator-initiated clinical 
trials and conducts phase 1 through to phase 3 and outcomes-based clinical 
trials. SCRI’s academic partnerships with Yale Cancer Center, Peggy and 
Charles Stephenson Cancer Center at The Oklahoma University and University 
College London, enables SCRI to provide academic and collaborative 
leadership.  
Sarah Cannon Research UK is a unique standalone trial facility that 
collaborates and works closely with clinical investigators to develop new and 
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innovative therapies for patients. Sarah Cannon Research UK is part of the 
Hospital Corporation of America (HCA) network, which comprises six central 
London hospitals. They specialise in the development of novel therapies and 
provide a clinical research option for patients in London and the United 
Kingdom. All clinical trials conducted via the Sarah Cannon Research UK goes 
through a rigorous process of research governance which includes approval by 
an independent Research Ethics Committee and the Medicines and Healthcare 
Products Regulation Agency (MHRA). 
Following two unsuccessful applications to the Ethics Committee, a meeting 
was convened by the Head of SCRI UK and the SCRI research team and it was 
concluded that the study should be revised to examine and research the current 
practice and management of saliva in patients who have a tracheostomy tube 
in-situ. It was also determined that ethical approval was no longer required, 
following the MHRA’s algorithm guiding whether a study is research, audit or 
evaluation, which determined that the study was a service evaluation of current 
practice. (Appendix F). Approval for this revised study was obtained from the 
Wellington Hospital’s Executive Board and HCA’s Clinical Governance Board. 
It was suggested that in order to increase the potential number of participants in 
this evaluation, patients could be recruited from a number of hospitals within the 
HCA International Ltd. group. This proposal was presented to two of The 
Wellington Hospital’s sister hospital boards (The Harley Street Clinic and The 
London Bridge Hospital), but although initially agreed, was subsequently 
withdrawn, as the consultants in charge of the patients within the intensive care 
units at these hospitals felt they could not wholly commit to the study and could 
not fulfil data collection. Therefore participant recruitment was restricted to the 
Wellington Hospital.  
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3.5 The phases of clinical-outcome research  
 
Robey (Robey 2004) suggested an adaptation of a five-phase model of clinical-
outcome research as a means for structuring forms of clinical research 
throughout audiology and speech-language pathology. He suggests that the 
sequence of research tasks are; Phase I for identifying treatment protocols, 
justifying the enormous expense of extensive clinical testing; Phase II for 
making all of the preliminary tests and preparations necessary for testing the 
protocol in a clinical trial; Phase III for conducting a clinical trial to test efficacy; 
and Phase IV for testing the effectiveness of efficacious treatments. For 
treatment protocols proving effective, an additional phase of research is 
required: Phase V for testing the worth of a treatment (i.e., does the obtained 
value justify the cost of achieving that value?). This interrupted times-series 
evaluation would constitute a Phase II study (Robey 2004), whereby the 
research is exploring the dimensions of the therapeutic effect and making the 
necessary preparations for conducting a clinical trial. In 2010 the CONSORT 
(Consolidated Standards of Reporting Trials) (Schultz, Altman et al. 2010) 
statement updated guidelines for reporting parallel group randomised trials as a 
result of inadequate reporting and developed a 25 item check list to provide 
guidance for reporting all randomised control trials (Schultz, Altman et al. 2010). 
This CONSORT 2010 (Schultz, Altman et al. 2010) aims to assist authors in 
writing reports of randomised controlled trials, editors and peer reviewers in 
reviewing documents for publication, and assisting readers in critically 
appraising published articles. Although this study can be considered to be a 
Phase II study (Robey 2004), elements from the evidence based approach used 
for CONSORT 2010 can be used to guide reporting in other studies that are not 
randomised controlled trials (Schultz, Altman et al. 2010).    
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3.6 Identification of patient population and referral trends 
 
3.61 Wellington Hospital Tracheostomy Team Service Review from 2009 to 2011 
 
The Wellington Hospital Tracheostomy Team is primarily a therapy led team 
comprising a Specialist Speech and Language Therapist and Senior 
Physiotherapist responsible for the co-ordination of patient tracheostomy tube 
management. All patients on the intensive care, rehabilitation and acute 
(medical / surgical) wards who have a tracheostomy tube in-situ are referred to 
the service. The service reviews patients on a weekly basis with the aim of 
ensuring an appropriate weaning plan is in place, referring to specialist services 
as appropriate (e.g. ENT and respiratory physicians) trouble shooting for 
complex patients and ensuring safety standards are maintained. 
A retrospective review within the Rehabilitation Unit at the Wellington Hospital 
for the years 2009 to 2011 was undertaken to evaluate the number of referrals, 
service demands and the outcomes for patients on the acute wards.   
3.62 Review Findings 
 
There were a consistently high number of referrals to the Tracheostomy Team 
within acute service areas (149 patients between 2009 and 2011) in comparison 
to the Rehabilitation Unit (78 patients between 2009 and 2011,) (Figure 1).  
There has been a decline in referral numbers year on year across both service 
areas but this decline is more significant in the Rehabilitation Unit, with a 19% 
drop in referral numbers between 2009 and 2010, and a 12% drop between 
2010 and 2011. 
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Figure 1 Acute and Rehabilitation Tracheostomy Team referrals at The Wellington 
Hospital from 2009 to 2011 
The largest group of patients referred to both services were those with a 
diagnosis of stroke (35% acute, 44% rehabilitation), followed by those who had 
sustained a traumatic brain injury (17% acute, 24% rehabilitation) (Figures 2 
and 3).  
 
 
 
 
 
 
 
 
 
 
Figure 2 Number of Acute referrals by aetiology, The Wellington Hospital from 2009-2011 
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Figure 3 Number of Rehab referrals by aetiology, The Wellington Hospital from 2009-2011 
Sixty three percent of rehabilitation patients were successfully decannulated 
(had their tracheostomy removed) during their admission. Of the 37% who were 
not decannulated, 66% were discharged with a weaning (removal process) plan 
in place, 17% were discharged with no plan to wean and 17% died (Figure 4).  
In the acute service, 17% of patients were decannulated. Of the 83% who were 
not decannulated, 59% were discharged from the acute services with a weaning 
plan in place, 16% were discharged with no plan to wean and 25% died (RIP) 
(Figure 4). 
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Figure 4 Tracheostomy tube outcomes for acute and rehabilitation services, at The 
Wellington Hospital from 2009 to 2011  
 
The successful removal of the tracheostomy tube involves a number of graded 
stages, from tolerating tracheostomy tube cuff deflation, to eventual closing-off 
/capping-off of the tube and subsequent removal (decannulation). This process 
is known as “weaning”.  Within the acute intensive care setting, patients are 
typically capped for 24 hours or less before decannulation of the tracheostomy 
tube.  On the Rehabilitation Unit the patients were typically capped for more 
than 48 hours prior to decannulation (Figure 5). This is primarily due to there 
being a medical intensivist doctor available 24-hours a day, 365 days a year 
within the intensive care unit, who is able to decannulate the patient, whereas in 
comparison a reduced medical presence of a consultant who is able to 
decannulate the patient at a ward level (rehabilitation setting), where the Ear, 
Nose and Throat (ENT) consultant visits only at the request of the primary 
neurologist, which can potentially delay the process of decannulation. 
 
 
Figure 5 Duration of tracheostomy tube capping prior to decannulation 
 
The duration of the tracheostomy tube weaning programme is significantly 
longer in the rehabilitation setting compared to the acute setting (Figure 6). The 
range of the duration of tracheostomy weaning in the acute setting is as follows; 
2-32 days (2009), 4-48 days (2010) and 1-24 days (2011). In comparison, the 
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range of the duration of tracheostomy weaning in the Rehabilitation service is 
as follows; 12-148 days (2009), 36-152 days (2010) and 8 -148 days (2011). 
The primary difference is explained by the fact that patients admitted to the 
Rehabilitation Unit had a number of pre-existing co-morbidities, such as chronic 
obstructive pulmonary disease, difficulties with the tracheostomy tube, such as 
tracheal stenosis (narrowing of the tracheal cartilage) and tracheomalacia 
(weakness of tracheal cartilage).  
During the period of 2009-2011 there were two failed decannulations on the 
Rehabilitation Unit, due to tracheomalacia in one patient and due to 
gastroparesis in the second patient therefore being dependent on the 
tracheostomy tube, due to risk of aspiration from gastric contents. There was 
one failed decannulation on the acute wards as this patient’s vocal cords were 
in an adducted position and therefore dependency on the tracheostomy tube for 
breathing. 
 
 
Figure 6 Mean duration from initial cuff deflation to decannulation  
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3.7 Referrals to the Tracheostomy Team at The Wellington 
Hospital in 2012 
 
Comparing referral trends from the previous three years against those received 
in 2012, there was a dramatic decline in the number of referrals for patients with 
a tracheostomy tube within both the acute and rehabilitation service areas 
(Figure 7). The average number of referrals received per year was 72 compared 
to the 28 referrals received during 2012. This was due to the reduced number of 
patients admitted to the hospital (acute and rehabilitation service areas) who 
had a tracheostomy tube in-situ.  
 
 
Figure 7 Acute and Rehabilitation Tracheostomy Team referral rates at The Wellington 
Hospital in 2012  
 
Five of the six (83%) rehabilitation patients were successfully decannulated 
during their hospital stay. One was not decannulated due to ongoing vomiting, 
as a result of diabetic gastric paresis and therefore could not have the 
tracheostomy tube cuff deflated. Because of continuing vomiting, a weaning 
programme could not be established.  
In acute services, 36% of patients were decannulated. Of the 64% who were 
not decannulated, 7% were discharged from the acute services with a weaning 
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plan in place, 57% were discharged with no plan to wean, due to their 
dependency on the tracheostomy tube for ventilation, and poor prognosis and 
36% died (RIP) (Figure 8). 
 
 
Figure 8 Tracheostomy tube outcomes for acute and rehabilitation referrals in 2012 
Of the total of 28 referrals received to the acute and rehabilitation services, nine 
(32%) were discharged with no weaning plan and decannulation was not 
considered an option, due to sepsis, requirement of continuous ventilation and 
poor prognosis, due to comorbidities, as determined by the primary Consultant 
(Figure 9). 
82 
 
 
Figure 9 Reasons for unsuccessful weaning from the tracheostomy tube in nine patients  
 
 
3.71 Reasons for reduced referral rates of tracheostomised patients 
 
Patients admitted to the acute and rehabilitation wards of the Wellington 
Hospital are accommodated in private rooms, behind closed doors, with the 
exception of those in intensive care. For those patients with a tracheostomy 
tube in-situ in a private room a one-to-one 24-hour nurse is essential, especially 
when the patient is unable to swallow safely and/or clear saliva that has fallen 
into the airway. Therefore this one-to-one nurse is required to provide 
tracheostomy tube care, including tracheal suctioning as and when required. 
The decrease in overall referral rates may have been as a result of the 
withdrawal of funding, by the funding Embassy or funding body, for this one-to-
one nursing care within the rehabilitation service. Subsequently patients who, in 
the past, would have been transferred to the rehabilitation wards, have 
remained in the acute service areas, including intensive care, where funding for 
one-to-one nursing continued to be provided.    
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Over the past four years there has been a decline in the number of referrals 
made to the Tracheostomy Team as the Wellington Hospital has received fewer 
patients who have a tracheostomy tube in-place. This decline is particularly 
observed in 2012. The referrals that were received in 2012 were for acutely 
unwell patients who presented with multiple co-morbidities and high 
dependency on mechanical ventilation, and therefore not suitable for 
rehabilitation or weaning from their tracheostomy tube. Having conducted an 
investigation as to why there had been a decline in the number of referrals 
received from overseas referral sources, it was discovered that a number of 
local hospital facilities had been established in the countries of origin from which 
the patients came and these new hospitals were able to care for 
tracheostomised patients. For example, within the United Arab Emirates (UAE) 
the Al Rahba Hospital (John Hopkins is now within easy reach for patients from 
Abu Dhabi and Dubai). In Abu Dhabi, the Berlin Medical and Neurological 
Rehabilitation Center and The Sheikh Khalifa Medical City, managed by the 
Cleveland Clinic, USA, are now also able to take tracheostomised patients. All 
these facilities recruited internationally qualified and experienced staff that had 
experience in tracheostomy tube care and management. Patients who 
sustained injuries in these countries and who required a tracheostomy tube 
placement were no longer being sent overseas to the UK, but were being 
managed locally, rather than being transferred overseas for treatment. 
This significant decline in admission of patients who had a tracheostomy tube 
in-situ resulted in smaller numbers of patients who met the inclusion criteria and 
could be recruited into this study. Consequently the study design was changed, 
in agreement and in consultation with Sarah Cannon Research (SCR) UK, The 
Wellington Hospital and HCA’s Clinical Governance Board, to a case study 
design, using an interrupted time series design (Appendix G). 
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3.8 Patients and Methods  
 
This case series study is a prospective interrupted time-series design, involving 
patients who have been identified as having difficulties in managing their 
secretions and thus requiring a tracheostomy tube for dependency on tracheal 
suctioning to clear secretions from within the airway. 
 
3.9 Overview 
 
Across a consecutive 12-18 month period, participants that fulfilled the study 
inclusion criteria at The Wellington Hospital, London were enrolled in this study. 
Participants were eligible for the study if following a clinical bedside swallowing 
examination by the speech and language therapist, they were reported to have 
a tracheostomy tube in-place, exhibited difficulties in managing their saliva. 
They were dependent on tracheal suctioning in order to clear saliva that had 
fallen into the airway and who therefore required active treatment to manage 
their saliva. Also participants, who at time of enrolment, were dependent on 
alternative tube feeding to maintain their nutrition and hydration, as defined by 
the functional oral intake scale (FOIS) in table 1 (Crary, Mann et al. 2005). They 
also had to meet all inclusion criteria as listed below (section 3.114). 
 
Table 1 Functional oral intake scale (FOIS) (Crary, Mann et al. 2005)  
 
TUBE DEPENDENT (levels 1 - 3) 
 
Level 1 - No oral intake 
Level 2 - Tube dependent with minimal / inconsistent oral intake 
Level 3 - Tube supplements with consistent oral intake 
 
TOTAL ORAL INTAKE (levels 4 - 7) 
 
Level 4 - Total oral intake of a single consistency 
Level 5 - Total oral intake of multiple consistencies requiring special preparation 
Level 6 - Total oral intake with no special preparation, but must avoid specific foods or liquid 
items 
Level 7 - Total oral intake with no restrictions 
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3.10 Ethical Approval 
 
This service evaluation has been approved by both HCA’s Clinical Governance 
Team, Sarah Cannon Research (SCR) UK and The Wellington Hospitals’ 
Clinical Audit and Executive Board. 
 
3.11 Participants  
 
All eligible participants were asked to participate and given an information sheet 
relating to the service evaluation. They were given 24-hours in which to decide 
whether they wished to participate, following which, if they agreed, they were 
asked to consent in participation. Participants were given a tracheostomy tube 
self-perception survey (Appendix H), which was created for the purpose of this 
study and developed with feedback obtained from the speech and language 
therapy department and the Wellington Hospital’s Tracheostomy Team. The 
tracheostomy tube self-perception survey asked participants and/or their carers 
questions relating to their tracheostomy tube, tracheal suctioning, reports on 
saliva and management and social aspects of having a tracheostomy tube in-
situ.  The survey asked respondents to rate a statement relating to their 
tracheostomy tube, saliva management, suction and social well-being, using a 
‘Likert’ rating scale, rating from 1 (“always”) to 5 (“never”). Patients were asked 
to complete and return the survey to their designated speech and language 
therapist.   Patient’s characteristics, including their level of consciousness, using 
the Glasgow Coma Scale (Teasdale and Jennett 1974) and their oral intake 
status using the functional oral intake scale (FOIS) (Crary et al. 2005) is shown 
for each participant (case) in table 2. Table 3 shows the tracheostomy tube size 
and type and routine nursing and therapy interventions with the tracheostomy 
tube.  
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Table 2 Patient characteristics, with Glasgow Coma Scale (GCS) score (Teasdale and 
Jennett 1974) and functional oral intake score (FOIS) (Crary, Mann et al. 2005)      
 
Patient          Sex (M/F)          Age          Primary Diagnosis                   GCS
1    
        FOIS
2
 
 
Case 1            M                      69            Cerebral Vascular Accident        11/15          Level 2   
Case 2            M                      18            Hypoxic Brain Injury                    8/15            Level 1 
Case 3            M                       22           Head Injury                                  5/15           Level 1 
Case 4            M                       68           Cerebral Vascular Accident        12/15         Level 2  
 
1 
Glasgow Coma Scale (GCS) score 
 
2 
Functional Oral Intake Scale (FOIS)  
 
Table 3 Tracheostomy tube characteristic for each participant and intervention status 
Patient Tracheostomy Tube Tracheostomy 
Tube Cuff 
Status 
Routine 
Nursing care 
Therapy 
Intervention 
Size Type 
Case 1 Size 8 Cuffed, 
unfenestrated 
Cuff fully inflated Tracheal 
suctioning, as 
required; oral 
hygiene care 
Swallow 
stimulation 
programme 
Case 2 Size 6 Cuffed, 
unfenestrated 
Cuff fully inflated Tracheal 
suctioning as 
required; oral 
hygiene care 
Sensory 
stimulation / oral 
desensitisation 
programme. 
Swallow 
stimulation 
programme 
Case 3 Size 6 Cuffed, 
unfenestrated 
Cuff fully inflated Tracheal 
suctioning as 
required; oral 
hygiene care 
Sensory 
stimulation / oral 
desensitisation 
programme. 
Swallow 
stimulation 
programme 
Case 4 Size 6 Cuffed, 
unfenestrated 
Cuff fully inflated Tracheal 
suctioning as 
required; oral 
hygiene care  
Swallow 
stimulation 
programme 
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Of the initial four participants who enrolled within the study only full sets of data 
were recorded for three participants as one participant (case 4) withdrew. 
 
 
3.111 Case 1 
 
A 69-year-old man who had a cerebral vascular accident (CVA) on 05/12/2011, 
who presented awake and alert with a Glasgow Coma Scale score of 11 out of 
15 (E4, V2, M5) (Teasdale and Jennett 1976). He was non-mobile and had 
difficulties in following commands and in expressing his needs or wants. He had 
a size 8, cuffed, tracheostomy tube inserted on 05/12/2011. The cuffed 
tracheostomy tube blocked any air from flowing around the tube and assured 
that the patient was well oxygenated for ventilation purposes and also 
minimised the amount of saliva that fell into the airway by attempting to make a 
seal between the tube and the airway. The tracheostomy tube was initially 
inserted for the purpose of providing ventilation assistance, as he had difficulties 
in maintaining oxygen saturation levels whilst breathing on room air, and 
thereafter, once weaned from ventilation, for management of saliva falling into 
his airway due to severe oral and pharyngeal stage swallowing dysfunction. He 
had a 24-hour one-to-one (1:1) nurse to provide tracheostomy tube care and 
tracheal suctioning and set-up and delivery of alternative percutaneous 
endoscopic gastrostomy (PEG) tube feeding. He was prescribed transdermal 
patches of Scopoderm TTS® five days post insertion of the tracheostomy tube, 
due to copious amounts of pooled saliva within his oral cavity, which 
subsequently was falling into his airway necessitating tracheal suctioning at 
least every hour.  
 
3.112 Case 2 
 
An 18 year old male was admitted to the Wellington Hospital on 12/11/2012 
having sustained a closed head injury on 30/07/2012, resulting in hypoxic brain 
damage. He was in a low-awareness state, unresponsive with a Glasgow Coma 
Scale score of 8 out of 15 (E4, V1, M3) (Teasdale and Jennett 1976). He was 
fully dependent on 24-hour one-to-one (1:1) nursing to provide all his daily care, 
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including positioning and meeting his alternative feeding and hydration needs, 
via a percutaneous endoscopic gastrostomy (PEG) feeding tube. He also 
presented with a bite-reflex, which was triggered by placement of a swab or 
tongue depressor against his teeth or on his tongue, which made it difficult to 
perform oral hygiene or clear pooled saliva from within the oral cavity. He had a 
size 6, cuffed tracheostomy tube which was inserted in August 2012 for the 
management and clearance of copious amounts of saliva falling into his airway, 
secondary to severe oral and pharyngeal stage swallowing difficulties. The 
tracheostomy tube was replaced with a size 6, cuffed, ‘Tracoe-twist’ 
tracheostomy tube on 14/11/2012. He was commenced on treatment of 
Scopoderm TTS® transdermal patches for management of his saliva on 
05/02/2013. 
 
3.113 Case 3 
 
A 22 year old male was admitted to the Wellington Hospital on 03/04/2013 in a 
low-awareness and unresponsive state, with a Glasgow Coma Scale score of 5 
out of 15 (E2, V1, M2) (Teasdale and Jennett 1976), having sustained a closed 
head injury, following a road traffic accident on 07/02/2013. He was fully 
dependent on 24-hour one-to-one (1:1) nursing to provide all daily care, 
including positioning, meeting alternative feeding and hydration needs via a 
percutaneous endoscopic gastrostomy (PEG) feeding tube and oral hygiene 
care, which were made difficult due to the presence of a bite-reflex and 
inaccessibility to the tongue and floor of the mouth. He initially had a size 7, 
cuffed tracheostomy tube which was inserted in February 2013, for the 
management and clearance of copious amounts of saliva falling into the airway 
due to severe oral and pharyngeal stage swallowing difficulties. The 
tracheostomy tube was replaced with a size 6, cuffed, tracheostomy tube on 
08/04/2013. He was commenced on treatment of ‘Scopoderm TTS®’ 
transdermal patches for management of his saliva on 25/04/2013. 
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3.114 Inclusion Criteria 
 
 Participants had to meet all of the following criteria to be enrolled in this study: 
 
 Males or females over the age of 18 years 
 Participants who had a tracheostomy tube in-situ 
 Breathing on room air, without the need for any mechanical ventilation 
 Requiring tracheal suctioning in order to clear saliva from within the airway 
 Requiring pharmacological intervention to manage their saliva 
 Participants who were able to consent, or included as part of their 
treatment evaluation, as agreed with their carer / next-of-kin and primary 
consultant 
 Participants who were ‘Nil-By-Mouth’ (NBM) , receiving alternative tube-
feeding at the time of recruitment, scoring levels 1 – 3 on the functional 
oral intake scale (FOIS) (Crary, Mann et al. 2005) 
 Participants who were not on any prescribed medications that are known 
to induce hypersalivation or inhibit saliva flow 
 
3.12 Measurements 
 
3.121 Collection of unstimulated whole saliva 
 
Unstimulated whole saliva was collected using the ‘swab’ method, which 
involved the placement of three absorbent cotton dental rolls intra-orally, placed 
by the primary investigator, for duration of 5 minutes, before being removed. 
The weights of the cotton dental rolls were established before and after 
measurement. All data collection for saliva was made by the primary 
investigator. A protocol for collection was used, whereby three dry dental rolls 
were placed and sealed within a clear sterile bag and then weighed to gain the 
dry-weight of the bag and rolls; this dry-weight reading was recorded to a 
sensitivity of 1/100 of a gram (0.01g). Prior to data collection participants were 
positioned as close to a 900 seated position as possible, by their 1:1 nurse and 
the previously weighed dry dental rolls were removed from the sterile bag and 
placed intra-orally by the primary investigator, using sterile tweezers into the 
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oral cavity (one in the anterior sulcus, behind the lower front lip, between the lip 
and gum and one-each in the lateral sulci, between the cheek and lower gum). 
The patient was not given any other stimuli, such as oral hygiene care or 
therapy intervention prior or during data collection, to avoid any potential stimuli 
that might physically cause an increase in saliva flow, however continued to 
follow any regimes in relation to therapy intervention relating to the 
tracheostomy tube, such as placement of the speaking valve onto the end of the 
tracheostomy tube or trials of closing-off (capping) the tracheostomy tube at 
times of data collection. The dental rolls were left in place for a total of five 
minutes, monitoring that they had not dislodged in this duration of time, by the 
primary investigator. At the end of the five minute placement period, the dental 
rolls were removed by the primary investigator, using sterile tweezers and were 
replaced into the clear sterile bag from which they had been removed and were 
re-weighed and the wet-weight was recorded to a sensitivity of 1/100 of a gram 
(0.01g), within one to two minutes after collection, by the primary investigator. 
The dental roll dry and wet weights were recorded by the primary investigator, 
using the ‘Shimadzu TXB222L’ electronic weighing scales, which are scales 
with an in-built calibration and levelling function. The differences in the weight of 
the dry versus the wet dental rolls were recorded to a sensitivity of 1/100 of a 
gram (0.01). Readings of the weights were taken across three equally spaced 
time intervals: early morning (10:00am), midday (1:00pm) and late afternoon 
(4:00pm), for three consecutive days, and an average reading was obtained. 
These data readings were repeated throughout the inpatient stay by the primary 
investigator at the following time intervals: one-week prior to treatment; one-
week, two weeks, four weeks, eight weeks and at 12 weeks post treatment.  
 
3.122 Determination of the frequency and reasoning of tracheal suctioning 
 
The frequency of tracheal suctioning performed across a 12-hour period, from 
8:00am to 8:00pm, was recorded using the patient’s tracheostomy nursing care 
chart (Appendix I), along with the primary reasoning for performing tracheal 
suctioning (Appendix A), which were listed as; 1) secretions audible; 2) 
ventilator shows high peak pressures; 3) increased peak inspiratory pressures 
associated with volume control; 4) audible or visible secretions; 5) increased 
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work of breathing; 6) deteriorating oxygen saturations; 7) routine; and 8) other. 
The nurse caring for the patient on each 12-hour (day) shift was the same 
nurse, who was present for the duration of their inpatient stay and their 
consistent 1:1 nurse whilst the patient was a participant within the study. This 
nurse was asked to record (via tally) on a tracheostomy nursing care chart each 
time a catheter was passed via the tracheostomy tube in order to perform 
tracheal suctioning. At the same time the nurse was also asked to document on 
another sheet, which listed the main reasons for performing the tracheal 
suctioning (Appendix A).  The measurements of frequency of tracheal 
suctioning were calculated across the twelve-hour period for three consecutive 
days and an average was obtained. The 3 day cycle of measurements were 
made at one-week prior to treatment and then again at five time points post 
treatment: at one week, two weeks, four weeks, eight weeks and at 12 weeks 
post treatment. 
 
 
 
3.123 Participant / primary carer self-perceptions on tracheal suctioning/saliva flow 
  
The responses from the participants and/or the same primary carer reports of 
the amount of saliva, frequency of tracheal suctioning and perceptions of having 
a tracheostomy tube in-situ, using a tracheostomy tube self-perception survey 
(Appendix H) were also recorded at the same time intervals: one-week prior to 
treatment, one week, two weeks, four weeks, eight weeks and at 12 weeks post 
treatment. This survey used a series of statements, asking participants or their 
carers to rate from 1 (‘always’ / ‘very much true’) to 5 (‘never’ / ‘not at all true’), 
using a ‘Likert’ rating scale, relating to their tracheostomy tube, tracheal 
suctioning, saliva management and well-being (Appendix H). 
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3.124 Nursing perceptions on tracheal suctioning/saliva flow 
 
Nursing staff perceptions on the amount of saliva and the frequency of tracheal 
suctioning required by participants were also recorded by the same 1:1 nurse 
carer (Appendix J). Saliva was rated on a visual analogue scale (0 – 100) and 
frequency of tracheal suctioning on a ‘likert’ scale from a score of 1 (“very much 
true”) to a score of 5 (“not true at all”). These scores were recorded at the same 
time intervals: one-week prior to treatment, one week, two weeks, four weeks, 
eight weeks and at 12 weeks post treatment. 
 
3.13 Treatments 
 
The current medical treatment interventions used at the Wellington Hospital for 
saliva management include injections of botulinum toxin to the salivary glands 
or placement of Scopoderm TTS® transdermal patches. The treatment to be 
prescribed is the decision of the primary consultant, thus assignation to the 
intervention is the sole decision of the consultant. The need for management of 
saliva is raised to the primary consultant by the multidisciplinary team caring for 
the patient. It is also highlighted and documented by the hospital’s 
tracheostomy team, who perform ward-rounds, at least once-a–week, with 
every patient who has a tracheostomy tube in-situ. The tracheostomy team, 
which primarily consists of a nurse, speech and language therapist, 
physiotherapist and ear, nose and throat (ENT) specialist, determines through 
rounding which patients have copious amounts of saliva, difficulties with 
management of their saliva and therefore requiring regular tracheal suctioning. 
Following team discussion recommendations are made to the primary 
consultant to consider treatment options to assist in the management of saliva 
in their patient. 
 
All patients within this series evaluation underwent treatment using placement 
of Scopoderm TTS® transdermal patches. 
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3.131 Intervention using Scopoderm TTS
®
 transdermal patches 
 
Scopoderm TTS® transdermal patches of 1.5mg dosages were placed behind 
one ear. Each patch released 1mg of Hyoscine across a 72 hour period. Each 
Scopoderm TTS® transdermal patch was replaced every 72 hours and was 
discontinued if the patients no longer had difficulties in managing their saliva 
and were able to clear orally pooled saliva, either by expectorating it 
independently or swallowing their saliva. The treatment was also discontinued if 
there were any identified adverse reactions to the treatment, such as evidence 
of visual disturbances, skin irritation, dryness of the mouth, drowsiness or 
confusion and hallucinations, as described in the products summary of 
characteristics.  
 
 
3.132 Speech and Language Therapy intervention and routine care provided 
 
Whilst engaged within this study each participant continued to receive daily 
speech and language therapy intervention, for tracheostomy tube assessment 
and treatment, treatment for severe oral and pharyngeal stage swallowing 
difficulties and communication difficulties. In addition two participants (case 2 
and 3) who were in a low-awareness, unresponsive state had therapy to treat 
the presence of a bite-reflex. Patients received a range of therapy interventions, 
which incorporated a global sensory stimulation programme, including oral 
desensitisation for the patients who presented with hypersensitivity and bite 
reflex (cases 2 and 3) and swallowing stimulation, using differing flavoured 
swabs and ice-chips. In case 1, where the participant was awake and alert, 
instrumental diagnostic assessment of his swallow was performed and this 
confirmed he could be commenced on small amounts of controlled oral trials of 
a modified diet (pureed diet) with the speech and language therapist only. 
 
These participants were at high risk of oral health complications, due to a 
combination of factors, which included reduced level-of-awareness, inability to 
participate in self-care and inability to effectively clear oral saliva. This may 
cause pathogens to colonise in the oral cavity, which if aspirated may contribute 
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to serious respiratory complications, such as aspiration pneumonia. All 
participants within this study received regular oral hygiene care, which was 
performed primarily by the one-to-one nurse, this involved 2-4 hourly brushing 
and debriding with the use of a suction toothbrush / swab system, antiseptic 
mouthwash, non-foaming toothpaste and mouth moisturiser. 
 
As all participants were self-ventilating, breathing on room air and not requiring 
additional oxygen therapy and were routinely prescribed with 4-6 hourly saline 
nebulisers, which was administered by the one-to-one nurse. Saline 
nebulisation was prescribed in order to loosen and thin secretions, to prevent 
atelectasis and sputum consolidation within the airway and promote clearance 
via coughing and/or assisted tracheal suctioning. Saline nebulisers were given 
outside of data collection times and did not interfere with the placement of the 
dental rolls within the oral cavity. 
 
All data collection was structured around therapy and nursing interventions, so 
as to minimise the effect of external stimuli and treatments, which may have 
inadvertently caused a change in saliva flow.   
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Figure 10 Schedule of data collection in each participant (case). All dental roll readings 
made by the primary investigator. All nurse/carer questionnaires completed by the same 
nurse/same carer.  
Referral to SLT of the 
Tracheotomised patient 
(inclusion criteria met) 
Intra-oral dental rolls and 
12-hour suction  
(two-weeks post) 
Intra-oral dental rolls and 
12-hour suction  
(one-week post) 
Intra-oral dental rolls and 
12-hour suction  
(four-weeks post) 
Administration of treatment 
Intervention (Rx) as currently determined by primary 
consultant either Botulinum Toxin Injection – type A or, 
Scopderm TTS® transdermal patch 
Baseline of secretions; 
 Intra-oral dental rolls 
12-hour tracheal suction 
(One-week prior) 
Pre- intervention 
questionnaire to primary 
carer 
 
Pre- intervention 
questionnaire to primary 
1:1 Nurse carer 
 
Post- intervention 
questionnaire to the same 
1:1 Nurse carer 
 
Post- intervention 
questionnaire to the 
same primary carer 
 
Post- intervention 
questionnaire to the same 
1:1 Nurse carer 
 
Post- intervention 
questionnaire to the same 
1:1 Nurse carer 
 
Post- intervention 
questionnaire to the 
same primary carer 
 
Post- intervention 
questionnaire to the 
same primary carer 
 
Post- intervention 
questionnaire to the same 
1:1 Nurse carer 
 
Post- intervention 
questionnaire to the same 
1:1 Nurse carer 
 
Intra-oral dental rolls and 
12-hour suction  
(eight-weeks post) 
Intra-oral dental rolls and 
12-hour suction   
(12-weeks post) 
Post- intervention 
questionnaire to the 
same primary carer 
 
Post- intervention 
questionnaire to the 
same primary carer 
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3.14 Equipment 
 
 
‘Shimadzu TXB222L Series’ electronic balance scales (220g in 0.01g 
intervals) 
‘Nu-Care Products Ltd’; Dental Rolls D882, Size No. 2 
Sterile tweezers 
Sterile clear plastic bags 
Tracheostomy nursing care chart (Appendix I) 
Reasons for performing tracheal suctioning chart (Appendix A)  
Tracheostomy tube self-perception survey (Appendix H) 
Nurse-rating saliva perception scale (Appendix J) 
3.15 Statistical Analysis 
 
Linear regression analysis was used to analyse the relationship between 
salivary flow rate pre and post treatment and a P value of 0.05 or less was 
considered statistically significant.  
 
The data was analysed using linear regression once all assumptions required 
for linear regression analysis were met, namely; 
 
1) The two variables were measured at a continuous level 
2) There was a linear relationship between the two variables, which was seen 
once the data was displayed in a scatterplot graph 
3) There were no significant outlying data readings observed, when the data 
was plotted on a scatterplot 
4) There were independence of observations, which was checked using the 
‘Durbin-Watson’ statistic 
5) The data showed homoscedasticity, in that the variances along the line of 
best fit remained similar, whilst moving along the line 
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6) Finally, that the residuals (errors) of the regression line are approximately 
normally distributed, which was checked by plotting a histogram with a 
superimposed normal curve 
 
The data collected met all assumptions required in order to proceed with linear 
regression analysis, which was performed in each case pre and post 
intervention and further follow-up tests were carried-out comparing the dental 
roll weights pre intervention and at each time-point post intervention (at one, 
two, four, eight and 12 weeks post intervention) for each participant (case). 
 
A Chi-Square test was performed analysing the frequency of tracheal suctioning 
performed by the same primary nurse caregiver for all participants. Further 
follow-up analyses using Chi-Square Goodness of Fit tests were performed for 
each case for tracheal suctioning performed across time and are shown under 
each case. In order to avoid type I errors (false positive errors) in the analyses, 
the significant level was taken from P=0.05 to p=0.01, which was calculated by 
dividing 0.05 by the number of tests, which were 5 (α=0.05 / 5), giving a p value 
= 0.01. 
  
The data was entered into a Statistical Package for the Social Sciences (SPSS) 
software (version 22) and linear regression analysis was used to determine the 
relationship between dental roll weights over time, pre and post treatment and a 
Chi-Square test and Chi-Square Goodness of Fit tests were performed to 
analyse the frequency of tracheal suctioning. 
 
The results from the primary caregiver questionnaires were analysed to provide 
a qualitative review on caregivers’ perceptions on the tracheostomy tube, saliva 
and social consequences of having a tracheostomy tube in-place. The results of 
frequency of tracheal suctioning and reasoning for suctioning as recorded by 
the same 1:1 nurse was also analysed (quantitatively and qualitatively) in each 
case and nursing perceptions on saliva ratings were also recorded and reported 
in the results.  
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Chapter 4  
 
4 Results 
 
Of the four participants within this study, three full sets of data were obtained 
(cases 1–3) and one participant (case 4) withdrew one week post intervention. 
This participant withdrew one-week post intervention, after being re-advised of 
the potential side-effects of the Scopoderm TTS® transdermal patches, despite 
no adverse side-effects being recorded or reported in this participant. The three 
full sets of data were analysed and results presented in each case below. There 
were no documented adverse reactions or side-effects in any of the patients 
who received treatment using transdermal patches of Scopoderm TTS®. 
4.1 Case reports 
 
4.11 Case 1  
 
Using linear regression analysis there was a significant reduction in the amount 
of oral secretions pre and post treatment, (P <0.001, F= 27.252, df= 1, 52). The 
most significant change in oral secretions occurred post one-week of 
intervention (P<0.001, F= 153.532, df= 1, 16). The average weights of the wet 
dental rolls at each time point are shown in table 1.  
 
Table 1 Average wet weights of dental rolls at pre and post intervention time-points  
(case 1)  
 
Time  Weight in grams 
One-week prior treatment 4.02 
One-week post treatment 2.65 
Two-weeks post treatment 2.78 
Four-weeks post treatment 2.87 
Eight-weeks post treatment 2.73 
Twelve-weeks post intervention 2.68 
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Figure 1 shows the weights of the wet dental rolls for each observation for this 
individual (Appendix K). 
The visual analogue scale (VAS) score for saliva ranged from 100 (copious 
amounts of saliva) to 0 (no difficulties with saliva). In case 1 the primary one-to-
one nurse rated the saliva score at 80 out of 100, prior to treatment, suggestive 
of large amounts of saliva presence and at 10 out of 100 at 12-weeks post 
treatment, suggestive of minimal amounts of saliva presence (Appendix K). 
The VAS score for saliva was rated at 100 out of 100 by the patient’s primary 
carer pre-treatment intervention, suggestive of large amounts of saliva presence 
and at 12-weeks post intervention by the same carer at 10 out of 100, 
suggestive of minimal amounts of saliva presence (Appendix K). 
The primary one-to-one nurse reported that pre-treatment the patient was 
requiring tracheal suctioning as ‘very much true’ and at 12-weeks post 
treatment intervention requiring tracheal suctioning as being rated as ‘not at all 
true’ (Appendix K). Tracheal suctioning was performed on average 13 times 
during a 12-hour period pre-treatment and on average six times during a 12-
hour period, post one-week intervention and to once a day, during a 12-hour 
period post 12-weeks intervention (Figure 2; Appendix K). Analysis of the 
frequency of tracheal suctioning performed across time, using The Chi-Square 
Goodness of Fit test, showed a significant reduction in the frequency of tracheal 
suctioning performed, at two weeks post intervention, p=0.007. 
The primary reason for performing tracheal suctioning was documented by the 
one-to-one nurse as audible or visible secretions in the tracheostomy tube 
(Appendix K). One-week after data collection ceased the tracheostomy tube 
was successfully removed and the patient was breathing on room air, without 
the need for any further tracheal suctioning. 
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Figure 1 Dental rolls wet weights in grams, at pre and post intervention time-points   
(case 1) 
  
        
 Figure 2 Average suctioning frequency (12-hour period), pre and post treatment (Rx) 
(case 1) 
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4.12 Case 2  
 
Using linear regression analysis there was a significant reduction in the amount 
of saliva pre and post treatment, (P <0.001, F= 11.622, df= 1, 52). The most 
significant change in saliva occurred post one-week of intervention (P<0.001, 
F= 138.573, df= 1, 16). The average weights of the wet dental rolls at each time 
point are shown in table 2. 
 
Table 2 Average wet weights of dental rolls at pre and post intervention time-points  
(case 2) 
 
Time  Weight in grams 
One-week prior treatment 6.07 
One-week post treatment  4.52 
Two-weeks post treatment  3.86 
Four-weeks post treatment  4.30 
Eight-weeks post treatment  4.40 
Twelve-weeks post intervention  4.84 
 
Figure 3 shows the weights of the wet dental rolls for each observation for this 
individual (Appendix L).  
The visual analogue scale (VAS) score for saliva was rated at 100 out of 100 by 
the primary one-to-one nurse, prior to treatment intervention, suggestive of 
large amounts of saliva presence and at 12-weeks post intervention by the 
same nurse carer at a score of 40 out of 100, suggestive of moderate amounts 
of saliva presence (Appendix L). 
The VAS score for saliva was rated at 100 out of 100 by the patient’s primary 
caregiver pre-treatment intervention, suggestive of large amounts of saliva 
presence and at 12-weeks post intervention by the same caregiver at 50 out of 
100, suggestive of moderate amounts of saliva presence (Appendix L). 
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The primary one-to-one nurse rated that pre-treatment intervention the patient 
was requiring tracheal suctioning as ‘very much true’ and at 12-weeks post 
treatment intervention requiring tracheal suctioning as being rated as 
‘somewhat true’ (Appendix L). Tracheal suctioning was performed on average 
10 times during a 12-hour period pre-treatment intervention and on average 10 
times during a 12-hour period, post one-week intervention and an average of six 
times a day, during a 12-hour period post 12-weeks intervention (Figure 4; 
Appendix L).  
Analysis of the frequency of tracheal suctioning performed across time in this 
case, using The Chi-Square Goodness of Fit test, did not show any significant 
changes at any time-point, when comparing pre and post intervention tracheal 
suctioning. 
The primary reason for performing tracheal suctioning was documented by the 
one-to-one nurse as audible or visible secretions in the tracheostomy tube 
(Appendix L).  
 
Post data collection the patient continued to require tracheal suctioning and the 
tracheostomy tube continued to be in-situ for this purpose, although there were 
short-periods throughout the day when a one-way valve was placed onto the 
end of the tracheostomy tube to allow airflow to be directed across the larynx. 
Three-weeks after data collection ceased the tracheostomy tube was 
successfully removed and the patient was breathing on room air, without the 
need for any further tracheal suctioning. 
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Figure 3 Dental rolls wet weights in grams, at pre and post intervention time-points (case 2) 
 
 
 
Figure 4 Average suctioning frequency (12-hour period) pre and post treatment (Rx) 
(case 2) 
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4.13 Case 3  
 
Using linear regression analysis there was a significant reduction in the amount 
of saliva pre and post treatment, (P <0.001, F= 159.314, df= 1, 52). The most 
significant changes in saliva occurred in the periods one-week, two-weeks and 
at four-weeks post intervention (P<0.001, F= 54.379, df= 1,16; P<0.001, F= 
22.098, df= 1,16 and P<0.003, F= 12.312, df= 1,16). The average weights of the 
wet dental rolls at each time point are shown in Table 3. 
 
Table 3 Average wet weights of dental rolls at pre and post intervention time-points  
(case 3) 
 
Time  Weight in grams 
One-week prior treatment 4.91 
One-week post treatment 4.45 
Two-weeks post treatment 4.20 
Four-weeks post treatment 4.06 
Eight-weeks post treatment 4.01 
Twelve-weeks post intervention 3.97 
 
Figure 5 shows the weights of the wet dental rolls for each observation for this 
individual (Appendix M). 
 
The visual analogue scale (VAS) score for saliva was rated at 100 out of 100 by 
the primary one-to-one nurse, prior to treatment intervention, suggestive of 
large amounts of saliva presence and at 12-weeks post intervention by the 
same nurse at a score of 20 out of 100, suggestive of minimal amounts of saliva 
presence (Appendix M). 
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The VAS score for saliva was rated at 100 out of 100 by the patient’s primary 
caregiver pre-treatment intervention, suggestive of minimal amounts of saliva 
presence and at 12-weeks post intervention at 20 out of 100 suggestive of 
minimal amounts of saliva presence (Appendix M). 
The primary one-to-one nurse rated that pre-treatment intervention the patient 
was requiring tracheal suctioning as ‘very much true’ and at 12-weeks post 
treatment intervention requiring tracheal suctioning as being rated as ‘a little 
true’ (Appendix M). Tracheal suctioning was performed on average 15 times 
during a 12-hour period pre-treatment intervention and on average nine times 
during a 12-hour period, post one-week intervention and an average of three 
times a day, during a 12-hour period post 12-weeks intervention (Figure 6; 
Appendix M). Analysis of the frequency of tracheal suctioning performed across 
time, using The Chi-Square Goodness of Fit test, showed a significant reduction 
in the frequency of tracheal suctioning performed, at four weeks post 
intervention, p=0.078. 
The primary reason for performing tracheal suctioning was documented by the 
one-to-one nurse as audible or visible secretions in the tracheostomy tube 
(Appendix M). Following the data collection the patient’s tracheostomy tube was 
successfully closed for a full 24 to 48 hours, with routine peripheral tracheal 
suctioning performed once to twice a day to clear saliva from within the inner 
tube of the tracheostomy tube. One-week after data collection ceased the 
tracheostomy tube was successfully removed and the patient was breathing on 
room air, without the need for any further tracheal suctioning. 
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Figure 5 Dental rolls wet weights in grams, at pre and post intervention time-points (case 3) 
 
 
 
Figure 6 Average suctioning frequency (12-hour period) pre and post treatment (Rx) 
(case 3) 
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4.14 Cases 1 – 3 
 
In all cases each primary caregiver rated that the tracheostomy tube caused 
them concern and that they were scared when tracheal suctioning was required, 
and rated these statements as being ‘very much true’ throughout (Appendices 
K, L and M). All caregivers also reported that their relative having the 
tracheostomy tube in place made them feel sad and discouraged and all 
reported ‘very much true’ a sense of feeling frustrated (Appendices K, L and M). 
There was a significant reduction (P<0.001) in saliva, in all participants post one 
week treatment intervention. The primary caregivers reported a change in the 
amount of tracheal suctioning required, with two rating requiring regular 
suctioning as ‘very much true’ pre-treatment intervention to a ‘little true’ post 12-
weeks intervention and the other rating it as ‘very much true’ pre-treatment 
intervention to ‘somewhat true’ post 12-weeks intervention (Appendices K, L 
and M).  
The visual analogue scale (VAS) score for saliva ranged from 100 (copious 
amounts of saliva) to 0 (no difficulties with saliva). In all cases both the one-to-
one nurse and the patient’s primary caregiver reported a reduction of saliva on 
the visual analogue scale, with all rating saliva pre-treatment at 100 (copious 
amounts of saliva). In two cases (cases 1 and 3) at 12-weeks post-intervention, 
the one-to-one nurse and caregiver rated the saliva at 10 (case 1) and 20 (case 
3), suggestive of minimal amounts of saliva. In case 2 the one-to-one nurse 
rated saliva at 40 and caregiver at 50, suggestive of moderate amounts of 
saliva presence at 12-weeks post-intervention (Appendices K, L and M). 
Table 4 Average number of tracheal suctioning performed for each participant (case) at each 
time-point 
Participant Pre 
intervention 
1 week post 
intervention 
2 weeks 
post 
intervention 
4 weeks 
post 
intervention 
8 weeks 
post 
intervention 
12 weeks 
post 
intervention 
Case 1 13 6 2 2 1 1 
Case 2 10 10 12 15 8 6 
Case 3 15 9 9 6 3 3 
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When analysing the frequency of tracheal suctioning using a Chi-Square test 
across all case participants there was a significant reduction in the frequency of 
tracheal suctioning performed post treatment intervention, Fisher’s Exact Test 
p=0.094 and Cramer’s V=0.253, suggesting an approximate variance of 25%.  
In all three cases there was a reduction in the frequency to perform tracheal 
suctioning, as measured across a 12-hour period (08:00-20:00), in case 1 the 
average frequency of tracheal suctioning pre-intervention was 13, which was 
reduced to an average of 1, at 12-weeks post-intervention. In case 2 tracheal 
suctioning was performed on average10 times pre-intervention and scored at an 
average of 6 times at 12-weeks post-intervention. In case 3 tracheal suctioning 
was performed on average15 times pre-intervention and scored at an average 
of 3 times at 12-weeks post-intervention. In all cases the primary reason for 
performing tracheal suctioning was cited as being ‘secretions audible’, followed 
by ‘secretions visible’ and then listed as ‘other’, describing the need to perform 
tracheal suctioning due to the patient coughing (Appendices K, L and M). 
In all cases pre-treatment intervention all one-to-one (the same) nurse rated the 
statement ‘the patient constantly requires tracheal suctioning’ on the nurse 
survey as ‘very much true’ and at 12-weeks post-intervention at ‘not at all true’ 
(case 1) (Appendix K); ‘somewhat true’ (case 2) (Appendix L) and ‘a little true’  
(case 3) (Appendix M). 
Throughout the study the patients primary caregivers rated that having a 
tracheostomy tube in-situ made them feel frustrated and sad as ‘true’ 
(Appendices K, L and M). Caregivers also all rated that they were scared when 
tracheal suctioning was required, rating this as ‘very much true’ (cases 2 and 
case 3) (Appendices L and M) or in case 1 as ‘quite true’ (Appendix K).  
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Chapter 5  
 
5 Discussion of results  
 
Saliva is a valuable oral fluid that is often taken for granted. Saliva is produced 
in and secreted by the salivary glands and is crucial to the preservation and 
maintenance of oral health. However, it is not until a change in the quantity or 
quality that it becomes an area of concern. When saliva is diminished, this may 
lead to a dry mouth, resulting in feelings of discomfort and difficulties in 
swallowing. Conversely too much saliva or inability to control saliva may have 
more serious consequences, affecting quality of life and health status. Drooling 
is rarely due to excessive production of saliva, but is a problem in the 
coordinated control of the muscles of the oral cavity, face, tongue and palate, 
usually due to impaired neurological control. This impaired control results in a 
dysfunctional swallow and may lead to excessive accumulation of saliva in the 
oral cavity and the unintentional loss of saliva from the mouth or into the 
pharynx.  Furthermore, the inability to swallow adequately also increases the 
risk of developing aspiration pneumonia, which can be life-threatening and in 
some cases fatal. Patients with copious amounts of saliva, who are unable to 
clear material effectively from the airway may require assistance in manually 
removing the saliva, using suctioning, via a tracheostomy tube, to prevent saliva 
obstructing the airway, making it difficult for the lungs to get the oxygen they 
need. Tracheal suctioning involves the removal of secretions, including saliva 
from the trachea or bronchi, by inserting a catheter through the tracheostomy 
tube.  
There are no licensed products that are available to assist in reducing saliva in 
patients who may require a tracheostomy tube for the purpose of providing 
tracheal suctioning, but often unlicensed medications are prescribed ‘off-label’ 
to assist in this regard. This study showed that ‘Scopoderm TTS®’ transdermal 
patches were effective in reducing saliva in all three patients and thereby 
resulted in a reduction in the frequency of tracheal suctioning required.   
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In this study saliva was collected using the swab method (White 2007) and 
dental rolls were placed intra-orally, but placement had to be modified in each 
case. Two participants who presented with head injury and in a low-awareness 
state (cases 2-3) and who had a bite reflex, therefore placement of dental rolls 
on the tongue or sublingually were not possible, as it would’ve been difficult to 
place and / or retrieve the rolls after placement. There was also a risk that the 
dental rolls may fall into the airway if placement onto the tongue was possible 
and then non-retrievable following a bite-reflex response. Therefore all data 
collection of saliva involved placement of three dental rolls; one in the anterior 
sulcus and one-each in the lateral sulci, which was the same in each case 
series. As data was compared within participants this did not affect the overall 
outcome of data collected.  
All participants were non-mobile and therefore dependent on being positioned 
as close to 90 degree sitting, by the one-to-one nurse, with placement of the 
dental rolls made by the primary investigator in each case. Using the swab 
method of saliva collection (White 2007) would have been more challenging 
with participants who were more mobile or presented with cognitive deficits, as 
they may not have co-operated in holding the dental rolls orally for the duration 
of five-minutes and spat-out the rolls, making it difficult to gain accurate 
readings of saliva collection.  
Concurrent speech and language therapy intervention, which involved a 
sensory stimulation programme, including swallowing stimulation was offered 
alongside the pharmacological treatment in each of the participants. It is difficult 
to dissociate the effects of therapy intervention from that of the pharmacological 
intervention and how this may have influenced the amount of intra-oral saliva 
collected, however it was not possible to withhold therapy intervention as doing 
so would have been unethical.  Data collection of saliva  made by the primary 
investigator for each participant occurred at three fixed time-points (10:00am, 
1:00pm and 4:00pm) and were recorded at these set time intervals pre and post 
treatment and did not coincide with any speech and language therapy sessions, 
or other interventions, so thereby limiting any immediate effects of therapy 
intervention on saliva data collection.   
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With an increasing demand for intensive care beds more nurses in acute and 
high dependency wards are expected to care competently for patients who have 
a tracheostomy tube in-situ (Haines and Coad 2001). Tracheal suctioning is an 
essential part of effective airway management in these patients. However, 
tracheal suctioning has many associated risks and complications, ranging from 
trauma and hypoxaemia to, in extreme cases, cardiac arrest and death (Santus, 
Gramegna et al. 2014).  
 
In a study by Day (Day, Farnell et al. 2002), looking at nursing knowledge of 
tracheal suctioning, Day concluded that there was a poor level of knowledge for 
many nurses and this was also reflected in practice, as suctioning was 
performed against many of the recommended guidelines. Many practitioners 
were unaware of recommended practice and a number demonstrated 
potentially unsafe practice. In addition, there was no significant relationship 
between knowledge and practice (Day, Farnell et al. 2002). In their study they 
concluded that in practice only 2 out of the 28 nurses provided pre-oxygenation 
prior to suctioning, although 10 indicated knowledge to do so. Also despite a 
large number (n=19) indicating that suctioning should be performed after 
auscultation, in actual practice only 2 did so. Furthermore they found that there 
were errors associated to infection control prior to tracheal suctioning with only 
2 nurses carrying-out correct hand-washing procedures (Day, Farnell et al. 
2002). This study did not investigate the competencies of the nursing staff, but 
all nurses who were providing the one-to-one care for the patients were deemed 
to be competent in caring for patients who required tracheostomy tube care and 
tracheal suctioning.  
If the frequency and the need to perform tracheal suctioning are reduced, by 
diminishing saliva flow, this may reduce the amount of saliva that potentially 
falls into the airway, thereby reducing the need and known associated risks with 
performing tracheal suctioning (Fiorentini 1992; Kapadia, Bajan et al. 2000). 
Furthermore reducing the need for performing tracheal suctioning may assist in 
successful removal of the tracheostomy tube and thus no longer necessitates a 
one-to-one nurse to provide care, which may assist in reducing costs. In all 
case series (cases 1-3), the primary reason for a one-to-one 24-hour nurse, 
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was to provide regular tracheal suctioning in order to clear saliva that had fallen 
into the airway, as these participants were unable to independently clear their 
saliva. All other care could be provided as routine care, such as regular 
positioning, set-up and deliverance of PEG tube feeding and washing and 
dressing, not necessitating one-to-one nursing care.   
In each case the saliva flow rate pre-treatment for each case was at 0.38ml/min 
(case 1), 0.76ml/min (case 2) and at 0.53ml/min (case 3). This flow rate 
corresponds to a normal rate in an unstimulated state (Tenovuo and Lagerlof 
1994). So each participant had a normal salivary flow rate, but associated 
swallowing dysfunction which led to an accumulation of saliva in the oral cavity 
and subsequent posterior overspill into the airway (Reddihough, Erasmus et al. 
2010). However one week post treatment there was a reduction in the saliva 
flow rate for each patient which was at 0.19ml/min (case 1), 0.36ml/min (case 2) 
and at 0.45ml/min (case 3), which can be classified as low rate in the 
unstimulated state in case 1 and within the normal range in the unstimulated 
state for cases 2 and 3 (Tenovuo and Lagerlof 1994). The greatest change in 
saliva flow rate occurred in the case of the patient who had a primary diagnosis 
of cerebral vascular accident (case 1) and although there was a significant 
reduction in the two other patients whose primary diagnosis was head injury, 
the change was not as great, but it did lead to a reduction in the need to 
perform tracheal suctioning in each case. 
Where individuals were identified as requiring tracheal suctioning to assist in the 
clearance of saliva from within the trachea, the medical teams seemed to have 
a preference to use off-labelling prescription of Scopoderm TTS® transdermal 
patches over the use of other pharmacological options such as the off-label 
prescribing of botulinum toxin, despite not being coerced by the primary treating 
speech and language therapist, tracheostomy team or nursing staff as to which 
treatment approach to prescribe. Despite the average frequency of tracheal 
suctioning identified pre-treatment in each case (13 in case 1,  10 in case 2 and 
15 in case 3), there was no discussion between the team, consultant or 
participants and/or carers to agree an acceptable treatment intervention. As 
botulinum toxin or any other pharmacological treatment was not prescribed in 
any of these cases, it is difficult to speculate whether the treatment affect would 
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have been more instantaneous and resulted in a quicker reduction in the 
amount of saliva. Jongerius et al (Jongerius, Rotteveel et al. 2004) concluded in 
their study that there was a greater effect, when comparing single-dose 
botulinum toxin injections into the salivary glands with scopolamine treatment, in 
children with Cerebral Palsy. 
   
It is difficult to say whether the treatment intervention led to a reduction in saliva 
or whether this was related to an increase in the number of reflexive swallows to 
clear saliva or a combination of both, although data recordings were collected at 
times of non-stimulation. Throughout the course of normal therapy intervention 
the tracheostomy tube may be capped-off (closed-off), where appropriate, or a 
one-way valve applied to the end of the tracheostomy tube. This valve allows air 
to enter via the tracheostomy tube and closes upon exhalation to direct air 
through the mouth and nose, normalising airflow across the larynx and 
facilitating an oral airstream (Hess 2005). Normalising airflow and promoting an 
oral airstream, causing greater airflow across the larynx increases sensitivity 
and may assist in increasing the number of reflexive swallows to clear saliva 
(Windhorst, Harth et al. 2009). However in each case series, the tracheostomy 
tube was not closed-off until the later-part of post-intervention treatment, after 
10-12 weeks post intervention in case 1 and intermittently for a couple of hours 
during the day post eight-weeks intervention in case 2 and at post 12-weeks 
intervention in case 3. All participants were assessed by the speech and 
language therapist within 24-hours of admission and therapy intervention 
commenced thereafter, which continued until they were discharged from the 
hospital. 
In the stimulated state, saliva flow rates drastically change the percentage 
contributions from each gland, with the parotid gland contributing more than 
50% of total salivary secretions (Edgar 1990), producing large volumes of 
serous saliva, in response to a stimulant. The Wellington Hospital has an 
established oral hygiene protocol and policy for all non-ventilated patients, 
which comprehensively details how and when to perform oral hygiene care. 
Providing this care and physically placing the dental rolls might have stimulated 
an increase in saliva, but in order to minimise this occurrence oral hygiene was 
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not performed in any of the participants within an hour of the data collection 
times (10:00am, 1:00pm and 4:00pm). Care was also taken when placing the 
dental rolls, so as to minimise the level of intra-oral stimulation and external 
stimuli given, which was performed by the primary investigator who collected all 
data recordings. 
All patients routinely received saline nebulisers, every 4-6 hours pre and post 
treatment intervention to avoid any possible complications of ‘plugging-off’ of 
the tracheostomy tube, which is caused by thick saliva blocking the inside of the 
tracheostomy tube. Saline nebulisers are sodium chloride water solutions that 
convert liquids into aerosol droplets, which assist in breaking down thick saliva 
(AARC 2003). In each case series nebulisation was not administered at times 
around data collection (10:00am, 1:00pm and 4:00pm). 
All patients in this case series were non-verbal, unable to follow verbal 
commands or swallow to command, and unable to report any adverse side-
effects to the treatment. They were therefore dependent on their primary care-
giver, nursing reports and chart observations to indicate any adverse reactions 
to the treatment. Despite the fact that the patients were unable to report any 
adverse side effects, such as dizziness, blurred vision or dry-mouth, it was 
deemed in their best interest that the treatment benefits of reduced oral saliva 
and reduction in the potential need for tracheal suctioning would outweigh the 
potential adverse side-effects of Scopoderm TTS® transdermal patches. None 
of the patients within this study were on any known medications that would 
induce or inhibit saliva flow (Nahri 1994). All patients continued to receive 
therapy with no observed adverse reactions that were reported by the therapy 
team or the one-to-one nurse special or primary care-giver.     
In each case series, saliva as measured using the swab method (White 2007) 
did not show an increase from baseline (pre-treatment) and at each recorded 
time-point remained at a stable level or showed a reduction. As it would be 
unethical to remove the treatment once instigated, we could not show that it 
was largely the Scopoderm TTS® transdermal patch that had a causal 
relationship in reducing the saliva. Removing the treatment may have shown an 
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increase in saliva weights, which may then be directly attributed to the 
Scopoderm TTS® intervention. 
In this case series a single Scopoderm TTS® transdermal patch (1.5mg) was 
administered and replaced every three days, which on average allows the 
absorption of 1mg across three days (Novartis Consumer Health UK Ltd 2016). 
In every-day practice following periods of prescribed Scopoderm TTS® patches 
(1.5mg), where there is no perceived changes in the amount of pooled saliva, 
prescribers often use greater dosages, prescribing one and a half patches 
(2.25mg) instead of one patch, particularly in cases where there are copious 
amounts of saliva. It is therefore questionable whether an increased dosage 
may have resulted in a greater reduction in oral saliva. However in this study 
each participant received a single patch of Scopolamine TTS® throughout the 
study, therefore not affecting the data collection. 
The patient’s tracheostomy tube chart (Appendix I) recorded the number of 
tracheal suctions performed and the reasoning for this was also noted 
(appendix A), indicating that the one-to-one nurse was systematically thinking 
and documenting why and when tracheal suctioning was required and 
performed. However the nurse did not document if and when oral suctioning 
was performed to remove pooled saliva from within the oral cavity, which may 
have influenced the subsequent need to then perform tracheal suctioning. Oral 
suctioning reduces the amount of orally pooled saliva, which may have led to a 
reduction in the amount of saliva overspill into the airway and therefore reduced 
the need to perform tracheal suctioning. This would then result in altered 
recordings of tracheal suctioning; however this was controlled by avoiding any 
therapeutic or nursing interventions at or around times of data collection. Also 
an average of tracheal suctioning was taken across three consecutive days at 
one-week prior treatment, one-week, two-weeks, four-weeks, eight-weeks and 
at 12-weeks post treatment and an average obtained across the three days of 
readings.    
Participants and care-givers in this study were not ‘blinded’ to the treatment and 
intervention could not be withheld or a placebo could not be administered 
instead, as we were observing the clinical management of saliva in these 
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participants. Knowing that treatment was prescribed may have caused bias 
from the one-to-one nurse and also from the primary caregiver, which may have 
influenced the scores they rated on the saliva visual analogue scale. Although 
the carer and nursing staff were unaware of the weights of the intra-oral dental 
rolls at each time-point, being aware that saliva was being monitored may have 
influenced their decisions on the need and frequency to perform tracheal or oral 
suctioning; however this was regulated by providing guidelines and recording 
charts, to document clearly as to why tracheal suctioning was being undertaken. 
There was also a reduction recorded at each time-point (one-week, two-weeks, 
four weeks, eight weeks and at 12-weeks) post intervention in the weight of the 
dental rolls, and also a reduction in the mean frequency of tracheal suctioning 
performed at each of the time-points, so suctioning should not have influenced, 
the dental roll weights.    
Post one week treatment there was a reduction in the saliva flow rate for each 
patient of 0.19ml/min (case 1), 0.36ml/min (case 2) and at 0.45ml/min (case 3), 
which can be classified as a low rate in the unstimulated rate in the first case 
and within the normal range in the unstimulated state for the subsequent two 
cases (Tenovuo and Lagerlof 1994). In the case of low rate in the unstimulated 
condition (case 1), the primary diagnosis was cerebral vascular accident and 
different to that of the two other cases, which were diagnoses of head injury 
(case 2 and 3). In future studies it may be useful to compare between 
diagnoses, in order to compare outcomes in patients who have a focal injury 
versus that of diffuse brain injury. It is difficult to make a definitive conclusion 
between the saliva flow rates in the patient with a cerebral vascular accident 
versus the other patients with head injuries, as the sample size was small. 
When analysing the frequency of suctioning there appears to have been a 
significant reduction in amount of tracheal suctioning performed two-weeks post 
intervention in case 1 (p=0.007), and at four-weeks post intervention in case 3 
(p=0.078), but no significant differences found in case 2. This finding may be 
related to the primary medical diagnoses of each of the participants in that 
cases 2 and 3 were diagnosed with a hypoxic brain injury and Head Injury, 
resulting in a Glasgow Coma Scale (GCS) (Teasdale and Jennett 1976) of 8 out 
of 15 and 5 out of 15 respectively, whereas in comparison, case 1 had a 
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diagnosis of cerebral vascular accident with a GCS of 11 out of 15. A GCS of 8 
or less indicates severe injury, one of 9-12 a moderate injury, and a GCS score 
of 13-15 is obtained when the injury is minor (Teasdale and Jennett 1974). 
Taking the these differences in GCS into account the participants in case 2 and 
3 had more severe diffuse brain injury, whereas the participant in case 1 had a 
moderate injury, which was a focal brain injury, which may have influenced the 
outcome. McPherson and Stephens reported that patients with a reduced 
conscious level are unable to clear their own secretions and cannot protect their 
own airway (McPherson and Stephens 2012). They suggested that a Glasgow 
Coma Scale of 8/15 or below is often considered the threshold at which 
intubation is necessary (McPherson and Stephens 2012) and that patients with 
reduced conscious level are at risk of aspiration (McPherson and Stephens 
2012). 
Both participants in cases 2 and 3, were dependent on tube feeding with no oral 
intake and scored at level 1, as rated on the functional oral intake scale (FOIS) 
(Crary, Mann et al. 2005), whereas the participant in case 1 was tube 
dependent for feeding, but receiving inconsistent oral trials with their speech 
and language therapist and scored at level 2 on the FOIS (Crary, Mann et al. 
2005).This difference may explain the improvement in case 1 with an earlier 
significant reduction in saliva, as measured by dental roll weights, and also a 
reduction in the frequency of tracheal suctioning, in that this individual was 
starting to receive inconsistent oral trails, thus showing an improvement in their 
swallowing status and therefore beginning to swallow their secretions.  
 
Drooling occurs in about one in two patients affected with Motor Neurone 
Disease and one in five needs continuous saliva elimination (Giess 2000), its 
prevalence is about 70% in patients with Parkinson Disease (Jongerius 2004), 
and between 10 to 80% in patients with Cerebral Palsy (Boothwell 2002). 
Despite this high rate of prevalence and the need to eliminate saliva in these 
patient populations there are no recognised national, government-led 
guidelines, policies or procedures to manage saliva in these patient populations, 
as well as in patients who have a tracheostomy tube in-situ. 
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The National Institute for Health and Care Excellence (NICE) Guideline for the 
use of non-invasive ventilation in the management of Motor Neurone Disease 
(National Institute for Health and Care Excellence 2010), states that before 
starting non-invasive ventilation, the multidisciplinary team should prepare a 
comprehensive care plan, after discussion with the patient and their family. This 
should include ‘secretion management and respiratory physiotherapy 
assessment, including cough assist’, and how the team should assist in saliva 
management. It does not however make any other reference to the 
management options of saliva in the event of difficulties in managing excessive 
saliva and difficulties due to neuromuscular weakness. 
 
In the NICE full Clinical Guideline on the management of Parkinson’s Disease, 
injection of salivary glands with botulinum toxin A is one option suggested for 
the treatment of hypersalivation (The National Collaborating Centre for Chronic 
Conditions 2006), but no mention of other treatments for drooling. However 
there are no recommendations for the treatment or management of saliva in the 
case of drooling in the NICE guideline for spasticity in children and young 
people with non-progressive brain disorders (National Institute for Health and 
Care Excellence 2012). The guideline advises on the use of botulinum toxin 
type A for focal spasticity and advises children, young people and their parents 
or carers that one of the serious side effects and complications of its use is 
swallowing difficulties. The guideline makes no reference to the management of 
drooling or management options for excessive saliva. Systematic reviews of 
botulinum toxin in the management of hypersalivation have been published (Lim 
2006; Stone 2009) and overall suggest that botulinum toxin treatment is a safe, 
minimally invasive. It is accepted that the use of botulinum toxin is a useful tool 
in the treatment of hypersalivation in Parkinson’s disease, despite not being 
licensed for this purpose. There are also a number of studies that have 
investigated the management of drooling in children with Cerebral Palsy 
(Walshe, Smith et al. 2012). In their study Jongerius et al.(Jongerius, Rotteveel 
et al. 2004), carried-out a controlled clinical trial on the treatment of drooling in 
children with Cerebral Palsy, in which botulinum toxin injections to the 
submandibular glands were compared with scopolamine treatment and 
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botulinum toxin injections were found to significantly reduce drooling from 
baseline measures, when compared to the effects of scopolamine treatment. 
Despite the use of botulinum toxin injections in these studies with these patient 
populations there seems to be a reluctance to consider the use of botulinum 
toxin injections into the salivary glands with patients who have a tracheostomy 
tube in-situ. The primary treatment prescribed by the consultant to manage 
saliva in this patient population, was the use of Scopolamine TTS® transdermal 
patches. One possible reason for using transdermal patches as a primary 
treatment method is that it is a non-invasive treatment option and is preferred 
over the more invasive technique of injecting botulinum toxin into the salivary 
glands. 
Since the administration of botulinum toxin is invasive and requires expertise to 
perform the intervention, patient access to treatment is restricted (Hyson 2002) 
and this may further have restricted the referral to this treatment modality over 
the use of Scopoderm TTS® transdermal patches. Furthermore the effects of 
repeated injections of botulinum toxin over time, or the risk of developing 
antibodies, are not known (Meningaud 2006). Jongerius et al. (Jongerius 2004), 
showed that both treatments of scopolamine and botulinum toxin injections into 
the salivary glands significantly reduced drooling compared with baseline. In 
their study the outcomes of both treatment modalities were in the same range 
and no significant differences were found between Drooling Quotient 
measurements. However a disadvantage in the treatment using scopolamine 
was the high percentage of observed adverse reactions, which were 
xerostomia, restlessness, drowsiness, blurred vision and confusion, whereas 
botulinum toxin injections only required a general anaesthesia and had minimal 
reported temporary adverse reactions (Jongerius 2004). Given that the patients 
within this study were in a low-arousal condition, they were unable to provide 
details of any possible perceived adverse reactions they may have experienced 
during therapy sessions, although none were reported by the same one-to-one 
nurse or the primary care-giver.  
Another reason for choosing Scopoderm TTS® transdermal patches over 
injections of botulinum toxin into the salivary glands is that the cost of botulinum 
toxin and procedure is much higher than that of prescribing and applying 
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transdermal patches. A local cost analysis estimated that the costs associated 
with intra-glandular botulinum toxin injections would be seven times more costly 
than an equivalent three-month supply of Scopoderm TTS® transdermal 
patches.  
The known risk factors and possible adverse side-effects of each of the 
treatment interventions are well documented in the summary of product 
characteristics for each medication (Allergan 2015).  The main side effects of 
injecting botulinum toxin into the salivary glands are dysphagia, due to diffusion 
into nearby bulbar muscles, weak mastication, parotid gland infection, damage 
to the facial nerve/artery and dental caries (Allergan 2015). In comparison the 
use of Scopolamine TTS® transdermal patches may cause drowsiness, 
dizziness, confusion, visual hallucinations and possible urinary retention issues, 
albeit rarely (Novartis Consumer Health UK Ltd 2016).  In conjunction with 
these possible adverse side-effects, the clinical effect of botulinum toxin 
injections lasts for approximately 2 - 6 months (Allergan 2015) and then 
resolves once new axon terminals form. In comparison the Scopolamine TTS® 
transdermal patches can be removed immediately upon any report of clinical 
adverse side-effects (Novartis Consumer Health UK Ltd 2016). The length of 
reversal of the botulinum treatment would take much longer in the event of any 
identified adverse side-effects, and again would be a contributing factor when 
deciding upon which treatment modality to prescribe. The main side effects of 
Scopolamine TTS® transdermal patches are it may cause drowsiness, 
dizziness, confusion or visual disturbances in certain individuals, which may 
affect the ability of the patients to participate and engage within a therapeutic 
programme; however two patients (cases 2 and 3) were in a low-awareness 
state with a Glasgow Coma Scale (GCS) (Teasdale and Jennett 1974) of 8/15 
and 5/15 respectively and case 1 did not appear to present with any of these 
side-effects, who had a GCS of 11/15. 
The initial treatment of preference offered by the primary consultant was the use 
of Scopoderm TTS® transdermal patches. Given that there was an overall 
reduction in salivary flow, as measured using the saliva swab collection method 
(White 2007) and no reported adverse side-effects in these three cases an 
alternative treatment intervention was not sought.   
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Although there was a positive outcome in the reduction of saliva flow in these 
three case series, further studies using more participants with multiple 
diagnoses and using a range of treatment modalities need to be undertaken. 
Considering the social burden to the affected patients and known associated 
complications of tracheal suctioning (Fiorentini 1992; Kapadia, Bajan et al. 
2000), it is relevant to develop national clinical guidelines to distinguish the 
types of treatment that are available to manage saliva in patients who have a 
tracheostomy tube in-situ and to optimise the treatment that are specifically 
effective.  
In conclusion, during treatment intervention using Scopoderm TTS® transdermal 
patches there was a clinically relevant reduction of saliva in these case series, 
in adults who had a tracheostomy tube in-situ, with the maximum effect 
occurring between 1 to 2 weeks post intervention. There was also a reduction in 
the frequency and need to perform tracheal suctioning in each case and all one-
to-one nurses and patients’ primary caregivers reported a reduction in saliva as 
reported on a visual analogue scale (Appendices K, L and M). Additional 
research is required with a larger sample size and range of treatment modalities 
to optimise the therapeutic effect of each treatment. 
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Chapter 6 
  
 6 Conclusions 
 
The result of this pilot study indicates that excessive saliva can be successfully 
managed in tracheostomised patients with the use of Scopoderm TTS® 
Transdermal patches. This is the first study which has investigated the medical 
management of saliva in this patient population. Other studies have reported 
the successful use of botulinum toxin injections into the salivary glands to 
manage drooling in other patient populations(Jongerius, Rotteveel et al. 2004; 
Lagalla, Millevolte et al. 2006); however in this study the medical teams did not 
prescribe the use of botulinum toxin injections as a treatment intervention for 
these tracheostomised patients. 
 
During Scopolamine TTS® transdermal patches application, a clinically relevant 
reduction in saliva was achieved in the three patients in this study, 
demonstrating maximum effect 1- 2 weeks after application. In these three 
cases there were no reported side-effects and all participants were successfully 
decannulated from their tracheostomy tube: one-week post data collection in 
cases 1 and 3 and three-weeks post data collection in case 2. In this pilot study 
the sample size was very small and all three participants were treated solely 
with Scopolamine TTS® transdermal patches, as prescribed by their primary 
consultant. It is recommended that future research implements a multi-site 
centred study, thus promoting a larger sample size and comparing the use of 
different interventions at reducing saliva. Furthermore it is important to provide 
education to the medical teams of the benefits and potential side-effects of each 
of the intervention options in order to allow informed decision making.  
 
 
 
A recent report produced by the National Confidential Enquiry into Patient 
Outcome and Death (NCEPOD), reviewing the care received by patients who 
underwent insertion of a tracheostomy tube (Wilkinson, Martin et al. 2014), 
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explored factors surrounding the insertion and subsequent management of 
tracheostomy tubes in both the critical care and ward environments by: 
 
• ‘Exploring (percutaneous and surgical) tracheostomy-related complications 
following insertion in the operating theatre or the critical care unit’ 
 
• ‘Exploring remediable factors in the care of adult patients (aged 16 and over) 
undergoing the insertion of a surgical or percutaneous tracheostomy tube’ 
 
• ‘Assessing the number and variability of percutaneous tracheostomies 
performed annually in the critical care unit’ 
 
• ‘Making recommendations to improve future practice’ (Wilkinson, Martin et al. 
2014) 
 
However the document does not address or highlight issues related to patients 
who have a tracheostomy tube in-situ, who present with difficulties in managing 
excessive pooled saliva or discuss any management options that can be 
considered in order to aid in the reduction of saliva and reduce the need for 
tracheal suctioning. This report was undertaken to help identify the difficulties in 
the pathway of care for patients with a tracheostomy and in various hospital 
settings and subsequent NCEPOD report produced (Wilkinson, Martin et al. 
2014). 
 
There are no national government supported policies or documents that provide 
guidelines or procedures in the management of excessive saliva and no 
officially licensed medications to assist in reducing the amount of saliva 
produced in any patient populations. A larger scale study to investigate the 
management of saliva in this patient population would assist in developing best 
practice guidelines and inform healthcare professionals, patients and their 
families in making informed decisions when addressed with difficulties in the 
clinical management of saliva.  
 
A Clinical Trial Authorisation (CTA) is required for any clinical trial of an 
investigational medicinal product (CTIMP) to be conducted in the UK that fall 
within the scope of the EU Clinical Trials Directive and the Medicines for Human 
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Use (Clinical Trials) Regulations 2004 (MHRA 2013). The application for a CTA 
is made to MHRA who are responsible for advising on the Regulations and the 
requirements for CTA. There are 4 phases of a clinical trial, and a product can 
only go to the next phase if it has passed the safety and effectiveness tests of 
the previous one (MHRA 2013). When making an ethics application for a clinical 
trial the application must specify the phase in which your study lies. 
 
 
In order to make such an application to ethics for consideration of a clinical trial 
of an investigational medicinal product an application must be made to the 
MHRA for an EudraCT number and then this must be included within ethics 
application form stating in which phase (I-IV) your clinical trial will be (MHRA 
2013). The four phases of a clinical trial are listed below and a product can only 
go to the next phase if it has passed the safety and effectiveness tests of the 
previous one (MHRA 2013).  
 
Phase I trials, sometimes called first-in-human trials, test a small number of 
subjects to find out how the treatment works in the body. This type of trial aims 
to find the lowest dose at which the treatment is effective (the minimum 
therapeutic dose) and the highest dose at which it can be taken without causing 
harm. 
 
Phase II trials test the treatment in several hundred people with a given disease 
or condition. They aim to find out how well the treatment works in larger 
numbers, identify common side effects, and refine the dose and length of 
treatment. 
 
Phase III trials typically compare the treatment across several thousand patients 
to gather more detailed information on how well it works in groups of patients 
and its safety. The results influence the prescribing and patient information of a 
medicine once it is marketed. 
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Phase VI Trials are carried out after a medicine has been licensed and put on 
the market. These trials are designed to find out more about the long term 
harms and benefits of a medicine and to discover new uses for it. 
 
Robey (Robey 2004) suggested an adaptation of a five-phase model of clinical-
outcome research as a means for structuring forms of clinical research 
throughout audiology and speech-language pathology. He suggests that the 
sequence of research tasks are; Phase I for identifying treatment protocols, 
justifying the enormous expense of extensive clinical testing; Phase II for 
making all of the preliminary tests and preparations necessary for testing the 
protocol in a clinical trial; Phase III for conducting a clinical trial to test efficacy; 
and Phase IV for testing the effectiveness of efficacious treatments. For 
treatment protocols proving effective, an additional phase of research is 
required: Phase V for testing the worth of a treatment (i.e., does the obtained 
value justify the cost of achieving that value?). This interrupted times-series 
evaluation falls within the domains of a Phase II study (Robey 2004), whereby 
the research is exploring the dimensions of the therapeutic effect and making 
the necessary preparations for conducting a clinical trial. Further Phase II 
studies (Robey 2004) are required with a larger sample size, with patients with 
varying primary diagnoses, to determine the presence and magnitude of 
efficacy.  
 
 
In a report by the National Confidential Enquiry into Patient Outcome and Death 
(NCEPOD) (Wilkinson, Martin et al. 2014), NCEPOD states in its report that one 
of its important roles is to ‘provide an amplifier for the professional voices who 
need to insist to management that training is not an optional extra or a one-off 
episode. It has to be part of the day to day work of a unit managing these 
patients’ (Wilkinson, Martin et al. 2014). However it omits an important part of 
the daily care in managing patients who have a tracheostomy tube in-situ, in 
providing care and treatment for pooled saliva and potential complications 
associated with knowledge and practice in clearing aspirated saliva via tracheal 
suctioning. The report acknowledges that an assessment of the upper airway by 
a speech and language and the patient’s ability to deal with saliva and therefore 
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more accurately quantify the risk of aspiration is valuable (Wilkinson, Martin et 
al. 2014), but does not advise on saliva management options. 
 
The Royal College of Speech and Language Therapists (RCSLT) produced the 
‘Tracheostomy Competency Framework’ (Royal College of Speech and 
Language Therapists 2014), although the core competencies makes reference 
to having theoretical knowledge of being aware of use and timing of different 
instrumental tools (e.g. Fibreoptic Endoscopic Evaluation of Swallowing (FEES), 
Videofluoroscopy (VFS) to assess laryngeal integrity for phonation, secretion 
(saliva) management and swallow function, it does not make reference to 
intervention options in order to manage excessive saliva. Instead the document 
relates to how able the individual is to swallow their own saliva and the ability of 
the speech and language therapist (SLT) to identify food / fluid stained 
secretions in the tracheostomy tube or at the stoma site.  
 
In section 2 of the RCSLT competency document under the core tracheostomy 
skills it states the importance of training others, which includes members of the 
multidisciplinary team, the family and the patient. It recommends that training 
should include the impact of a tracheostomy tube on communication and 
swallowing, use of one-way / speaking valves and the use of heat moisture 
exchange (HME) devices. Many of these individuals who have a tracheostomy 
tube in-situ will be dependent on tracheal suctioning to clear saliva that has 
fallen into the airway but the report states that ‘SLT suctioning is not covered 
within the scope of this document’ (Royal College of Speech and Language 
Therapists 2014). Without having the knowledge and skills on saliva 
management options, which have implications for communication and 
swallowing and will impact on the ability to use one-way / speaking valves and 
HME devices, the therapist cannot be fully informed and fully achieve these 
core skills. 
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6.1 Clinical Implications 
 
Speech and language therapists are asked to assess, diagnose and treat 
patients who have a tracheostomy tube in-situ and present with associated 
swallowing difficulties post neurological insult. They are often the professionals 
who comment on the ability of the patient to safely swallow their saliva and in 
collaboration with the medical and other allied health professionals if the 
tracheostomy tube can therefore be closed-off and eventually removed, as it is 
no longer required for tracheal suctioning to clear aspirated saliva from within 
the airway. However to date there are no recognised guidelines or policies that 
directs the medical management of saliva in this patient population or in any 
other patient populations. Furthermore there are no licensed medications that 
assist in the medical management of excessive saliva. Most prescribed 
medications are done so ‘off-label’ (Blum 2002; Kelly, Gazarian et al. 2005).  
 
There have been several reported studies in the treatment of drooling in people 
with Parkinson’s Disease and in patients with Amyotrophic Lateral Sclerosis by 
using injections of botulinum toxin into the salivary glands (Bushara 1997; 
Moller, Karlsborg et al. 2011). These injections have successfully been 
administered by land-marking the injection site, without the need to use ultra-
sound guidance or electromyography and have led to a successful reduction in 
drooling (Pal, Calne et al. 2000; Ondo, Hunter et al. 2004).  
 
In everyday practice there are regular clinics for patients with Parkinson’s 
disease and associated drooling difficulties, where injections of botulinum toxin 
are administered to the parotid salivary glands through land-marking, which 
have proved to be beneficial in reducing drooling. Speaking to a Consultant 
Maxillofacial Surgeon, who leads one of these clinics in London, she stated that 
there was high demand for this service and a clinic which was ceased had to be 
re-instated at the request of patients and their carers. 
 
Although botulinum toxin injections into the salivary glands cannot be 
considered non-invasive, it is less invasive than surgery and has none to 
minimal side effects, as do most pharmacologic treatments. As mentioned 
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above, significant education regarding the benefits versus the potential side-
effects needs to occur. The impact on the patient of having the tracheostomy 
tube ultimately removed, given the known evidence regarding the lack of 
knowledge and skills in tracheostomy care (Day, Farnell et al. 2002), outweighs 
the potential side-effects in the majority of cases. It would therefore be 
beneficial if the multidisciplinary team consider and discuss all treatment options 
including the potential use of botulinum toxin, especially in this patient 
population, who already have a tracheostomy tube in-situ, for the main purpose 
of providing tracheal suctioning to clear saliva that has fallen into their airway, 
so any transitory, minimal side-effects of dysphagia would not cause further 
detriment. McGowan et al. (McGowan, Ward et al. 2014) recognised that there 
appears to be a lack of consistency or guidance and that decision making is not 
provided in an optimal team environment, despite emerging evidence that 
tracheostomy teams may enhance patient outcomes (McGowan, Ward et al. 
2014). The majority of these patients are also ‘nil-by-mouth’, not eating and 
drinking orally, but dependent on tube feeding at level three or below on the 
functional oral intake scale (FOIS) (Crary, Mann et al. 2005), therefore any 
transitory, minimal side-effects of dysphagia should not cause further detriment. 
 
 
.   
The US Food and Drug Administration (FDA) had received concerning systemic 
adverse reactions (Food and Drug Administration 2008), including ‘respiratory 
compromise and death’, following the use of botulinum toxin. 
The warning section of the labelling for botulinum toxin products note that 
important systemic adverse effects, including severe difficulty swallowing and 
difficulty breathing have occurred in patients with neuromuscular disorders after 
local injection of typical doses of botulinum toxin. The use of botulinum toxin 
has increased tremendously in the United Kingdom, not only for use in 
neurological conditions but predominantly for a variety of cosmetic uses. 
Concern has been expressed as to who was injecting botulinum toxin, citing 
Dentists, General Practitioners, and Physiotherapists (The Dystonia Society 
2012).   
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It is recommended that botulinum toxin should only be administered by qualified 
medical personnel (The Dystonia Society 2012), who have experience in 
making-up the correct dosages and ability to inject through land-marking into 
the salivary gland. I believe that while it is essential for speech and language 
therapists to be knowledgeable regarding botulinum toxin and its uses, allowing 
them to be able to offer sound advice to patients / primary caregivers and the 
medical teams, they are not qualified to administer the toxin. 
 
It is hoped that the information contained in this study provides speech and 
language therapists with information and guidelines regarding treatment options 
in the medical management of excessive saliva in this patient group. 
 
The aetiology of excessive saliva needs to be carefully considered by the 
speech and language therapist before a recommendation as to which treatment 
to consider is made. Primary drooling is caused by an increase in saliva 
production, which may be associated with inflammation, enlarged adenoids and 
tonsils, dental caries, mouth infections, specific medications, and oesophageal 
reflux. Often drooling of this nature can be improved by attending to the primary 
cause of the drooling. Secondary drooling is due to impaired neuromuscular 
control and / or sensory dysfunction, which can lead to an accumulation of 
excessive saliva within the oral cavity. Whether drooling is anterior or posterior 
(Reddihough, Erasmus et al. 2010) also warrants close examination, as 
posterior drooling can lead to congested breathing, coughing, gagging, vomiting 
and occasionally aspiration of saliva into the trachea leading to possible 
pneumonia (Smith 2008). This may then warrant the insertion of a tracheostomy 
tube to manage this aspirated saliva.  
 
Factors that can exacerbate drooling, such as poor body and head positioning, 
poor oral-motor control, and a constantly open mouth need to be considered. 
Treatment should focus on these areas first before considering any other 
invasive treatment interventions.  
 
Presently there are no formalised assessment tools or models to determine 
eligibility and for determining the use of one treatment intervention against 
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another, for managing excessive saliva or drooling in any patient population. 
When making an informed decision as to which treatment intervention to 
prescribe in the management of saliva, information from the case history, 
provided by numerous professionals, as well as the primary caregivers, needs 
to be collated before a decision can be made as to which treatment intervention 
to prescribe (Figure 1).  
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Figure 1 A proposed suggestion for the decision making process in determining 
treatment intervention for the management of saliva and subsequent drooling 
Case History / Pre-morbid Information Discussion with Patient / Primary 
Caregiver(s) 
Diagnosis; Age; Medical history; 
Dental Health history; 
Medications; previous history of 
dysphagia; management of 
excessive saliva /drooling 
Pre-morbid level of ability; eating 
and drinking skills; previous 
swallowing difficulties; including 
saliva or any previous reports of 
drooling difficulties 
AETIOLOGY 
Discussion with Patient and / or 
Primary Caregiver(s) 
Assessment by the Nursing, 
Therapy and Medical Teams 
Baseline measurement; severity 
and frequency of excess saliva; 
frequency / amount of tracheal 
suctioning; throughout the day; 
records of anterior and posterior 
drooling; Dysphagia; pneumonia 
risks 
Treatment options to manage 
excessive saliva; quality of life 
issues; limitations / potential side-
effects; benefits versus risks;  
Decision 
Making Process 
Botulinum Toxin 
Treatment Intervention 
Alternative Treatment 
Intervention 
Referral to appropriate 
source 
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At present no pharmacological interventions (including the use of botulinum 
toxin or Scopolamine TTS® transdermal patches) are licensed for the 
management of anterior or posterior drooling (Reddihough, Erasmus et al. 
2010). In this study it can be seen that the medical teams preferred the 
prescription of Scopolamine TTS® transdermal patches over that of prescribing 
botulinum toxin intra-glandular injections. Several studies have investigated the 
cost effectiveness of using botulinum toxin for dystonia or spasticity (Jankovic 
2004; Esquenazi 2006). The conclusions are that the financial expense involved 
with botulinum toxin is more than justified when compared to the cost of drugs, 
physiotherapy or surgery (Jankovic 2004; Esquenazi 2006). Cost effectiveness 
studies related to the use of botulinum toxin for the management of excessive 
saliva need to be performed. As can be seen from this study, there was a 
significant reduction in saliva with treatment intervention using Scopolamine 
TTS® transdermal patches, which was most effective one to two weeks post 
intervention; however if treatment using botulinum toxin injections into the 
salivary glands was administered, the effect may have been more 
instantaneous and the requirement for the tracheostomy tube for the purpose of 
tracheal suctioning made redundant, thus leading to quicker removal of the 
tracheostomy tube and negating the need and associated costs for one-to-one 
nursing care. So ultimately the use of botulinum toxin could possibly provide 
numerous benefits, one of which could be reduced overall costs through the 
removal of one-to-one specialist nursing and, improved quality-of-life, post 
removal of the tracheostomy tube (Gilony, Gilboa et al. 2005).  
 
6.2 Quality of Life / Patient Well-Being  
 
One of the aims of reducing saliva in this patient population is to reduce the 
need to perform tracheal suctioning, which is known to be associated with 
varying levels of bad practice (Day, Farnell et al. 2002). Although at this stage 
there are few studies and little known about the relationship between having a 
tracheostomy tube in-situ and tracheal suctioning and patients / carers 
perceptions, it is known that patients who have a tracheostomy tube have 
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significantly reduced life-satisfaction and body-image perceptions (Gilony, 
Gilboa et al. 2005). Thus by assisting in the successful closure and ultimate 
removal of the tracheostomy tube, patients may show improvements in their 
body-image perceptions, life-satisfaction and reduce any secondary 
complications associated with mal-practice related to tracheal suctioning (Figure 
2). 
In all three case reports all primary caregivers reported that the “tracheostomy 
tube causes me concern”, and the statement “I get scared when I require 
suctioning via the tracheostomy tube”, and rated these statements in the 
tracheostomy tube self-perception survey as being ‘very much true’ throughout 
the study from pre-intervention until the end of data collection at 12-weeks post-
intervention (Appendices K, L and M). All caregivers rated in the self-perception 
survey that “having a tracheostomy tube in-place makes me feel sad” and the 
statement, “I’ve been discouraged by having a tracheostomy tube” as either 
‘very much true’ (cases 2 and 3) (Appendices L and M) or ‘quite a bit true’ (case 
1) (Appendix K). In cases 2 and 3 it was indicated ‘very much true’ a sense of 
“feeling frustrated” throughout the study (Appendices L and M), whereas in case 
1, this was recorded as ‘somewhat true’ throughout the study (Appendix K). The 
difference may have been related to the fact that the participant in case 1 was 
far less dependent than in cases 2 and 3, with a higher Glasgow Coma Scale 
(Teasdale and Jennett 1974) and was more awake, with his eyes open. All 
three participants had their tracheostomy tube successfully removed once data 
collection had ceased at post 12-weeks intervention. In cases 1 and 3 this was 
after one-week post data collection and three-weeks post data collection in case 
2. In each case participants required routine tracheal suctioning to clear any 
coughed sputum from within the tracheostomy tube and needed to be able to 
have their tube closed for a full 24-72 hours, before considering removal, this 
did not occur until the end of data collection in cases 1 and 3 and two-three 
weeks after data collection in case 2. They were not asked to complete a 
questionnaire post removal of the tracheostomy tube, which would have been a 
useful comparator, to see if there had been changes in their responses.  
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Figure 2, possible benefits as a result of effectively managing excessive saliva in 
tracheostomised patients  
 
6.3 Research Implications 
 
The results of this study have highlighted several areas for further research, 
which includes further Phase II type studies (Robey 2004) with larger numbers 
of participants, determining the presence and magnitude of efficacy of the 
intervention and any associated side-effects. Likewise a replication of the study 
with larger numbers of participants categorised with a number of different 
primary diagnoses and severity of injury as indicated by their GCS score 
(Teasdale and Jennett 1974), age, sex and baseline ratings of saliva would be 
beneficial and help determine if there is a relationship between efficiency of 
THE MEDICAL MANAGEMENT OF SALIVA IN TRACHEOSTOMISED PATIENTS 
Reduced need for 
tracheal suctioning 
Reduced risk of 
secondary 
complications 
Improved Quality-
of-Life (QOL) for 
patient / carer 
Improved oral 
sensation and 
awareness 
 
Closure / removal of 
tracheostomy tube 
Improved communication 
/ swallowing 
OVERALL REDUCED COSTS / IMPROVED QOL 
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response to either of the treatment interventions. Furthermore trends relating to 
diagnoses, age and severity of injury can be grouped and effectiveness of one 
treatment intervention against that of another can be compared. 
 
6.4 Limitations of the Study 
 
In this study the ‘swab’ method (White 2007) for collecting saliva was utilised, 
but due to the presentation of the participants the swabs could not be safely 
placed within the intra-oral cavity, because of the risk of either having the swab 
falling into their airway, or being unable to retrieve the swab, as a result of the 
participant having a bite-reflex response to items being placed onto their 
tongue. Future studies may wish to use alternative methods of saliva collection, 
which allows collection of saliva from within the intra-oral cavity. This might 
include collecting drooled saliva through the use of collection cups and/or 
measuring the ‘wetness’ of bibs as a result of drooling.   
 
During this study all patients continued to receive speech and language therapy 
intervention, in conjunction with the prescribed Scopolamine TTS® transdermal 
patches treatment. During this study none of the interventions were withdrawn 
and participants continued to receive therapy alongside the medical treatment, 
but in order to be sure it was solely the prescribed Scopoderm TTS® 
transdermal patches intervention that related to a reduction in saliva, future 
research may want to consider a control group, that receives neither of the 
treatment interventions, or a placebo intervention, which then compares 
outcomes, with and without therapy intervention. Alternatively a study that 
adopts a within-subject design, where each participant receives one treatment 
and then the next treatment, with a washout period between each treatment 
could be used. 
The primary swab readings were collected and made by the primary 
investigator and future research may wish to use independent individuals who 
collect and record the weight of the saliva collected, who are ‘blinded’ to the 
intervention treatment, thus avoiding any possible bias. In this study ‘swab’ 
recordings were taken at three specified time-points across a 12-hour period, a 
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larger number of readings across a 24-hour period may have resulted in 
differing trends of saliva throughout the day and throughout the night-time 
(Dawes 1974) and future studies may wish to take this into consideration.   
  
In this study the same one-to-one nurse who provided tracheal suctioning was 
asked to record the reason for administering tracheal suctioning each time it 
was performed, but no official training was given, other than a list of most-
common reasons to provide tracheal suctioning. This might have biased the 
nurse into recording why they provided suctioning, whereas not being as 
prescriptive and withdrawing a list of reasons, allowing the nurse to cite why it 
was performed may have been a better indicator as to why tracheal suctioning 
was administered. 
  
All patients within this study were in a low-awareness state, with varying 
degrees of consciousness (Teasdale and Jennett 1974), it is suggested that 
future research, uses a wider cohort of patients with differing primary diagnoses 
and presentation, so that this would enable not only the primary care-givers to 
respond to questions relating to the tracheostomy tube, but also allow those 
patients who are not in a low-awareness state to also respond.  
 
There is no universal scale to clinically measure the amount of excessive saliva, 
or classification of what constitutes mild, moderate or severe anterior or 
posterior drooling of saliva (Reddihough, Erasmus et al. 2010), but this is just 
an objective clinical judgement, which clinicians refer to as copious amounts or 
large amounts of saliva in this patient population.  It would be advantageous to 
have a scale that clinicians and medical teams can use with inter-rater reliability 
to classify and grade amounts of excessive saliva. In this study the use of a 
small sample prevents generalisation to the wider population.   
 
When statistically analysing the data, linear regression was used with the 
assumption that there was a linear relationship between the two variables, 
which were a reduction in saliva over time, post intervention, which in all three 
case reports there was; however in a larger study there may be other 
confounding variables, such as medications that may increase or decrease 
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saliva flow (Allergan 2015; Novartis Consumer Health UK Ltd 2016), which may 
result in a non-linear relationship, in which case linear regression analysis 
cannot be utilised. In these three case reports participants were not on any 
known prescribed medications that are known to induce saliva flow or cause 
hypersalivation. Due to small numbers in this study, the participants could not 
be grouped to analyse across diagnoses or compare against ages and 
outcomes. A larger multicentre study with greater numbers of participants, 
presenting with a range of differing variables, such as age and diagnoses, in 
which participants can be grouped, would allow for wider analysis and 
generalisation of findings to be applied.  
 
6.5 Concluding Remarks 
 
There is every indication to suggest that there is more research required 
investigating the medical management of saliva in patients who have a 
tracheostomy tube in-situ. The current medical management options for the 
treatment of excessive saliva in everyday practice have been shown to be very 
limited.  Although the use of botulinum toxin injections into the salivary glands to 
reduce drooling in neurologically impaired patients has been shown to be 
effective (Porta, Gamba et al. 2001), there appears to be some reluctance in its 
application in this patient population. It is important that medical teams and 
allied health professionals are fully aware of all treatment options available in 
the medical management of saliva in patients who have a tracheostomy tube in-
situ, thus enabling the patient, their carers and the treating team to make an 
informed decision as to which intervention to prescribe. 
 
Given the known secondary complications associated with having a 
tracheostomy tube in-situ (Beards and Nightingale 1994) and evidence that 
supports the lack of knowledge and skills in providing tracheal suctioning (Day, 
Farnell et al. 2002), it would make clinical sense to assist in successfully aiding 
in its removal as soon as is possible, by effectively managing the excessive 
saliva and making the need for tracheal suctioning redundant thus allowing the 
tube to be closed-off and ultimately removed. This would not only be cost-
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effective, but improve the quality of life, not only for the participants, but also for 
their primary caregivers.  
 
If the judicious use of prescribed drugs are to be extended to treat excessive 
saliva and be licensed for this use, all stakeholders, from pharmaceutical 
companies, hospitals, medical aids and government need to work 
collaboratively to issue policies, procedures and national guidelines in its use in 
this patient and wider patient population.   
 
Whilst I am aware of the expense and the tremendous hurdles needed to make 
this happen, the use off-label drugs (Blum 2002; Kelly, Gazarian et al. 2005) in 
managing excessive saliva in patients who have tracheostomy tube in-situ may 
help in minimising the event of any secondary complications (Beards and 
Nightingale 1994) associated to mal-practice in tracheal suctioning in caring for 
patients who have a tracheostomy tube and in-turn reduce the need for one-to-
one care in a specialised setting, thus in the longer-term driving down overall 
costs.  
 
In this study pharmacological intervention was administered with the use of 
Scopoderm TTS® transdermal patches in the medical management of saliva in 
tracheostomised patients and was shown to significantly reduce saliva in all 
participants. There was also a significant reduction in the need to perform 
tracheal suctioning in all cases and a reported reduction in the amount of saliva, 
as reported by both the same one-to-one nurse special and the patient’s same 
caregiver on a visual analogue scale. Further research needs to be conducted 
comparing the using a range of differing interventions in the medical 
management of saliva in tracheostomised patients. These interventions might 
include the use of other anticholinergic medications and the use of botulinum 
toxin to reduce saliva flow in this patient population and determining the most 
effective treatment, monitoring for the presence and severity of any potential 
side-effects of each intervention, in the immediate and longer-term, ensuring 
that follow-up is provided, even after successful decannulation (removal) of the 
tracheostomy tube.    
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